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Abstract 
 
Introduction 
 
Some clinical practice guidelines recommend peritoneal dialysis (PD) as the dialysis 
treatment of choice for adults with residual kidney function and without significant 
comorbidities. However, PD-related infections (defined as exit-site infections, tunnel 
infections, and peritonitis) are a serious complication for PD patients. For a PD 
program to be successful, the prevention of PD-related infections must be a top 
priority. The most important of these infections is peritonitis. 
Although incidence rates of peritonitis have decreased substantially with changes in 
procedure and the use of improved connection systems, peritonitis remains a major 
problem with PD. The International Society for Peritoneal Dialysis (ISPD) 
guidelines published in 2011 suggested that renal units should have a peritonitis rate 
of <0.36 episodes per patient- year as their benchmark. The current peritonitis rates 
in Australia (0.41; 95% CI 0.37-0.43 episodes per patient-year) and New Zealand 
(0.47; 95% CI 0.43-0.52 episodes per patient- year) are higher than this suggested 
target. Data from various countries show that while mortality directly related to 
peritonitis is low (less than 4%), peritonitis is a “contributing factor” to death in 16% 
of deaths on PD. Furthermore, peritonitis can result in peritoneal membrane failure 
and is a leading cause of technique failure in PD and transfer to hemodialysis. 
Peritonitis is also a leading cause of hospitalisation. 
To improve outcomes in PD patients, it is important that the prevention of peritonitis 
be a focus. In addition, the treatment of peritonitis should aim for rapid resolution of 
inflammation and preservation of peritoneal membrane function. Challenges in the 
prevention of peritonitis include the fact that peritonitis rates vary greatly between 
different renal centres and the peritonitis risk appears to vary from patient to patient, as 
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some patients never get peritonitis but others have frequent episodes. The reasons for 
the variability are complex and largely unexplained. Studies on preventing PD-related 
infections are limited both in number and in quality, and practice recommendations are 
a compilation of expert opinion combined with the available evidence. It is not known 
how good the uptake of guideline recommendations for the prevention of PD-related 
infection is in Australia and New Zealand, and what the reasons for their non-uptake 
might be. 
From the patient’s perspective, not much is known about the beliefs, needs and 
experiences of PD patients in relation to peritonitis. Concern about the risk of 
peritonitis can lead to fear and anxiety, and the experience of peritonitis can result in 
immense pain, humiliating events, financial stress, added burden on family members 
and reluctant admission to hospital. A number of participants were unsure about the 
symptoms of peritonitis. 
The aim of the studies in this thesis is to establish current practice patterns (re 
antimicrobial prophylaxis) in a selected number of renal units in Australia and New 
Zealand (ANZ) and to identify barriers to the uptake of relevant guideline 
recommendations, to establish current practice patterns in relation to antimicrobial 
prophylaxis in ANZ units more broadly by survey, to assess the evidence base for the 
antimicrobial agents used to prevent PD-related infections, and to explore patient 
experiences and beliefs about peritonitis so that the management of these patients and 
the support they receive can be improved. This is a hybrid thesis with several separate 
publishable projects presented as chapters. The studies that form this thesis evaluate 
and summarise the existing literature relating to the prevention of PD- related 
infections (chapter 2), assess current practice and barriers to antimicrobial prophylaxis 
at 8 renal units in ANZ (chapter 3), evaluate and summarise the available evidence for 
the use of antimicrobial agents to prevent peritonitis in PD patients (chapter 4), assess 
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current practice at ANZ renal units in relation to antimicrobial prophylaxis by survey 
(chapter 5), and explore patient experiences and beliefs about peritonitis (chapter 6). 
 
Methods and Main Findings 
 
 
Prevention of peritoneal dialysis-related infections* 
 
*Campbell DJ, Johnson DW, Mudge DW, Gallagher MP, Craig JC. Prevention of 
peritoneal dialysis-related infections. Nephrol Dial Transplant 2014; doi: 
10.1093/ndt/gfu313. 
Chapter two summarises the evidence relating to the various interventions that have 
been employed to prevent exit-site infection (ESI), tunnel infection and peritonitis. 
The strategies include the use of antibiotic prophylaxis at Tenckhoff catheter insertion, 
the use of oral, nasal and topical antibiotics once the catheter has been implanted, the 
use of disinfectants at the exit site, modifications of the transfer set used in continuous 
ambulatory peritoneal dialysis (CAPD), changes to the catheter design, the surgical 
method used to implant the PD catheter, the type and length of training given to 
patients, the making of home visits by trained PD nurses, the use of antibiotic 
prophylaxis in patients undergoing certain invasive procedures and the co-
administration of antifungal prophylaxis to PD patients whenever they are given an 
antibiotic treatment course. The review showed that, overall, there is a lack of RCTs 
for many interventions and data from less rigorous study designs such as cohort 
studies are the current best available evidence. In addition, the quality of the available 
RCTs is variable. The quality of the evidence is strong for some aspects such as the 
PD connection method and the use of antibiotic to prevent ESI but is weak for other 
areas such as the method for training patients. 
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Assessment of current practice and barriers to antimicrobial prophylaxis in 
peritoneal dialysis patients* 
*Campbell DJ, Brown FG, Craig JC, Gallagher MP, Johnson DW, 
Kirkland GS, Kumar SK, Lim WH, Ranganathan D, Saweirs W, Sud 
K, Toussaint ND, Walker RG, Williams LA, Yehia M, Mudge DW. 
Assessment of current practice and barriers to antimicrobial 
prophylaxis in peritoneal dialysis patients. Nephrol Dial Transplant 
2015; doi: 10.1093/ndt/gfv115. 
In chapter three, the current practice in relation to antimicrobial prophylaxis in PD 
patients was assessed at eight renal units located in Australia (7) and New Zealand (1). 
Barriers and enablers to good practice were also evaluated. This was a prospective 
study with a focus on adherence to evidence-based guideline recommendations on 
antimicrobial prophylaxis in PD patients. Current practice was established by asking 
the PD unit heads to respond to a short survey about practice/protocols/policies and by 
interviewing the primary PD nurse at each unit, after which a ‘process map’ was 
constructed. The perceived barriers/enablers to adherence to the relevant guideline 
recommendations were obtained from the completion of ‘cause and effect’ diagrams 
by the nephrologist and PD nurse at each unit. Data on PD- related infections were 
obtained from the Australia and New Zealand Dialysis and Transplant Registry 
(ANZDATA) for the baseline period 1 January 2011 to 31 December 2011. A number 
of perceived barriers and enablers were identified. It was also found that the 
definitions of PD-related infections used by some units varied from those 
recommended by the International Society for Peritoneal Dialysis (ISPD), particularly 
with regard to exit-site infection (ESI). PD-related infection rates for the baseline 
period were found to vary widely. We found wide variation in adherence to guideline 
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recommendations between PD units which might contribute to the variation in PD-
related infection rates. Although individual patient characteristics may account for 
some of this variability, inconsistencies in the processes of care to prevent PD-related 
infection also play a role. 
Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
(Cochrane Review) 
In chapter 4, an update to a Cochrane systematic review was conducted. This 
review evaluated the effectiveness of antimicrobial agents which have been 
used to prevent peritonitis in PD patients. We identified 39 trials eligible for 
inclusion, involving 4374 patients. Twenty more trials (2183 patients) were 
included than in the original review of 2004. The following antimicrobial 
interventions were analysed: oral or topical or intraperitoneal antibiotics; 
nasal antibiotic prophylaxis; pre/peri-operative intravenous antibiotic 
prophylaxis; topical disinfectants of the exit site; germicidal systems for 
connection devices; dressing systems for exit sites; silver ring system on 
catheter; anti-staphylococcal vaccine; and antifungal agents. The primary 
outcomes assessed were: peritonitis; exit-site infection/tunnel infection; and 
catheter removal/catheter replacement. Six secondary outcomes were also 
assessed. We found that of the various interventions, pre/peri-operative 
intravenous vancomycin compared with no treatment appears to reduce the 
risk of early peritonitis (but has uncertain effects on the risk of exit-
site/tunnel infection) and antifungal prophylaxis with oral nystatin or 
fluconazole compared with placebo/no treatment appears to reduce the risk of 
fungal peritonitis after a patient has had an antibiotic course. However, no 
other antimicrobial interventions had proven efficacy and no intervention 
reduced the risk of catheter removal or replacement. The findings highlight 
 
 
ix  
the lack of adequately powered and high quality randomised controlled trials 
(RCTs) to inform decisions about how to prevent peritonitis in PD patients. 
Infection prophylaxis in peritoneal dialysis patients: results from an 
Australia/New Zealand survey 
Chapter 5 presents the results of a web-based survey of consultant nephrologists who 
were members of the Australian and New Zealand Society of Nephrology (ANZSN) 
and was conducted between June and September 2013. Various evidence-based 
guideline recommendations exist for the prevention of PD-related infections in PD 
patients and this survey aimed to describe the prophylactic clinical practices used by 
nephrologists in Australia and New Zealand. An initial email inviting nephrologists to 
participate and three reminder emails were sent out via the ANZSN office. The survey 
questions asked about the use of antibiotic and antifungal prophylaxis in PD patients. 
The ISPD guideline recommendations we focused on state that: prophylactic 
antibiotics administered at the time of insertion decrease the infection risk; all PD 
patients should use topical antibiotic either at the catheter exit site or intranasally or 
both; most episodes of fungal peritonitis are preceded by courses of antibiotics; and 
fungal prophylaxis during antibiotic therapy may prevent some cases of Candida 
peritonitis in programs that have high rates of fungal peritonitis. The KHA-CARI 
guideline recommendations are similar. We received 133 responses to the survey, 
which represents an estimated 39.9% response rate as it was considered there were 333 
registered consultant nephrologists in ANZ at the time. We found that most 
nephrologists (127; 95.5%) prescribed antibiotics at the time of Tenckhoff catheter 
insertion, 85 (63.9%) routinely screened for nasal S. aureus carriage but only 76 
(88.4%) reported they treated S. aureus carriers with mupirocin ointment. Following 
Tenckhoff catheter insertion, 79 (59.4%) prescribed mupirocin ointment at the exit site 
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or intranasally and 93 (69.9%) of nephrologists routinely prescribed a course of oral 
antifungal agent whenever their PD patients were given a course of antibiotics. The 
study shows that clinical practice among practising nephrologists in ANZ is variable, 
with 11.6% of identified nasal S. aureus carriers not being treated, with nearly 40% of 
patients not receiving antibiotic prophylaxis at the exit site or intranasally, and 
approximately 30% of patients not being co-prescribed an antifungal agent when they 
are administered an antibiotic course. This practice variation may contribute to the 
wide range of PD-related infection rates that is seen between units. 
Patients’ perspectives on the prevention and treatment of peritonitis in 
peritoneal dialysis: a semi-structured interview study 
Chapter 6 is a qualitative study of patient perspectives on the prevention and treatment 
of peritonitis in peritoneal dialysis. Semi-structured, face-to-face interviews were 
conducted with 29 patients from three renal units in Australia who had previous or 
current experience of PD. The interview transcripts were thematically analysed. Four 
themes were identified: constant vigilance for prevention (conscious of vulnerability, 
sharing responsibility with family, demanding attention to detail, ambiguity of 
detecting infection, ineradicable inhabitation, jeopardising PD success); invading harm 
(life-threatening, wreaking internal damage, debilitating pain, losing control and 
dignity); incapacitating lifestyle interference (financial strain, isolation and separation, 
exacerbating burden on family); and exasperation with hospitalisation (dread of 
hospital admission, exposure to infection, gruelling follow-up schedule, exposure to 
harm). The findings suggest that peritonitis is viewed by patients as a threat – one that 
can affect their health, choice of dialysis modality, and lifestyle. As a consequence, 
they were motivated to be vigilant when doing an exchange and paid great attention to 
hygiene. Patients felt a loss of control due to the debilitating symptoms they 
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experienced, having to be hospitalised and were not sure of the signs of peritonitis. 
Providing patients with education about the causes and signs of peritonitis and 
addressing their concerns about lifestyle impact, financial impact, hospitalisation, and 
peritonitis-related anxieties may improve treatment satisfaction and outcomes for 
patients on peritoneal dialysis. Based on the findings, patient- and family-centred 
education and care strategies that may help to inform and support patients on PD are 
outlined in this chapter. 
Conclusion 
 
This thesis outlines what clinical practice in relation to the use of prophylaxis in PD 
patients is like in ANZ and identifies some barriers to the uptake of relevant guideline 
recommendations. The evidence base for the use of various antimicrobial agents to 
prevent PD-related infections has been assessed and only a few interventions can be 
held to be effective. Studies on the prevention of PD-related infections are limited both 
in terms of quantity and quality and hence, guideline recommendations are based on a 
mixture of expert opinion and the available evidence. PD patient beliefs and 
experiences about peritonitis are also described. Patients are threatened by the prospect 
of peritonitis and constantly act to minimise the chance of it occurring. An episode of 
peritonitis leads to patients experiencing a loss of control and impacts on lifestyle and 
finances, among other things. Patients need to be educated about the causes and signs 
of peritonitis and to have their concerns about the impacts of a peritonitis episode 
addressed. These findings have implications for clinical practice and provide a 
suggestion for future research in this area. 
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Chapter 1: Introduction 
 
1.1 Background 
 
Peritoneal dialysis (PD) is a well-established major option for renal replacement 
therapy in patients with end-stage kidney disease (ESKD). This dialysis modality is 
often chosen by patients as their initial mode of therapy and is an option for patients 
wishing or needing to swap from haemodialysis (HD) and after renal transplant failure 
(1). Some clinical practice guidelines recommend PD as the dialysis treatment of 
choice for adults with residual kidney function and without significant comorbidities 
(2). Globally, PD is used to treat ESKD in more than 200,000 patients and represents 
about 11% of the global dialysis population (3, 4). However, PD-related infections 
(defined as exit-site infections, tunnel infections, and peritonitis) are a serious 
complication for PD patients and a barrier to their uptake (5). 
One of the most important complications of PD is peritonitis, which creates 
considerable morbidity and mortality. While mortality directly related to peritonitis is 
low (less than 4%), peritonitis is a “contributing factor” to death in 16% of deaths on 
PD (6). Furthermore, peritonitis can result in peritoneal membrane failure, is a 
leading cause of technique failure, and a leading cause of hospitalisation (7, 8). For 
all of these reasons, the prevention and treatment of PD-related infections is a clinical 
priority. 
Peritoneal dialysis technique survival in Australia and New Zealand is lower than in 
other parts of the world but has improved in recent years. Data for the year 2007 found 
the median time of technique survival in Australia was 1.8 years while in New Zealand 
it was 2.4 years (9). Data for the 2014 year showed this had increased to 2.7 years for 
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Australia and 3.0 years for New Zealand (10). In comparison, two countries with high 
proportions of PD patients, Thailand and Mexico, have median technique survival 
times of 3.4 and 4.0 years, respectively (9). Registry data for 2014 show that in 
Australia and New Zealand, infective causes are listed as the reason why 33% and 
30% of patients, respectively, experience technique failure and stop using PD as their 
dialysis modality. Peritonitis is the most common cause of technique failure in 
Australia and the second most common cause in New Zealand (10). The issue is 
complicated. For example, the number of patients on PD in each country needs to be 
considered as clinicians in those countries with policies that promote PD as initial 
therapy will presumably not always be able to choose the most suitable patients for PD 
and this will affect patient outcomes.  
It is known that peritonitis rates among PD patients vary considerably between renal 
centres in Australia and New Zealand (11). Peritonitis poses an immediate and direct 
mortality risk to patients and is a factor over which a renal unit (and associated 
services) has a substantial degree of influence (12). The protocols and procedures in 
place at a unit have an influence on the peritonitis rate. Practice patterns vary greatly 
and many PD units in Australia and New Zealand do not meet the revised ISPD 
minimum accepted peritonitis rate of <0.36 episodes per patient-year (13). The current 
peritonitis rates in Australia (0.41; 95% CI 0.37-0.43 episodes per patient-year) and 
New Zealand (0.47; 95% CI 0.43-0.52 episodes per patient- year) are higher than this 
suggested target (11). 
In many cases, poor peritonitis outcomes reflect significant deviations from practice 
guidelines. A survey conducted by the Australasian Kidney Trials Network of exit-site 
care in PD units in Australia and New Zealand found that many units do not adhere to 
the national guidelines (KHA-CARI guidelines) and that there was an absence of a 
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uniform, standard practice of exit site care (14). The development of an exit-site 
infection (ESI) is known to place patients at substantially increased risk of developing 
peritonitis and the simultaneous occurrence of ESI and peritonitis results in catheter 
removal in approximately 50% of cases (15). 
Challenges in the prevention of peritonitis include the fact that peritonitis rates vary 
greatly between different renal centres and the peritonitis risk appears to vary from 
patient to patient (10, 16-19). Some factors such as older age at the start of PD and 
having diabetes mellitus have been associated with the development of peritonitis and 
death from peritonitis (20, 21). 
The reasons for the variability are complex and largely unexplained. A further 
challenge is the fact that there are only a limited number of studies with strong 
evidence to support the use of various interventions. The pre-operative administration 
of intravenous antibiotic (usually cephalosporin) prior to PD catheter insertion to 
reduce the risk of early peritonitis (within 4 weeks of insertion) has RCT evidence to 
support it (22, 23). The obtaining of nose cultures before placement of the catheter and 
subsequent treatment of anyone who tests positive for Staphylococcus aureus nasal 
carriage, is an opinion-based recommendation and no data on the usefulness of that 
approach is available (13). There is evidence to support the use of nasal mupirocin 
prophylaxis, exit-site mupirocin prophylaxis, exit-site gentamicin prophylaxis and the 
use of antifungal prophylaxis to prevent fungal peritonitis and the ISPD guidelines and 
KHA-CARI guidelines support these practices (13, 24). 
Lastly, the existence of a clinical practice guideline does not guarantee that it will be 
used in practice. One study investigated guideline use among physicians in the United 
States and found a wide range of barriers that prevented physicians from adhering to 
practice guidelines (25). 
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1.2 Aims 
 
The primary aims of the research described in this thesis are: 
 
1. To summarise the current evidence relating to strategies used to 
prevent the occurrence of PD-related infections (i.e. exit-site 
infection, tunnel infection, peritonitis). 
2. To establish current practice patterns in relation to prevention of PD-related 
infection at 8 PD units in Australia and New Zealand and to identify 
perceived barriers and enablers to adherence to relevant guideline 
recommendations. 
3. To summarise and evaluate the current evidence relating to the 
effectiveness of various antimicrobial agents which have been used to 
prevent peritonitis in PD patients. 
4. To determine and describe the clinical practices currently being used by 
nephrologists in Australia and New Zealand in relation to key guideline 
recommendations regarding prophylaxis in PD patients. 
5. To explore patient perspectives in relation to the prevention and 
treatment of peritonitis in peritoneal dialysis. 
1.3 Thesis overview 
 
The aims and scope of this thesis exclude any discussion of the value of automated 
peritoneal dialysis (APD) compared with continuous ambulatory peritoneal dialysis 
(CAPD). No attempt has been made to separate APD from CAPD, either as an 
intervention or a target for intervention. The key objectives of the projects that make 
up this thesis are to inform the strategies used with PD patients to prevent PD-related 
infection and to help create family- and patient- centred care. The projects do this by 
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assessing the evidence on which various interventions are based, by describing 
clinical practice in Australia and New Zealand and identifying evidence-practice 
gaps, by identifying barriers which stop guideline recommendations from being 
adopted into practice, and by exploring the beliefs, needs and experiences of PD 
patients in relation to peritonitis. 
Chapter 2 is a narrative review of the current evidence underpinning strategies for the 
prevention of PD-related infections in PD patients. The evidence included was drawn 
from clinical practice guidelines, systematic reviews and randomised controlled trials 
(RCTs). The review summarises the evidence for 9 different categories of intervention 
which have been used to reduce the occurrence of peritonitis. The effect of each 
intervention on the outcomes of ESI, tunnel infection and peritonitis is reported (when 
available). 
Chapter 3 is a baseline study of 8 PD units in Australia and New Zealand where the 
current practice at each unit was established. The focus was on adherence to guideline 
recommendations on antimicrobial prophylaxis in PD patients. A ‘process map’ was 
constructed for each unit’s process from meeting with the nephrologist prior to referral 
to the surgeon, to the point at which the patient had been trained post catheter insertion 
and had commenced independent dialysis. A list of perceived barriers and enablers to 
the implementation of relevant guideline recommendations was made for each unit, 
following the completion of a ‘cause and effect’ diagram by the nephrologist and PD 
nurse at each unit. 
Chapter 4 is a systematic review of existing RCTs and pseudo-RCTs of the various 
strategies which have been developed to reduce the risk of peritonitis in PD patients. 
Nine categories of intervention were assessed with the main ones being the use of 
antibiotics, the use of topical disinfectants at the exit site and the use of antifungal 
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agents. The primary outcomes assessed were peritonitis, exit-site infection/tunnel 
infection, and catheter removal/catheter replacement. The Cochrane risk of bias tool 
was used to assess the quality of each included study. The systematic review includes 
forest plots which show the effect size and the 95% CI around the effect size for the 
studies which provide evidence for each intervention assessed, and provides a total 
effect size and 95% CIs. 
Chapter 5 is a summary of the survey results obtained from 133 consultant 
nephrologists who were practising in Australia and New Zealand (ANZ) between June 
and September 2013. The survey questions asked about the use of antibiotic and 
antifungal prophylaxis in PD patients and were framed around what the ISPD and 
KHA-CARI guideline recommendations state. 
This chapter describes the prophylactic practices that nephrologists in ANZ report 
they use and discusses the practice variation that was found. 
Chapter 6 is a qualitative in-depth interview study that explores patient perspectives on 
the prevention and treatment of peritonitis in peritoneal dialysis. The aim was to 
develop a better understanding of patient beliefs, needs and experiences in relation to 
peritonitis. Based on the findings, suggestions for clinical practice are made that may 
help to support patients and their families in general, and more specifically, assist 
patients during the treatment period for a peritonitis episode. 
Chapter 7 concludes this thesis with a summary of the main findings, a discussion of 
the strengths and potential limitations, and implications for clinical practice, policy 
making and future research. 
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2.1 Abstract 
The use of peritoneal dialysis (PD) varies widely from country to country, with the 
main limitation being infectious complications, particularly peritonitis, which leads to 
technique failure, hospitalization and increased mortality. A large number of 
prophylactic strategies have been employed to reduce the occurrence of peritonitis, 
including the use of oral, nasal and topical antibiotics, disinfection of the exit site, 
modification of the transfer set used in continuous ambulatory PD exchanges, changes 
to the design of the PD catheter implanted, the surgical method by which the PD 
catheter is inserted, the type and length of training given to patients, the occurrence of 
home visits by trained PD nurses, the use of antibiotic prophylaxis in patients 
undergoing certain invasive procedures and the administration of antifungal 
prophylaxis to PD patients whenever they are given an antibiotic treatment course. 
This review summarizes the existing evidence evaluating these interventions to 
prevent exit site/tunnel infections and peritonitis. 
Keywords: peritoneal dialysis, peritonitis, catheter-related infections, exit site, 
randomized controlled trial 
2.2 Introduction 
Peritoneal dialysis (PD)-related infection, including peritonitis, exit-site infection 
(ESI) and tunnel infection, is a common complication that results in considerable 
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morbidity and even death in up to 3.5-10.0% of patients [1]. Furthermore, peritonitis is 
a leading cause of patient transfer to haemodialysis [2] [3], which in turn leads to 
reduced quality of life for patients [4] and increased costs to the health system [5]. 
Peritonitis can also lead to loss of residual renal function and reduced dialysis 
adequacy, deteriorating ultrafiltration and, in some cases, encapsulating peritoneal 
sclerosis [6]. 
In this review, we discuss current evidence underpinning strategies for the prevention 
of PD- related infections, looking primarily at clinical practice guidelines, systematic 
reviews and randomised controlled trials (RCTs). Preference has been given to the 
inclusion of results from systematic reviews because explicit methods are used in their 
conduct, which aim to minimize bias and produce more reliable findings that can be 
used to inform clinical decision- making. 
The searches were conducted in MEDLINE (1946 to November, week 3, 2013) 
and EMBASE (1980 to 2013 week 50). The Cochrane Library was also searched 
for relevant systematic reviews using the term ‘peritoneal dialysis’. 
2.3 Use of prophylactic antibiotics at catheter insertion 
 
A number of randomized trials have examined whether intravenous antibiotic 
administration prior to or at the time of PD catheter insertion helps to reduce the 
infections that can occur with PD. The Cochrane systematic review by Strippoli et al 
[7] included 4 trials (355 patients) which gave various antibiotics at catheter 
placement versus none and concluded that the use of peri-operative intravenous 
antibiotic prophylaxis versus no treatment significantly decreased the risk of early 
peritonitis (relative risk [RR] 0.35, 95% CI 0.15 to 0.80) but not the risk of ESI and 
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tunnel infection (RR 0.32, 95% CI 0.02 to 4.81). The International Society for 
Peritoneal Dialysis (ISPD) guidelines published in 2011 suggests that each PD 
program should consider using vancomycin as prophylaxis at catheter placement but 
needs to carefully weigh the potential benefit against the risk of vancomycin use 
promoting the emergence of resistant organisms [8]. The UK guidelines recommend 
that antibiotic prophylaxis be used peri-operatively but do not stipulate which 
antibiotic should be used. The Kidney Health Australia – Caring for Australasians 
with Renal Impaiment (KHA-CARI) guidelines also recommend that intravenous 
antibiotic prophylaxis be used at catheter insertion and suggest that vancomycin, 
cephalosporins or gentamicin are suitable. The development of vancomycin-resistant 
enterococci and Staphylococcus aureus (including methicillin-resistant S. aureus) 
has caused alarm. Because of concerns about this development, the use of first-
generation cephalosporin is common despite it being slightly less effective than 
vancomycin.To summarize, a single dose of intravenous antibiotic given at the time 
of catheter insertion has been shown to decrease the risk of early peritonitis [9, 10] 
(Table 1). 
2.4 The role of PD catheter design 
 
The systematic review by Strippoli et al [11] assessed eight RCTs (405 patients) which 
compared the use of straight versus coiled catheters and found no significant 
difference in the risk of peritonitis (RR 1.14, 95% CI 0.73 to 1.79), peritonitis rate (RR 
0.89, 95% CI 0.63 to 
1.26), exit site/tunnel infection (RR 1.26, 95% CI 0.91 to 1.73) and exit site/tunnel 
infection rate (RR 1.04, 95% CI 0.73 to 1.47). More recently, a systematic review by 
Hagen et al [12] found no statistically significant differences between coiled and 
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straight catheters (6 studies, 454 patients) with respect to rates of exit site infection 
(risk difference [RD] 0.04, 95% CI -0.02 to 0.11; P = 0.22), peritonitis (RD 0.01, 95% 
CI -0.05 to 0.06; P = 0.83) or wound/tunnel infection (RD -0.00, 95% CI -0.04 to 0.04; 
P = 0.81). Hagen et al also assessed five studies (313 patients) that compared straight 
versus Swan neck catheters and found no statistically significant difference between 
the two regarding the risk of developing an exit site/tunnel infection (RD 0.04, 95% CI 
-0.06 to 0.15; P = 0.42) or peritonitis (RD 0.05, 95% CI -0.06 to 0.16; P = 0.34) (Table 
2). 
 
Only one RCT [13] has evaluated whether double-cuff catheters are superior to 
single-cuff catheters for the prevention of peritonitis. No significant differences were 
observed between the two groups with respect to number of peritonitis episodes (21 
versus 24, RD -0.10, 95% CI -0.35 to 0.15; P = 0.44)) or the mean interval between 
episodes (23.8 versus 21.6 months). 
 
However, the trial only included 60 patients and had limited statistical power. 
 
The latest ISPD guidelines on PD-related infections state that no particular catheter 
has been shown to be better than the standard silicone Tenckhoff catheter for the 
prevention of peritonitis [8]. The UK guidelines make a similar statement, saying that 
no particular catheter type has been proven to be better than another [9]. Overall, no 
one catheter type has been found to be associated with reduced PD-related infection 
outcomes. 
It should be emphasized that the centre variations in infection rates are greater than the 
differences seen between catheter types. For example, two large studies which audited 
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practice and peritonitis outcomes at a number of PD units, found considerable 
variation in the peritonitis rates at the different PD units [14, 15]. Both studies could 
find no single factor that could account for the different peritonitis rates seen at the 
units. 
In summary, the different catheter types are associated with similar PD-related 
infection outcomes. 
2.5 Method and location of PD catheter insertion 
Three RCTs comparing laparoscopic versus standard laparotomy PD catheter insertion 
have reported no significant difference in peritonitis rates after the initial post-surgery 
period [16][17][18]. The laparoscopic technique, however, had a lower incidence of 
early exit-site leak, fluid leakage and catheter tip migration. Moreover, a recent meta-
analysis by Hagen et al concluded that the laparoscopic insertion technique resulted in 
higher 1-year catheter survival (OR 3.93, 95% CI 1.80 to 8.57; P = 0.0006) and less 
frequent catheter migration (OR 0.21, 95% CI 0.07 to 0.63; P = 0.006), although there 
was no statistically significant difference in the occurrence of peritonitis (OR 0.83, 
95% CI 0.48 to 1.42; P = 0.49) or exit site/tunnel infection (OR 0.80, 95% CI 0.47 to 
1.37; P = 0.41) [12]. 
Another method that has been employed involves the burying of the entire PD catheter 
subcutaneously at the time of insertion, with subsequent exteriorization of the tip of 
the catheter at a later date (Moncrief-Popovich technique) [19]. A Cochrane 
systematic review found that burying the catheter did not significantly affect exit-
site/tunnel infection rates (RR 1.15, 95% CI 0.39 to 3.42) or peritonitis rates (RR 1.16, 
95% CI 0.37 to 3.60) compared with standard insertion techniques [11] 
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The technique of inserting the PD catheter in a midline versus lateral position has 
also been investigated. It was theorised that lateral insertion of the catheter might 
reduce the incidence of leakage and obstruction after insertion [20]. However, the 
Cochrane systematic review by Strippoli et al [11] found that midline versus lateral 
insertion of the PD catheter was not associated with a statistically significant 
difference for the risk of peritonitis (RR 0.65, 95% CI 0.32 to 1.33) or exit-site/tunnel 
infection (RR 0.56, 95% CI 0.12 to 2.58). 
The UK guidelines suggest that the method of PD catheter insertion should depend 
on the local expertise available at each unit [9]. While none of the different 
methods of catheter insertion have been found to be associated with a reduction in 
PD-related infection, the laparoscopic technique was associated with better 
catheter survival at 1 year and less instances of catheter migration. 
 
2.6 PD patient training 
The safe practice of PD requires that a patient be taught how to perform good hand 
hygiene while carrying out a bag exchange. The aim of this is to reduce the 
occurrence of touch contamination, which is the commonest cause of peritonitis [21] 
(Table 3). 
There are no RCTs comparing different initial training regimens for PD patients. 
There are, however, a number of prospective and retrospective observational studies 
that have looked at the features of training programs for new patients and the 
characteristics of those doing the training and have assessed these in relation to key 
patient outcomes. A non-randomized prospective multicentre study was conducted by 
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Hall et al [22] in which 620 new patients starting PD were trained on the PD technique 
and diet with an adult learning theory-based course or a conventional training 
program. Compared with the control group, the adult learning group took significantly 
longer to train (29 versus 22.6 h, P <0.0001), had comparable peritonitis rates (28.2 
versus 36.7 per 1000 patient-months, P = 0.09783) and had significantly lower ESI 
rates (0.22 versus 0.38/patient-year, P <0.004). A retrospective study conducted by 
Gadola et al over a 28-month period evaluated the practical skills of patients who 
started PD during this time, following the use of a new multidisciplinary education 
program. They found that overall peritonitis rates fell significantly (0.28 versus 
0.55/patient-year, P <0.05) [23]. 
A survey of 150 Italian PD centres found that lower peritonitis rates were associated 
with pre-dialysis education, home visits and retraining, but not with the presence of 
specialized personnel, the ratio of nurses to patients, or training time [24]. Kavanagh 
et al also found no link between the peritonitis rate and the nurse-to-patient ratio or 
the average continuous ambulatory peritoneal dialysis training time [15]. Other 
studies have reported conflicting results regarding the association between training 
time and PD-related infections [25-27]. 
It is also unclear if there is a correlation between home visits and peritonitis rates [25, 
28]. Nevertheless, home visits may highlight when retraining is necessary, with one 
study finding that 23% of the centre’s patients were not following exchange protocol 
procedures and 11% were non-compliant with the exit-site protocol procedures [29]. 
Dialysis centre size may have an effect on peritonitis rate, with one survey of 
paediatric patients reporting a rate of 1 episode/19.9 patient-months for large centres 
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and 1 episode/13.5 patient-months for small centres (P <0.05) [25]. 
In addition to patient training, the training given to the nurses teaching the patient is 
important. Although it seems counter-intuitive, one study found that the training 
nurses with ≥3 years of experience had a more than twofold increased likelihood of 
subsequent Gram- positive peritonitis in the patients they trained compared with the 
trainers with less training experience [30]. As explanation, it was suggested that more 
experienced nurses may be less familiar with the concept of using adult learning 
principles to train PD patients, nurses with more experience may be providing lower 
quality care and that nursing knowledge and skills are different to the skills needed to 
teach. It is also possible that the more experienced nurses were given the more 
challenging patients to train. There is also a study by Yang et al which found that 
when nurses with more general medicine experience (15 years) trained PD patients, 
the time to first-episode Gram-positive peritonitis was significantly better than when 
patients were trained by nurses with less experience [31]. 
The ISPD guidelines/recommendations published in 2006 [32] state that a nurse 
should provide PD training whenever possible (opinion based) and that one nurse 
should train one patient rather than one nurse train a group of patients (opinion). The 
principles of adult learning should be followed in the training sessions and a new PD 
trainer should be supervised for at least one patient training course before being 
considered an independent trainer (opinion). The fact that cognitive skills may be 
compromised in a CKD patient needs to be understood; their training will require 
much patience and repetition and a formalised program is needed. The UK guidelines 
state that education programs for CKD patients starting therapy should be 
multidisciplinary, multifaceted, tailored to individual needs and based on the 
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principles of adult learning. Different ways of delivering the education should be 
available, the information imparted should be relevant to the person and the method, 
amount and pace of the delivery should be suited to the person’s learning style, 
capacity and preferences [33]. 
Although there are no studies on the topic of retraining, the ISPD Nursing Liaison 
Committee recommends retraining after peritonitis, catheter infection, prolonged 
hospitalization, or any other disruption to PD [32]. The Committee also recommends 
periodic retraining should be performed on a regular basis for all patients. The UK 
guidelines make similar recommendations, stating that patients should be retrained at 
least annually and more often, if events such as an episode of PD-related infection or 
major interruption to the patient performing PD occurs [34]. 
To summarize, an observational study has found that patients taught according to 
adult learning theory did not experience reduced peritonitis rates compared with the 
control group, but they did experience significantly lower ESI rates. Other studies 
found that a multidisciplinary education program, pre-dialysis education and 
retraining were associated with lower peritonitis rates. It is not clear if the years of 
experience that the nurse doing the training has affects the patient outcomes, as 
different studies have yielded different conclusions. 
2.7 PD connection methods 
The standard connection system that used a ‘spike’ or a luer lock device has 
largely been replaced by the Y-set or twin-bag systems as spiking was shown 
many years ago to lead to more frequent peritonitis [8]. A systematic review has 
shown that peritonitis rates are reduced when disconnect systems (Y-set and twin 
bag systems) are used rather than conventional spike systems in PD (7 trials, 485 
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patients, RR 0.64, 95% CI 0.53 to 0.77) [35]. The use of the Y-set compared with 
the conventional spike system was associated with a significantly lower risk of 
peritonitis (7 trials, 485 patients, RR 0.64, 95% CI 0.53 to 0.77) and peritonitis rate 
(8 trials, 7417 patient-months, RR 0.49, 95% CI 0.40 to 0.61) but no difference 
was found in the incidence of exit-site/tunnel infection (3 trials, 226 patients, RR 
1.02, 95% CI 0.72 to 1.46) or rate (2 trials, 2841 patient-months, RR 1.24, 95% CI 
0.91 to 1.69). There was no significant difference in the risk of catheter removal (1 
trial, 40 patients, RR 0.33, 95% CI 0.04 to 2.94), technique failure (2 trials, 184 
patients, RR 0.45, 95% CI 0.19 to 1.05) or the risk of all-cause mortality with the 
Y-set compared with the standard spike systems (5 trials, 355 patients, RR 1.03, 
95% CI 0.48 to 2.21). 
The double-bag (twin-bag) system was developed in the 1980s and it was thought that 
this system would lead to reduced infection rates because there is one fewer 
connecting procedure [36]. There was a statistically significant difference found with 
use of the double bag system versus the standard system for the risk of peritonitis (2 
trials, 170 patients, RR 0.43, 95% CI 0.29 to 0.62) and the peritonitis rate (2 trials, 
2110 patient-months, RR 0.31, 95% CI 0.20 to 0.47). No significant difference was 
seen for technique failure (1 trial, 80 patients, RR 1.00, 95% CI 0.06 to 15.44), exit-
site/tunnel infection (1 trial, 80 patients, RR 0.75, 95% CI 0.18 to 3.14) and all-cause 
mortality (1 trial, 80 patients, RR 1.00, 95% CI 0.21 to 4.66). 
Comparison of the Y-set system with the double bag system [35] found no significant 
difference between the two for the risk of peritonitis (3 trials, 292 patients, RR 0.59, 
95% CI 0.35 to 1.01), peritonitis rate (4 trials, 4319 patient-months, RR 0.90, 95% CI 
0.49 to 1.66) and exit-site/tunnel infection rate (2 trials, 2319 patient-months, RR 
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1.04, 95% CI 0.52 to 2.06). However, the double bag system was associated with a 
trend towards fewer patients with peritonitis (RR 0.59, 95% CI 0.35 to 1.01, P = 
0.05). 
Both the UK and the ISPD guidelines recommend that flush-before-fill dialysis 
delivery systems be used because these reduce the risk of contamination [8, 34]. Use 
of the disconnect systems has been shown to be associated with a significantly 
reduced risk of peritonitis but to not alter the occurrence of exit-site/tunnel infection, 
catheter removal, technique failure and all-cause mortality [37]. There is little 
difference between the different disconnect systems in terms of PD-related infection 
outcomes. 
2.8 Exit-site care to prevent peritonitis 
One of the recognized ways for peritonitis to start is via the catheter tunnel in the 
presence of exit-site colonization and infection, most commonly with Staphylococcus 
aureus and Pseudomonas aeruginosa organisms. The cohort study by Luzar et al [38] 
looked at S. aureus nasal carriage and infection in 140 patients starting PD and found 
that nasal carriage of S. aureus was common (45%), carriers had significantly more 
ESIs than non-carriers, and that the peritonitis episodes caused by S. aureus all 
occurred in carriers. They recommended that nasal cultures be performed before 
catheter surgery to identify patients at high risk for subsequent S. aureus infection. 
Subsequent to this, a number of antibiotics were trialled with the aim of preventing 
ESI and peritonitis. An early RCT used intermittent oral rifampin, which was 
effective at reducing the catheter-related infection rate but not peritonitis, and was 
associated with patient withdrawal due to adverse effects [39]. Rifampin has not been 
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further used to eliminate nasal carriage because it can cause allergic reactions, has 
drug interactions and results in the rapid development of resistance [40]. 
The antibiotic mupirocin was first trialled in the 1990s and has excellent activity 
against Gram-positive organisms but does not affect Gram-negative organisms. A 
systematic review published in 2010 investigated whether the application of mupirocin 
(at the exit site or intranasally) was effective in the prevention of ESI and peritonitis in 
PD patients [41]. A total of 14 studies with 1233 enrolled patients and 1217 controls 
were included in the review. 
Mupirocin was associated with a significantly lower risk of ESI (0.57, 95% CI 0.46-
0.66, P <0.0001) and peritonitis (0.41, 95% CI 0.24-0.54, P <0.0001) due to all 
organisms. When only ESI and peritonitis due to S. aureus were considered, a bigger 
reduction in risk was seen for both outcomes (0.72, 95% CI 0.60-0.81, P <0.0001; 
0.70, 95% CI 0.52-0.81, P <0.00001). 
There are no published RCTs that have looked at the effectiveness of applying 
mupirocin to the catheter exit site as a routine practice. 
Gentamicin antibiotic cream can be applied topically to prevent ESI and is considered 
an alternative choice to mupirocin. The main study to support its use is a prospective 
RCT of 133 patients which compared the topical application of mupirocin cream (2%) 
or gentamicin sulphate cream (0.1%) to the exit site [42]. Application was daily and 
follow-up was for a median of 8 months per patient. Use of gentamicin was associated 
with a lower catheter infection rate (0.23/yr versus 0.54/year, P = 0.005), a longer time 
to first catheter infection (proportion without catheter infection 0.82/year versus 
0.65/year, P = 0.03) and a decrease in the peritonitis rate (0.34/year versus 0.52/year, P 
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= 0.03). The possibility of gentamicin resistance developing is potentially a major 
problem as gentamicin is used to treat PD-related peritonitis. The study by Pierce et al 
[43] found a significant increase in episodes of ESI (0.098 versus 0.153/yr, P = 0.024) 
and a decrease in gentamicin susceptibility for Enterobacteriaceae of 12% and for 
Pseudomonas of 14%, after their unit switched from routinely using mupirocin 2% 
cream to gentamicin 0.1% cream at the exit site.  
There is also the problem of the over-growth of non-susceptible organisms in response 
to routine gentamicin use. There has been a report of exit-site infection and peritonitis 
in CAPD patients which was associated with atypical mycobacteria. These patients 
were using prophylactic application of gentamicin cream at the exit site [44]. Despite 
these reports, gentamicin is still considered to be an acceptable alternative to 
mupirocin for prophylactic use at the exit site [45]. 
A potential alternative agent is medical-grade honey. Honey has long been known to 
possess antimicrobial properties and is thought to potentially be less likely to lead to 
the development of drug-resistant microorganisms compared with antibiotics. 
Medical-grade honey has been shown to be as efficacious as topical mupirocin in the 
prevention of catheter-associated sepsis in haemodialysis patients but without the 
problem of antibiotic resistance [46]. An RCT of its use in adult and paediatric PD 
patients in Australia and New Zealand has been completed, but the findings do not 
support a role for antibacterial honey in the prevention of PD-associated infections 
[47]. The intervention involved daily application of honey to the PD catheter exit site 
in one group and standard prophylactic care in the other group (application of 
mupirocin intranasally for 5 days each month for the duration of the study in S. aureus 
carriers only). 
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A multicentre RCT of mupirocin versus Polysporin Triple (P3) antibiotic ointment 
(containing bacitracin, gramicidin, and polymyxin B) randomised 201 adult PD 
patients to apply one or other of the ointments to the exit site with each dressing 
change [48]. Patients were followed for 18 months or until death or catheter removal. 
The primary study outcome was a composite endpoint of ESI, tunnel infection or 
peritonitis. The study found no difference between the two groups in the time to first 
event (13.2 months for P3, 95% CI 11.9-14.5; 14.0 months for mupirocin, 95% CI 
12.7-15.4; P = 0.41). However, a higher rate of fungal ESI was seen in patients using 
P3 (0.07 versus 0.01, P = 0.02) and there was a corresponding increase in fungal 
peritonitis (0.04 versus 0.00, P < 0.05). Consequently, the use of P3 over mupirocin as 
a prophylactic agent cannot be advocated. 
A single-centre RCT compared the antibiotic polyhexanide (solution) versus standard 
care at the exit site (saline solution and povidone-iodine) [49]. Patients were followed 
for 12 months. Thirty patients were randomised to each group but only 46 completed 
the 12-month follow- up. Both incident and prevalent patients were enrolled. The 
primary study outcome was ESI rate. The study found a significant difference between 
the ESI rate for the polyhexanide group compared with the standard care group (0.117 
per year versus 0.328 per year, P = 0.017). The authors suggest polyhexanide is 
efficient in the prevention of ESI and should be considered a prophylactic agent that 
can be routinely used at the exit site. 
The ISPD guidelines recommend that all PD patients use topical antibiotic either at 
the catheter exit site or intranasally or both [8]. The UK guidelines also recommend 
this [34]. The KHA-CARI guidelines are more specific, recommending the use of 
mupirocin ointment topically (intranasally or at the exit site) [10]. Patients who are 
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nasal carriers of S. aureus have been shown to be at increased risk for ESI and 
peritonitis [38]. Of the antibiotics/agents that have been trialled to prevent ESI, 
mupirocin has been found to be the best choice because it significantly reduces ESI 
and peritonitis without unwelcome effects such as those seen with P3. 
2.9 Prophylactic nasal antibiotic use 
A systematic review found that nasal mupirocin compared with placebo significantly 
reduced the exit-site and tunnel infection rates and the presence of S. aureus nasally 
but had no significant effect on peritonitis rates [50]. The Mupirocin Study Group ran 
a large multicentre RCT with 267 PD patients who were identified S. aureus nasal 
carriers randomized to receive intranasal mupirocin (2%) or placebo ointment [51]. 
Patients applied the nasal ointment twice daily for 5 consecutive days, every 4 weeks. 
The results did not show any significant difference between the two groups in terms of 
overall ESIs, but it did show a significant reduction in the number of episodes of ESI 
due to S. aureus in the mupirocin group. The regular use of mupirocin reduced nasal 
carriage of S. aureus to between 10 and 18%, however, the rates of tunnel infection 
and peritonitis showed no significant difference. 
The authors of the MediHoney® trial also performed a systematic review of topical 
antimicrobial prophylaxis for preventing infections in PD and found nine relevant 
trials (954 participants). They concluded that the results provide inconclusive 
evidence for nasal mupirocin, exit-site mupirocin, and exit-site gentamicin 
prophylaxis. 
Studies that looked at the use of nasal mupirocin in identified carriers yielded 
conflicting results as to whether or not ESI was reduced. Rates of tunnel infection and 
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peritonitis were unaffected. 
 
2.10 Development of antibiotic resistance to mupirocin 
There is concern that the routine use of mupirocin will lead to the emergence of 
resistant bacteria. The evidence to date suggests minimal development of resistance 
in the Mupirocin Study Group trial (nasal application), although it has been argued 
that a follow-up period of only 18 months was insufficient to adequately assess the 
development of resistance [52]. A study run over 10 years screened for nasal and 
pericatheter S. aureus colonization in PD patients and for nasal colonization in their 
dialysis partners and treated with mupirocin, if needed. The authors found 
concerning increases in high-degree mupirocin-resistant S. aureus rates (from 0% to 
12.9%) [53]. By the end of the study, nearly one-third of patients with S. aureus were 
colonized with mupirocin-resistant strains.  
Other studies have reported on the development of resistance to mupirocin when 
patients were applying the antibiotic to the exit site after cleaning. In one study, 
patients were assigned to apply either 2% mupirocin ointment or 0.1% gentamicin 
sulphate cream to the exit site after cleaning, on a daily basis [54]. The study ran for 
3 years. The mupirocin group experienced 18 Gram-positive ESIs, with 5 (27.8%) of 
these being due to S. aureus and 3 of these (16.7%) had high-level mupirocin 
resistance. The gentamicin group had 10 Gram-positive ESIs, with 3 (30%) of these 
being caused by S. aureus, and 1 (10%) of these showed resistance to gentamicin and 
1 (10%) had high-level mupirocin resistance. Furthermore, of those 13 patients in the 
mupirocin group who had a Gram-positive infection not due to S. aureus, 8 had high-
level mupirocin resistant isolates. Another study assessed the prevalence of carriage 
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of S. aureus, methicillin-resistant S. aureus and mupirocin-resistant S. aureus in 
chronic PD patients after the unit had in place for 4 years a policy of prophylactic 
application of mupirocin to the exit site in its PD patients [55]. Some patients were 
classed as intermittent mupirocin users (applying it 1-4 times per week) and others 
were classed as continuous users (applying it 5-7 times per week). Staphylococcus 
aureus was isolated from 26 of 149 (17.4%) patients and of these, 4 (15.4%) patients 
had isolates that showed high-level mupirocin resistance. The authors noted that all 4 
S. aureus carriers with mupirocin-resistant strains were applying mupirocin to the 
exit site 1 to 4 times per week. Lastly, another study determined the prevalence of S. 
aureus, methicillin-resistant S. aureus, and mupirocin-resistant S. aureus after their 
PD centre had a policy in place for 7 years re the use of mupirocin ointment at the 
exit site [56]. This centre allowed patients to use a range of prophlyactic measures 
which included application of mupirocin daily or three times per week or 
intermittently or to use mupirocin and polysporin alternately. In addition, 4 patients 
used an antibiotic other than mupirocin, 6 patients did not use any antibiotic and 1 
patient used mupirocin in the nares only. The study found that S. aureus was isolated 
from 16 of 147 (10.9%) patients and 4 of these (25%) were resistant to mupirocin 
with 3 (18.8%) having high-level resistance and 1 (6.3%) having low-level 
resistance. The authors noted that all 4 S. aureus carriers with mupirocin-resistant 
isolates were applying mupirocin to the exit site regularly (i.e. daily or 3 times per 
week). 
This development raises concerns about the ability to continue using mupirocin in the 
future to prevent S. aureus colonization in PD patients. In PD patients using 
prophylactic mupirocin, there is the potential for high-level mupirocin-resistant S. 
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aureus strains to develop and result in peritonitis due to S. aureus and treatment 
failure because of catheter loss. Antibiotic resistance is a growing problem and has 
also been seen with the development of vancomycin intermediate-susceptible S. 
aureus which shows reduced responsiveness to vancomycin, which is commonly used 
to treat methicillin-resistant S. aureus infections [57].  
2.11 Pre-procedural prophylaxis 
 
Although there are no RCTs in this area, intravenous antibiotic prophylaxis is 
recommended to prevent early peritonitis in PD patients undergoing invasive 
gastrointestinal and gynaecological procedures, such as colonoscopy with or without 
polypectomy, barium enema, laparoscopic cholecystectomy, uterine biopsy and 
hysteroscopy as these procedures have been shown to sometimes cause peritonitis in 
PD patients [8]. Peritonitis is thought to occur as a result of transient bacteremia, from 
the transmural migration of organisms from the gut into the peritoneal cavity and via 
the gynaecological tract [58]. Oral antibiotic prophylaxis 2 h before extensive dental 
work is also suggested because transient bacteremia resulting from the dental work can 
lead to peritonitis [8]. 
The UK guidelines recommend that invasive procedures are accompanied by 
antibiotic prophylaxis and emptying the abdomen of dialysis fluid for the period 
of time that the procedure takes [34]. 
2.12 Prophylaxis to prevent fungal peritonitis 
 
Fungi account for 1-15 % of PD peritonitis episodes and are associated with 
significant morbidity and mortality and high rates of permanent hemodialysis transfer 
[59]. Patients who receive prolonged or repeated antibiotics courses are at increased 
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risk of developing fungal peritonitis. A number of studies have looked at the use of 
antifungal prophylaxis but only two of these studies have been RCTs. The first of 
these by Lo et al [60] randomly allocated PD patients to treatment with oral nystatin 
tablets (500,000 units four times a day) whenever a course of antibiotics was 
prescribed or to no co-prescribed antifungal treatment (control). The proportion of 
patients who did not experience Candida peritonitis by the end of 2 years was higher 
in the group given Nystatin compared with controls (0.974 versus 0.915, P <0.05). 
This finding may be limited because the control arm had a relatively high incidence of 
Candida peritonitis [61] such that the results may not necessarily be generalizable to 
PD units with lower PD peritonitis rates (Table 4). 
A more recent RCT used oral fluconazole as the prophylactic agent and randomised 
420 patients with any PD-related infection to receive or not receive fluconazole (200 
mg every 48 h) for the period that they were receiving therapeutic antibiotics [62]. Of 
patients with bacterial peritonitis, those receiving fluconazole during all courses of 
antibiotics had significantly fewer fungal peritonitis episodes than did controls (3 
versus 15, P = 0.0051). 
The ISPD work group recommends that each PD program should look at their 
history of fungal peritonitis and decide if an antifungal with antibiotic protocol 
would be beneficial, particularly for patients taking prolonged or frequent courses 
of antibiotics [8]. The KHA- CARI guidelines state that oral antifungal prophylaxis 
should be considered when PD patients are given antibiotics to reduce their risk of 
developing fungal peritonitis [10]. 
In summary, two RCTs co-prescribed an antifungal agent to PD patients whenever 
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they were administered a course of antibiotics. The control group did not receive the 
antifungal treatment. The intervention group had significantly fewer episodes of fungal 
peritonitis than did the control group. This is a prophylactic measure that those caring 
for PD patients need to consider. 
2.13 Summary of the evidence 
 
Overall, there is a lack of RCTs for many interventions and so data from less rigorous 
study designs such as cohort studies are our current best available evidence. It also 
means that systematic reviews have few RCTs that can be included in the analysis. In 
addition, the quality of the RCTs is variable with some having small patient numbers, 
short follow-up times and an increased risk of bias because of poor or unclear 
randomization and blinding processes. In summary, the quality of the evidence is 
strong for some aspects such as the PD connection method and the use of antibiotic to 
prevent ESI but is weak for other areas such as the method for training patients. 
 
2.14 Conclusion 
 
Intravenous antibiotic administration prior to PD catheter insertion is well proven to 
prevent the occurrence of early postoperative peritonitis. The elimination of S. 
aureus nasal carriage using topical mupirocin reduces the risk of exit-site/tunnel 
infections but not peritonitis. The routine application of mupirocin at the exit site is 
recommended for all PD patients at increased risk for S. aureus infection. The daily 
use of gentamicin cream at the exit site reduces both the catheter-associated infection 
and peritonitis rates. The prescribing of oral nystatin with an antibiotic course 
reduces the development of Candida peritonitis. 
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While improvements in connection technology have reduced peritonitis rates in the 
past decade, PD-related infection remains a serious problem for PD patients. The 
disconnect systems are better than the standard spike system in terms of preventing 
peritonitis. No advantage can be found for using different catheter designs, surgical 
implantation techniques, catheter placement or automated peritoneal dialysis (APD) 
versus chronic peritoneal dialysis (CPD). Adoption of a team-based, multifaceted 
approach to continuous quality improvement with regular audit of infection rates and 
outcomes is considered essential to improving peritonitis rates. 
The training of patients is recognized as a modifiable risk factor for PD peritonitis 
and it is known that the training given to patients varies considerably between 
different centres. 
Patient training and retraining should become a major clinical and research focus for 
all units striving to improve their peritonitis rates. Future studies should specifically 
examine the roles of use of pretraining assessment tools, home-based versus centre-
based training, group versus single patient training, training programs using adult 
learning principles versus an alternative approach, and routine (pre-emptive) versus 
reactive re-training. The training of staff is also important, and active continued 
learning and retraining is required to achieve good outcomes. In addition, evidence-
based national and international guidelines exist in regard to optimal antimicrobial 
practice and PD units should review their protocols/policies to ensure that they accord 
with guideline recommendations. 
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Table 2.1: Characteristics of included studies – prophylactic use of antibiotic/antibacterial 
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Table 2.1: Characteristics of included studies – prophylactic use of antibiotic/antibacterial (continued) 
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Table 2.2: Characteristics of included studies – catheter design, method of insertion and connection method 
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Table 2.2: Characteristics of included studies – catheter design, method of insertion and connection method (continued) 
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Table 2.3:  Characteristics of included studies – patient training methods and assessment of trainers 
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Table 2.4: Characteristics of included studies – prophylactic use of antifungal 
 
 
Study 
author 
(year) 
Study 
design 
Intervention 
category 
Intervention 
(experimental 
group) 
Intervention 
(control group) 
N Duration of 
follow-up 
(months) 
Effect of 
intervention 
on ESI 
Effect of 
intervention on 
tunnel  infection 
Effect of 
intervention on 
peritonitis 
Lo et al. RCT Prophylaxis to Oral nystatin with No antifungal 397 18 (N), N/A N/A Reduced 
(1996)  prevent fungal antibiotic course treatment with  16.6 (C)   Candida 
  peritonitis  antibiotic course     peritonitis 
         episodes 4/199 
         versus 12/198 
         P < 0.05 
Restrepo RCT Prophylaxis to Oral fluconazole No antifungal 420 1–5   Reduced 
et al.  prevent fungal with antibiotic treatment with     RR: 0.20 
(2010)  peritonitis course antibiotic course     (0.06–0.68) 
         P < 0.05 
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3.1 Abstract 
Background: Existing Australasian and international guidelines outline 
antibiotic and antifungal measures to prevent the development of treatment-
related infection in peritoneal dialysis (PD) patients. Practice patterns and 
rates of PD-related infection vary widely across renal units in Australia and 
New Zealand and are known to vary significantly from guideline 
recommendations, resulting in PD technique survival rates that are lower than 
those achieved in many other countries. The aim of this study was to 
determine if there is an association between current practice and PD-related 
infection outcomes and to identify the barriers and enablers to good clinical 
practice. 
Methods: Multicentre network study involving eight PD units in Australia 
and New Zealand, with a focus on adherence to guideline recommendations 
on antimicrobial prophylaxis in PD patients. Current practice was established 
by asking the PD unit heads to respond to a short survey about 
practice/protocols/policies and a ‘process map’ was constructed following a 
face to face interview with the primary PD nurse at each unit. The perceived 
barriers/enablers to adherence to the relevant guideline recommendations were 
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obtained from the completion of ‘cause and effect’ diagrams by the 
nephrologist and PD nurse at each unit. Data on PD- related infections were 
obtained for the period 1 January to 31 December 2011. 
Results: Perceived barriers that may result in reduced adherence to guideline 
recommendations included lack of knowledge, procedural lapses, lack of a 
centralized patient database, patients with non-English speaking background, 
professional concern about antibiotic resistance, medication cost and the 
inability of nephrologists and infectious diseases staff to reach consensus on 
unit protocols. The definitions of PD-related infections used by some units 
varied from those recommended by the ISPD, particularly with exit site 
infection (ESI). Wide variations were observed in the rates of ESI (0.06 – 
0.53 episodes per patient-year) and peritonitis (0.31 – 0.86 episodes per 
patient-year). 
Conclusions: Despite the existence of strongly evidence-based guideline 
recommendations, there was wide variation in adherence to these 
recommendations between PD units which might contribute to PD-related 
infection rates, which varied widely between units. Although individual 
patient characteristics may account for some of this variability, 
inconsistencies in the processes of care to prevent infection in PD patients 
also play a role. 
KEY WORDS: Antibiotic; antifungal agents; catheters, indwelling; 
drug resistance, microbial; peritoneal dialysis; peritonitis. 
3.2 Background 
Adherence to evidence-based clinical practice guidelines is thought to 
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improve patient outcomes, particularly when there are significant variations 
in practice, excessive morbidity and/or mortality is associated with a disease 
process, when treatment has the potential to reduce this, and when the 
services involved are costly (1). Even though most healthcare workers are 
aware of the existence of evidence-based guidelines, many are unfamiliar 
with the content of these guidelines and they are not routinely adopted into 
clinical practice (2). Active implementation programs are needed to engage 
with stakeholders. It is also essential to identify areas of non-adherence to 
these guidelines and implement changes in clinical practice in accordance 
with guideline recommendations (3). 
Peritoneal dialysis is an accepted form of renal replacement therapy among 
Australians and New Zealanders with end-stage kidney disease (ESKD). More 
than 20% of all prevalent dialysis patients receive PD (4). However, PD 
technique survival in Australia and New Zealand is lower than in many other 
parts of the world, attributed to a higher incidence of peritonitis (5),(6). 
Clinical practice patterns are known to vary widely between centers in 
Australia and New Zealand and variations from clinical practice guidelines 
are known to contribute to poor infection outcomes (5). In 2008, over 30% of 
Australian and New Zealand PD units did not meet the ISPD minimum 
accepted peritonitis rate of 1 episode per 18 patient-months (0.67 episodes per 
patient-year) (5, 7-10). Peritoneal dialysis-related infections are also a key 
contributor to technique failure in PD patients in Australia and New Zealand 
with this being cited as the second and third most common cause of technique 
failure, respectively, in the 2012 ANZDATA registry report (9). 
The Kidney Health Australia - Caring for Australasians with Renal Impairment 
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(KHA-CARI) Guidelines are evidence-based clinical practice guidelines developed 
for use by healthcare workers primarily in Australia and New Zealand. The aim of 
these guidelines is to improve the health outcomes of patients with chronic kidney 
disease (CKD) by adhering to best clinical practice and improving the quality and 
cost-effectiveness of the care provided. The International Society for Peritoneal 
Dialysis (ISPD) is an international organization dedicated to the dissemination of 
education and research in the area of peritoneal dialysis (PD). Both organizations 
have developed guideline recommendations for the prevention of infections in 
patients maintained on PD (11-13). 
The KHA-CARI Guidelines PD Implementation Project commenced in 2011 
with the task of trying to improve PD outcomes through adherence to these 
established PD guidelines. The aims of this study were to accurately measure 
each participating PD unit’s performance with regard to infectious outcomes 
and to identify the barriers and enablers to adherence to best practice 
guidelines in an attempt to close the gap of continuous quality improvement 
between evidence and outcomes. 
This paper describes the baseline data obtained during the baseline phase for 
the subsequent guideline implementation project. 
3.3 Methods 
Study design 
 
The KHA-CARI Guidelines Peritoneal Dialysis Implementation Project is a 
prospective multicentre network study designed to assess the adherence to 
the KHA-CARI (published in 2004)(12) and ISPD guidelines (published in 
2011)(13) targeting the prophylactic use of antibiotics at the time of 
Tenckhoff catheter insertion, the prophylactic use of antibiotics to prevent 
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ESI, and the prophylactic use of antifungals during courses of antibiotic 
therapy [Appendix 1]. 
Participants 
 
Eight PD units took part in the study. All Australian (78) and New Zealand 
(11) renal units were invited to participate by an ‘Expression of Interest’ 
letter that was sent out via the local professional nephrology society. 
Participating units were selected based on seven selection criteria defined by 
the steering committee [Appendix 2]. 
 
Data collection 
 
A project coordinator (DC) was responsible for managing the project, for 
conducting interviews on site, and collecting information on PD-related 
infections in incident PD patients on a case report form developed for the 
study.  The interviews were semi-structured and aimed to identify key features 
of the clinical pathway that an incident PD patient with ESKD follows once 
referred to a nephrologist. A ‘process map’ was then developed for each PD 
unit. 
Data were collected using quantitative and qualitative approaches. 
Quantitative data included demographic and PD-related infection data for 
incident patients who experienced a PD- related infection during a baseline 
monitoring period. Qualitative data were collected by the project coordinator 
through face-to-face interviews with staff at each participating unit. The 
nephrologist and PD nurse from each unit attended two face-to-face meetings, 
as did the members of the project’s steering committee. At the initial meeting, 
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each PD unit was asked to outline what they thought were the barriers and 
enablers to optimal infection prevention at their unit. The units were given a 
cause-and-effect diagram to help identify barriers and enablers to good 
clinical practice (14). Data on each PD unit’s protocols, policies and usual 
practices were also collected by asking each unit to complete a survey. 
Information for each unit on PD-related peritonitis was obtained from the 
ANZDATA registry for the 12 months from 1 January 2011 to 31 December 
2011. The units were asked to provide data on ESIs for the same period. 
Currently, data on ESI are not submitted to ANZDATA. 
Study outcomes 
 
The following outcomes were assessed: 1) identification of key elements of 
current practice; 
 
2) rates of ESI and PD-related peritonitis; and 3) identification of the 
barriers and enablers relating to the guideline recommendations for the 
prevention of catheter surgery-related infection, ESI/tunnel infection and 
PD-related peritonitis. 
Statistical analysis 
 
Results are expressed as frequencies and percentages for categorical variables, 
and medians and interquartile ranges for continuous variables. Peritonitis and 
ESI rates were calculated by totalling all the peritonitis or ESI episodes that 
occurred during the entire time on PD for all patients at each unit in the 
program during the period 1 January to 31 December 2011. The total was then 
divided by the time at risk in years. This follows the suggested method for 
reporting outlined by the ISPD (13). 
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Data were analysed using the software package SAS version 9.3 (SAS 
Institute, Cary NC). 
3.4 Results 
Unit and patient characteristics 
 
Of the 10 PD units that responded, eight were selected by the steering 
committee. These units treated a total of 582 PD patients, which comprise 
28.1% of the total PD population in Australia and New Zealand (9). The 
numbers of patients receiving care in the individual units during the period 1 
January to 31 December 2011 were divided into quartiles and center size was 
categorized accordingly. Two of the units were categorized as large (>107 
patients), two were categorized as medium-large (57-107 patients), two were 
classified as small-medium (32-56 patients) and two units were classified as 
small (<32 patients). There was one Australian PD unit with an inner regional 
location; the rest were located in major cities. The two PD units that were not 
selected were based at large metropolitan hospitals. All patients in all units 
had access to the full range of renal replacement therapy as all 8 units offered 
both haemodialysis and peritoneal dialysis. Four of the 8 units were also 
transplanting centers and the models of care in Australia and New Zealand are 
hub and spoke so that all patients at all centers had access to transplantation as 
well. Peritoneal dialysis is a home-based therapy in Australia and New 
Zealand. All patients trained would be expected to be self-sufficient in the 
technique either alone or with the assistance of their spouse/carer. 
Table 1 shows the baseline demographic characteristics of patients in the 
individual units and the overall PD cohort. There were no significant 
differences between the PD units for sex, age, BMI or diabetes mellitus. There 
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were significant differences between PD units for race, numbers of patients 
per unit, duration per patient of treatment with PD and the numbers receiving 
APD or CAPD. The number of patients on APD and CAPD ranged from 26% 
to 89% and 11% to 74%, respectively. 
Current practice and organizational features 
 
There was considerable variation in nurse to patient ratios (median, 1:19, 
range 1:12 - 1:58) and the proportion of experienced surgeons to junior 
surgeons working at a unit (median, 2:0.5, range 0:1 - 5:2). The NZ unit did 
not have an experienced surgeon available to it for Tenckhoff catheter 
insertions. A majority of the PD units completed patient PD training within 
1 week (1-2 weeks) and 7 of 8 units offered home visits after 
commencement of PD. 
Prophylactic antibiotics 
 
All units had protocols in place for the administration of intravenous 
antibiotic to patients prior to catheter surgery. Seven of 8 units had protocols 
for the routine prescription of antibiotic prophylaxis against ESI and 5 of 8 
units had protocols for the routine prescription of an antifungal agent during 
courses of antibiotics. 
PD-related infection definitions 
 
We found that the definitions of the PD-related infectious outcomes were not 
consistent across the units. Three units were using peritonitis definitions that 
differed from the ISPD definition (8). Definitions of ESI and tunnel infection 
used differed from ISPD definitions in five and six units, respectively (Table 2). 
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Current ESI and peritonitis rates 
 
Figure 1 shows that the reported peritonitis rates for the selected units for the 
period 1 January to 31 December 2011, ranged from 0.31-0.86 (95% CI: 0.23-
1.39) episodes per patient-year. The reported ESI rates varied from 0.06-0.53 
(95% CI: 0.03-0.83) episodes per patient-year (Figure 2). The two large and 
the two medium-large Australian units had the best peritonitis rates and three 
of these units also had the best ESI rates. One of the small-medium size units 
and one of the small units had the worst peritonitis rates; the same two units 
and the other small size unit had the worst ESI rates. 
Of the six units that had a protocol prescribing ESI antibiotic prophylaxis, 
those that applied antibiotic to the exit site had better ESI rates than those that 
used nasal application. Of the two units that did not have such a protocol, one 
had a good ESI rate (Unit 4) while one had a poor ESI rate (Unit 3) [Table 3]. 
Of the five units that had a protocol directing that antifungal be given with any 
antibiotic course, two units had peritonitis rates close to the ISPD 
recommended standard of 0.36 episodes per patient-year. However, three units 
had peritonitis rates of 0.42 episodes per patient-year or greater. Interestingly, 
of the two units without this protocol, one unit had a good peritonitis rate 
while the other had a poor one [Table 3]. Thus, from the data there was not an 
obvious correlation between the presence of protocols and the perceived 
application of the protocols to the rates of infection. 
Perceived barriers to prophylaxis against PD-related infections 
 
Perceived organizational, medical staff and patient barriers to the use of 
antibiotic prophylaxis are summarised in Figure 3. At the time of Tenckhoff 
catheter insertion, the most common barrier reported by medical staff was the 
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nominated person forgetting to give antibiotic at surgery whereas the most 
common organization-based barrier was the lack of a centralized patient 
database so that staff could not check whether or not the antibiotic had been 
administered. Fifty per cent of the units did not have a centralized patient 
database. 
The most common barriers to ESI prophylaxis reported by medical staff was 
concern by Infectious Diseases staff that routine use of mupirocin would 
result in the development of antibiotic resistance, difficulty in gaining 
agreement on the routine use of mupirocin at the exit site at units with more 
nephrologists on staff, and insufficient staff to test and treat patients if nasal 
carriage of S. aureus was to be routinely monitored. The most common 
organization-based barrier was when the unit had a blanket policy against 
the routine use of antibiotic at the exit site. Of the various patient-based 
barriers identified, the most common was distance from the PD unit and 
when the patient’s first language was other than English. 
Perceived barriers to appropriate antifungal prophylaxis are outlined in Figure 
4. The most common medical staff-based barriers included lack of awareness 
of junior doctors or of doctors outside the hospital system of the need to co-
prescribe antifungal medication with an antibiotic course. The only 
organization-based barrier identified was the lack of a formal policy around 
the need for antifungal medication when an antibiotic course is prescribed to 
a PD patient. Of the patient-based barriers identified, the most common 
barriers were the taste of the antifungal medication, patient’s lack of 
understanding of the importance of taking the medication, and the cost of the 
medication. Only six fungal infections were reported over the study period, 
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with four of them occurring in units where antifungal prophylaxis was not 
routine. 
3.5 Discussion 
 
We found wide variation in the current practices in place at each PD unit. We 
found that clinical staff were generally aware of these clinical practice 
guideline recommendations but there was considerable variation in 
application of the recommendations in practice. All units had protocols in 
place for two of the three guideline recommendations of interest to this 
project but the variability in peritonitis and ESI rates experienced by the units 
raised questions as to how well these processes were being followed. 
We also identified a wide variation in the PD-related infection rates at the 
units. The peritonitis rates for the Australian units ranged from 0.31-0.86 
episodes per patient-year while the New Zealand unit had a rate of 0.52 
episodes per patient-year. These compare with median rates for all PD units 
in Australia in 2011 of 0.55 episodes per patient-year and a median rate of 
0.62 episodes per patient-year for all New Zealand PD units (4). Most of the 
units in this study did not meet the ISPD minimum recommended standard of 
0.36 episodes per patient-year and the rate was vastly inferior to the reported 
rate for countries such as Korea, Japan, Hong Kong and China (5). The ESI 
rates for the study units varied hugely from 0.06-0.53 episodes per patient-
year. It is not possible to compare these rates with other PD units in Australia 
and New Zealand because this information is not collected by the ANZDATA 
Registry. Other countries have reported ESI rates of 0.16 to 0.40 episodes per 
patient-year (15-18). 
Chapter 3: Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis 
patients 
57  
Several factors were identified that may explain the high rates of ESI and 
peritonitis seen at some units. Some of the selected PD units failed to adhere 
to the recommendations of the KHA-CARI and ISPD guidelines, 
particularly those on the routine use of antibiotics to prevent ESI and the 
need to co-prescribe antifungal medication when any course of antibiotics 
was given to a PD patient. Possible reasons for the non-adherence to 
guideline recommendations include the lack of policies/protocols (3 units), 
awareness of and attitudes towards the guideline recommendations (3 units), 
low (suboptimal) staff to patient ratios (2 units), lack of access to an 
experienced surgeon to do the catheter placement (1 unit), and resistance by 
Infectious Diseases staff to the routine use of mupirocin (3 units). No units 
identified the quality of the evidence underpinning the KHA-CARI 
guidelines or the ISPD guidelines as a reason for non-adherence. 
The fact that some units had protocols in place consistent with clinical 
guideline recommendations and yet appeared to have had less favourable 
outcomes in terms of infection rates and some units appeared to have better 
outcomes but no formal protocols suggests that other factors/variables are 
likely to explain these results (e.g. patient selection, definition of infection). In 
addition, although protocols consistent with the published clinical trial data 
were in place, the application or implementation of the protocols might have 
been suboptimal. Furthermore, patients entered into clinical trials are selected 
on particular criteria and may not be totally representative of the broad 
population treated in a study such as this one. 
The perceived barriers to putting into practice the guideline 
recommendations show the range of barriers that can occur across different 
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levels of health care. The perceived barriers were identified at three levels 
and included awareness of the relevant guideline recommendation and 
attitude to the guideline (healthcare providers); practical and cost 
impediments, knowledge and compliance issues (patients); and care 
processes, staffing and capacities (organization). 
The clinical uptake or implementation of guideline recommendations does not 
automatically follow the production and dissemination of clinical practice 
guidelines. Recommendations are not always put into practice and many 
patients do not receive evidence-based care (2, 19, 20). Research into 
guideline implementation has found that strategies such as interactive small 
group meetings, educational outreach visits, reminders, computerised decision 
support, introduction of computers in practice, substitution of tasks, 
multiprofessional collaboration, mass media campaigns and financial 
interventions are effective at changing practice (21). 
The use of educational materials, conferences/courses, opinion leaders, 
education, performance feedback and patient-mediated interventions were 
found to yield mixed effects in terms of practice change. Total quality 
management/continuous quality improvement strategies were found to have 
only limited effects. Most of the interventions studied had some effects on 
care improvement with an average change of about 10% for main targets (21). 
This study has a number of strengths. Firstly, current practice data and 
individual patient data on ESI for the year prior to the start of the study were 
directly collected from the units. This gave an accurate assessment of the 
pathways from catheter insertion to the development of infection. Secondly, 
the combined patients at the 8 selected PD units treated 28.1% of the total 
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population of PD patients in Australia and New Zealand and therefore 
provided a good evaluation of PD practices in our region. The selected PD 
units were of varying sizes and locations and were identified as a good 
representation of the variability seen in the two countries. These features 
may make the results potentially generalizable to other PD patient 
populations. Barriers to the successful implementation of the antibiotic and 
antifungal prophylaxis guideline recommendations were identified by 
mapping the steps in the care process and by using the National Institute of 
Clinical Studies barrier tool (22). 
This study also has some limitations. Due to resource constraints, more units 
were not able to be enrolled in the study.Secondly, the fact that the three 
process steps of interest were not directly audited was a limitation. For 
example, while the participating units were asked if they gave suitable 
antibiotics at catheter insertion, each unit was not specifically audited to 
establish if the antibiotics were reliably recorded when given and if they were 
given within an appropriate timeframe. In addition, patient-based barriers were 
reported by the healthcare professionals and not obtained directly from patient 
interviews. Furthermore, 6 of the 7 Australian PD units have a ‘major city’ 
classification according to the Australian Bureau of Statistics remote area 
index, which makes the patient population sample a mostly urban one (23). 
Lastly, participation in the study was voluntary with only 10 units offering to 
join the study. 
Implications for clinical practice 
 
The active implementation of nephrology guidelines based on appropriate 
evidence for reducing infections has the potential to improve a unit’s PD-
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associated infection rates, catheter loss and technique failure rates, as a 
consequence. Although there are some caveats around the quality of evidence 
in some areas of PD practice, the consistent use of appropriate antibiotics at 
catheter insertion should be associated with reduced occurrence of post-
surgery ESI and peritonitis. Our study does not conclusively show that 
mupirocin prevents exit site/tunnel infection and peritonitis. Although anti-
fungal prophylaxis can be beneficial, its use by individual PD units should 
depend on the background rate of fungal peritonitis and local geographical 
and patient demographic factors, as demonstrated in our study, whereby one 
of the units that had such a protocol had a higher fungal peritonitis rate than 
the three units that did not have an anti-fungal protocol in place. 
Implications for clinical research 
 
Further research is needed to determine which prophylactic strategies 
involving the application of antibacterial creams or solutions are most 
effective in preventing catheter ESI. Our results suggest that the units that 
used nasal mupirocin prophylaxis generally had higher ESI and peritonitis 
rates than those that used exit-site mupirocin prophylaxis. It has previously 
been noted that there have been no direct head-to head comparison studies of 
intranasal mupirocin against either exit-site mupirocin or exit-site gentamicin 
(6). In addition, the unit with the best infection rates did not use antibiotic at 
all but used daily application of povidone-iodine at the exit site. 
As the barriers to adherence to clinical practice guidelines vary from 
individual to individual and from unit to unit, the results of a barrier analysis in 
one setting may not be generalizable to another. Research into the barriers to 
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guideline adherence at a unit will benefit from being conducted locally and any 
implementation plan to improve adherence will need to address the identified 
factors. 
In conclusion, this study has identified several factors that may contribute to 
the high rates of ESI and peritonitis that occur in Australia and New Zealand 
compared with accepted international standards. Nearly all of these factors are 
potentially modifiable through improved education, creation of a centralized 
patient database, and routine checking of patient exit site care and exchange 
technique. The findings of this study will provide the first step in improving 
PD outcomes by having identified a number of perceived barriers and enablers 
to good antibiotic and antifungal practice in PD patients. Having an 
understanding of the barriers to good clinical practice that exist within each 
organisation can inform the development of a targeted implementation strategy 
aimed at improving PD-related infection outcomes (3). 
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Table 3.1: Demographic characteristics and dialysis details of PD patients at the eight participating units 
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Table 3.2: The PD-related infection definitions in use at each PD unit 
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Table 3.3: Comparison of the exit site and peritonitis rates with unit protocols (January to December 2011) 
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Figure 3.1: Peritonitis rates by unit (January to December 2011)  
 
 
 
 
 
 
 
 
Figure 3.2: ESI rates by unit (January to December 2011) 
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Figure 3.3: Perceived barriers to appropriate antibiotic prophylaxis in PD patients  
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Perceived barriers to appropriate antifungal prophylaxis in PD 
patients 
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Chapter 4: Antimicrobial agents for preventing peritonitis 
in peritoneal dialysis patients 
 
4.1 Abstract 
 
Background 
Peritoneal dialysis (PD) is an important therapy for patients with end-stage 
kidney disease (ESKD) and is used in more than 200,000 such patients 
globally (Jain 2012). However, its value is often limited by the 
development of infections such as peritonitis and exit-site and tunnel 
infections (Morton 2011). Multiple strategies have been developed to 
reduce the risk of peritonitis including antibiotics, topical disinfectants to 
the exit site and antifungal agents. However, the effectiveness of these 
strategies has been variable and are based on a small number of 
randomised controlled trials (RCTs). The optimal preventive strategies to 
reduce the occurrence of peritonitis remain unclear. 
This is an update of a Cochrane review first published in 2004. 
 
Objectives 
To evaluate the effectiveness of antimicrobial agents designed to prevent 
peritonitis in PD patients. 
 
Search methods 
We searched the Cochrane Kidney and Transplant Specialised Register to 5 
May 2015 through contact with the Trial Search Co-ordinator using search 
terms relevant to this review. 
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Selection criteria 
Randomised controlled trials (RCTs) or quasi-RCTs in patients receiving 
chronic peritoneal dialysis, which evaluated any antimicrobial agents used 
systemically or locally to prevent peritonitis or exit-site/tunnel infection 
were included. 
Data collection and analysis 
 
Two reviewers independently assessed risk of bias and extracted data. Results 
were expressed as risk ratio (RR) with 95% confidence intervals (CI). 
 
Main results 
 
Thirty-nine trials, enrolling 4374, patients met our inclusion criteria. Twenty 
more trials (2183 patients) were included than in the original review of 2004. 
The risk of bias domains were often unclear or high with low risk of bias 
reported in 19 (49%) studies for sequence generation, in 22 (56%) studies for 
incomplete outcome reporting, in 18 (46%) studies for selective outcome 
reporting and in 12 (31%) studies for allocation concealment. Blinding of 
participants and personnel was considered low risk in 8 (21%) and blinding 
of outcome assessors was also low risk in 10 (26%) studies but it should be 
noted that blinding of participants and personnel was not possible in many of 
the studies because of the nature of the intervention or control treatment. 
The use of oral or topical antibiotic compared with placebo/no treatment may 
reduce the risk of exit site/tunnel infection (3 trials, 191 patients, low quality 
evidence, RR 0.45, 95% CI 0.19 to 1.04) and may slightly reduce the risk of 
peritonitis (5 trials, 395 patients, low quality evidence, RR 0.82, 95% CI 0.57 
to 1.19). 
It is uncertain whether the use of nasal antibiotic compared with placebo 
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reduces the risk of exit-site/tunnel infection (3 trials, 338 patients, low 
quality evidence, RR 1.34, 95% CI 0.62 to 2.87) or the risk of peritonitis (3 
trials, 338 patients, low quality evidence, RR 0.94, 95% CI 0.67 to 1.31). 
Pre/perioperative intravenous vancomycin compared with no treatment 
appears to reduce the risk of early peritonitis (1 trial, 177 patients, low 
quality evidence, RR 0.08, 95% CI 0.01 to 0.61) but has uncertain effects 
on the risk of exit-site/tunnel infection (1 trial, 177 patients, low quality 
evidence, RR 0.36, 95% CI 0.10 to 1.32). 
The use of topical disinfectant compared with standard care or other active 
treatment (antibiotic or other disinfectant) may lead to little or no 
difference in the risk of exit- site/tunnel infection (8 trials, 973 patients, 
low quality evidence, RR 1.00, 95% CI 0.75 to 1.33) but may slightly 
reduce the risk of peritonitis (6 trials, 853 patients, low quality evidence, 
RR 0.83, 95% CI 0.65 to 1.06). 
Antifungal prophylaxis with oral nystatin/fluconazole compared with 
placebo/no treatment appears to reduce the risk of fungal peritonitis 
occurring after a patient has had an antibiotic course (2 trials, 817 patients, 
low quality evidence, RR 0.28, 95% CI 0.12 to 0.63). 
No intervention reduced the risk of catheter removal or replacement. 
 
Authors' conclusions 
 
In this 2015 update, we identified limited data from RCTs and quasi-RCTs 
which evaluated strategies to prevent peritonitis and exit-site/tunnel 
infections. This review demonstrates that pre/peri-operative intravenous 
vancomycin appears to reduce the risk of early peritonitis and that antifungal 
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prophylaxis with oral nystatin or fluconazole appears to reduce the risk of 
fungal peritonitis following an antibiotic course. However, no other 
antimicrobial interventions have proven efficacy. Given the large number of 
patients on PD and the importance of peritonitis, the lack of adequately 
powered and high quality RCTs to inform decision making about strategies 
to prevent peritonitis is striking. 
4.2 Plain language summary 
People with kidney failure may be treated with peritoneal dialysis where a 
catheter is permanently inserted into the peritoneum (lining around abdominal 
contents) through the abdominal wall and sterile fluid is drained in and out a 
few times each day. The most common serious complication is infection of the 
peritoneum, which is called peritonitis. This may be caused by bacteria 
accidentally being transferred from the catheter. This review found that 
antibiotics given when a peritoneal dialysis catheter is implanted appear to 
reduce the risk of early peritonitis but not of exit-site/tunnel infection. 
Antifungal prophylaxis with oral nystatin or fluconazole appears to reduce the 
risk of fungal peritonitis following an antibiotic course. The available studies 
are of low quality evidence and consequently, it is uncertain if there is any 
benefit from using nasal mupirocin or topical disinfectants or other 
interventions to reduce exit-site/tunnel infection or peritonitis. More large 
scale trials are needed. 
4.3 Background 
Peritoneal dialysis (PD) is one of the renal replacement therapies available to 
people with end-stage kidney disease. There is considerable variation in its 
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use from country to country, with the proportion of total dialysis patients on 
PD in developed countries ranging from 3.3% (Japan), to 7.0% (United 
States), 8.3% (Greece), 17.0 % (United Kingdom), 36.3% (New Zealand), and 
up to 79.4% (Hong Kong) (Jain 2012). Because PD and haemodialysis have 
similar outcomes and patients feel that PD, compared with HD, allows them to 
live life more fully (Morton 2011), PD should be used more frequently than it 
is but the risk of peritonitis may prevent this from occurring (Heaf 2004; 
Piraino 1998). 
 
 
Description of the condition 
Peritonitis due to various organisms (e.g. Staphylococcus aureus, 
Pseudomonas aeruginosa, coagulase-negative staphylococci) is a leading 
complication of PD resulting in technique failure (Woodrow 1997), 
hospitalisation (Choi 2004; Churchill 1997), peritoneal membrane failure, 
switching to haemodialysis (Jaar 2009; Piraino 1989) and increased mortality 
(Annigeri 2001; Digenis 1990; Fried 1996; Piraino 2000). There has been a 
dramatic reduction in the rates of peritonitis from the start of continuous 
ambulatory PD (CAPD), but rates above the minimum acceptable peritonitis 
rate recommended by the International Society of Peritoneal Dialysis of 1 
episode every 33 months (0.36 episodes/year at risk) are still common 
(Piraino 2011). 
Risk factors for peritonitis include older age (Nessim 2009; Oxton 1994; 
Salusky 1997), depression (Troidle 2003), coexisting diseases such as diabetes 
(Chow 2005; Ghali 2011) and cardiovascular disease (McDonald 2004; Nolph 
1987), obesity (McDonald 2004), connection methodology (Daly 2001), 
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presence of a peritoneal catheter exit-site infection (Lloyd 2013; van Diepen 
2012), and the presence of nasal carriage of S.aureus (Golper 1996; Mupirocin 
SG 1996; Perez-Fontan 1993; Schaefer 2003). Race is also an independent risk 
factor, with African-American, native Canadian and indigenous Australian 
Aborigines on PD being shown to be at increased risk (Farias 1994; Fine 1994; 
Golper 1996; Holley 1993; Lim 2005). 
 
 
Description of the intervention 
Different antimicrobial interventions are used at PD catheter insertion 
and on an ongoing basis to prevent peritonitis. These include 
intravenous antibiotics, oral antibiotics, topical antibiotics (Thodis 
2000), topical disinfectants, prophylactic treatment of S. aureus nasal 
carriage primarily with intranasal antibiotic ointment (Piraino 2002), 
different exit-site dressing systems and antifungal prophylaxis. All of 
these strategies, particularly the use of antibiotic at catheter insertion 
and the cleansing and disinfection of the exit-site, are widely accepted, 
but practice patterns are variable and it is not clear which practices have 
most benefit (Piraino 2011; Van Biesen 2014). Studies on preventing 
PD-related infections are limited in number and quality (Piraino 2011). 
International guidelines differ in their recommendations on preventing 
PD-related infections, with some countries not having relevant 
guidelines (Table 2). 
None of these interventions are free of risks or without cost. Antibiotic 
prophylaxis carries the risk of gastrointestinal toxicity and may be a cause of 
antibiotic resistance (Annigeri 2001; Bernardini 1996); it may also be 
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ineffective when patients already have resistance to some antibiotics. Care 
should be taken that any disinfectant used is at a concentration that is non-
cytotoxic (Piraino 2011). 
 
How the intervention might work 
For a patient to be able to successfully use PD as a dialysis therapy, PD-
related infections (exit-site infections, tunnel infections and peritonitis) need to 
be avoided. The most important infection is peritonitis and a number of 
prophylactic strategies have been employed to limit its occurrence. Bacteria 
are known to be able to gain entry to the peritoneum in a variety of ways and 
hence, various strategies have been used to prevent this occurring (Campbell 
2015). 
Oral or topical or intraperitoneal antibiotics: Oral antibiotics such as rifampin 
have been given as prophylaxis to PD patients to reduce catheter infections 
and peritonitis due to S. aureus (Bernardini 1996; Zimmerman 1991). This 
organism is a major cause of PD catheter infections which can result in S. 
aureus peritonitis and catheter removal. S.aureus nasal carriage is known to 
be a significant risk factor for S. aureus PD-related infections (Bernardini 
1996). Cyclic oral rifampin is superior to placebo in preventing S. aureus 
infections. Other oral antibiotics used include ofloxacin (Sesso 1994), 
cephalexin (Low 1980), and trimethoprim/sulphamethoxazole (Churchill 
1988). 
Topical antibiotics such as mupirocin have been applied to the exit site once 
daily because this antibiotic has good activity against gram-positive 
organisms such as staphylococci and streptococci, which are a common 
cause of exit-site infection and peritonitis in PD patients (Keane 2000; 
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Troidle 1998; Ward 1986). However, mupirocin is less active against most 
gram-negative bacilli and anaerobes (Sutherland 1985). Sodium fusidate 
ointment (2%) has also been applied to the exit site at one-month intervals and 
is known to have activity against staphylococci (Sesso 1994). Gentamicin 
cream is active against both gram-positive and gram-negative organisms and 
has been used long term on a once-daily basis at the exit site as prophylaxis for 
exit-site infection (Bernardini 2005; Chu 2008). Gentamicin is active against 
both S. aureus and Pseudomonas aeruginosa, two important causes of 
exit-site infection (Bernardini 2005). Polysporin triple ointment (P3) 
consists of bacitracin/gramicidin/polymyxin and has bacteriostatic activity 
against a wide range of skin flora and other organisms including gram-negative 
bacteria (MP3 Study 2008). 
Nasal antibiotic prophylaxis: Various antibiotic treatments have been trialled 
in attempts to eliminate S. aureus nasal carriage in PD patients. The nasal 
carriage of S. aureus is a well- recognised risk factor for the development of S. 
aureus infections in CAPD patients (Davies 1989; Luzar 1990; Piraino 1990). 
Neomycin sulphate ointment has been used prophylactically. Mupirocin has 
also been used to eliminate nasal S. aureus. While mupirocin is effective at 
reducing S. aureus nasal carriage rates, re-colonisation frequently occurs. 
Sodium fusidate ointment (2%) has also been used and is effective at reducing 
S. aureus nasal carriage rates (Sesso 1994). 
Pre/peri-operative intravenous antibiotic prophylaxis: The administration of 
intravenous antibiotics at catheter insertion has been found to reduce the risk 
of peritonitis within the first month following PD catheter placement. 
Although the insertion of a PD catheter involves "clean surgery involving the 
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placement of a prosthesis or implant", there is the potential for contamination 
of the peritoneum with microorganisms from the patient's own body during 
surgery. Hence, the giving of a single dose of antibiotic prophylaxis 
intravenously on starting anaesthesia is recommended (Collier 2008). 
Topical disinfectants of the exit site: Topical disinfectants have been applied 
to the exit site for many years, in an attempt to reduce the bacterial load 
around the exit site. It has been shown that PD patients with a history of an 
exit-site infection have twice the risk of experiencing a peritonitis episode 
(Canadian CAPD Clinical Trials Group 1989) so it is important to keep the 
exit site infection-free. Povidone iodine ointment is a broad spectrum 
antiseptic ointment that has been used and has minimal adverse events 
associated with its use (Waite 1997). Povidone iodine solution (20g/L) has 
also been used and shown to successfully reduce the number of exit-site 
infections (Luzar 1990). Other antiseptic agents such as  hydrogen peroxide, 
sodium hypochlorite and chlorhexidine have been used (Piraino 2011). 
 
The daily use of antibacterial honey at the exit site was trialled in the 
HONEYPOT study. This agent was used because it does not induce 
antimicrobial resistance and has been shown to be active against a broad 
range of bacteria and fungi (Cho 2014). 
Dressing systems for exit sites: A number of exit-site dressing systems have 
been devised, all with the aim of reducing exit-site/tunnel infection and any 
subsequent peritonitis. The agents used include topical disinfectants and 
different dressing types and require more or less frequent removal. More 
frequent removal is seen to risk damaging the skin around the exit site and less 
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frequent removal is felt to possibly encourage the growth of anaerobes. The 
concentration of topical disinfectants used need to be at non-cytotoxic levels. 
Silver ring system on catheter: The addition of a silver ring device mounted 
onto the PD catheter was trialled by German researchers in the 1990s 
(SIPROCE 1997). The silver ring was used because of the antimicrobial 
properties of silver. The use of silver-coated catheters in animals had shown 
a reduction in infectious events (Dasgupta 1994; Fung 1996) and offered a 
non-pharmaceutical approach to reducing PD catheter-related infections. 
 
Antistaphylococcal vaccine: An antistaphylococcal vaccine was trialled in the 
1990s for the purpose of immunising patients with an anti-staphylococcal 
agent. The expectation was that the vaccine would promote a significant 
increase in the dialysate level of specific antibodies against S. aureus and that 
this would lead to reduced peritonitis and exit-site/tunnel infection rates 
(Poole-Warren 1991). 
Antifungal agents: Antifungal prophylaxis to prevent fungal peritonitis 
when a PD patient receives an antibiotic course is based on the fact that 
most episodes of fungal peritonitis are preceded by courses of antibiotics 
(Piraino 2011). Patients receiving prolonged or repeated antibiotic courses 
are at increased risk of fungal peritonitis, mostly due to Candida spp. Trials 
that have given patients antifungal agents during antibiotic courses have 
shown fewer fungal peritonitis episodes arose (Lo 1996; Restrepo 2010). 
 
Why it is important to do this review 
The aim of this update was to include any new studies of antimicrobial 
interventions designed to prevent peritonitis in PD patients that have been 
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published since the original review was published in 2004. We also aim to 
provide a critical appraisal of the current available evidence. As peritonitis is a 
significant problem for patients using PD, frequently leading to morbidity and 
technique failure and sometimes to mortality, we have updated the review. 
4.4 Objectives 
To evaluate the benefits and harms of antimicrobial strategies used to 
prevent peritonitis in PD patients. 
4.5 Methods 
Criteria for considering studies for this review 
 
 
Types of studies 
We included randomised controlled trials (RCTs) and quasi-RCTs (studies in 
which allocation to treatment was obtained by alternation, use of alternate 
medical records, date of birth or other predictable methods) in which 
antimicrobial interventions designed to prevent peritonitis were compared in 
patients on PD. 
 
Types of participants 
We included adult and paediatric patients with ESKD who were undergoing 
PD treatment. 
Types of interventions 
We included studies involving the use of any antimicrobial agent, whether 
the interventions were tested between themselves (head-to-head) or against 
placebo/no treatment. The inclusion criteria have been expanded in this 
update, with the intervention "oral antibiotics" becoming "oral or topical or 
intraperitoneal antibiotics" and with the interventions "dressing systems for 
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exit sites" and "silver ring system on catheter" being added. 
Specifically, the following antimicrobial interventions were analysed: 
 
 
 Oral or topical or intraperitoneal antibiotics 
 
 Nasal antibiotic prophylaxis (mupirocin, rifampicin, other) 
 
 Pre/peri-operative intravenous antibiotic prophylaxis 
 
 Topical disinfectants of the exit-site (povidone-iodine, 
chlorhexidine, triclosan, soap and water, other) 
 Germicidal systems for connection devices 
 
 Dressing systems for exit sites 
 
 Silver ring system on catheter 
 
 Antistaphylococcal vaccine 
 
 Antifungal agents 
 
 
Types of outcome measures 
 
 Peritonitis-number of patients with peritonitis and peritonitis rate 
(peritonitis defined as dialysate count of > 100 cells/mm³ with > 50% 
being polymorphonuclear leukocytes; peritonitis rate defined as 
number of episodes of peritonitis over total patient months on PD) 
 Peritonitis relapse (reoccurrence of peritonitis due to the same 
organism within 2-4 weeks) 
 Death due to peritonitis 
 
 All-cause mortality 
 
 Exit-site and tunnel infection-number of patients with exit-site and 
tunnel infections and exit-site and tunnel infection rate 
 Catheter removal/catheter replacement 
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 Technique failure (transfer from PD to haemodialysis/transplant due to 
peritonitis) 
 
 Toxicity of antimicrobial treatments (nasal irritation, sneezing, 
generalised pruritus, headache, diarrhoea, nausea, vomiting, 
jaundice, local irritation, rash) 
 Time to first peritonitis episode 
 
 
Primary outcomes 
 
 Peritonitis 
 
 Exit-site infection/tunnel infection 
 
 Catheter removal/catheter replacement 
 
 
Secondary outcomes 
 
 Peritonitis relapse 
 
 Death due to peritonitis 
 
 All-cause mortality 
 
 Technique failure 
 
 Toxicity of antimicrobial treatments 
 
 Time to first peritonitis episode 
 
Search methods for identification of studies 
 
Electronic searches 
We searched the Cochrane Kidney and Transplant Specialised Register 
to 5 May 2015 through contact with the Trials' Search Co-ordinator 
using search terms relevant to this review. 
The Cochrane Kidney and Transplant Specialised Register contains studies 
identified from: 
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1. Monthly searches of the Cochrane Central Register of Controlled Trials 
CENTRAL; 
 
2. Weekly searches of MEDLINE OVID SP; 
 
3. Handsearching of renal-related journals & the proceedings of major renal 
conferences; 
 
4. Searching of the current year of EMBASE OVID SP; 
 
5. Weekly current awareness alerts for selected renal journals; 
 
6. Searches of the International Clinical Trials Register 
(ICTRP) Search Portal & ClinicalTrials.gov 
 
Studies contained in the Specialised Register are identified through search strategies 
for CENTRAL, MEDLINE, EMBASE based on the scope of Cochrane Kidney and 
Transplant. Details of these strategies as well as a list of handsearched journals, 
conference proceedings and current awareness alerts are available in the 'Specialised 
Register' section of information about Cochrane Kidney and Transplant.  
See Appendix 1 for search terms used in strategies for this review. 
 
 
Searching other resources 
 
 Reference lists of nephrology textbooks, review articles and relevant studies. 
 
 Letters to investigators seeking information about unpublished or incomplete 
studies. 
 
Data collection and analysis 
 
Selection of studies 
The search strategy described was used to obtain titles and abstracts of 
studies that were potentially relevant to the review. The titles and abstracts 
were screened independently by DC and GFMS, who discarded studies that 
were not applicable. However, studies and reviews that might include 
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relevant data or information on studies were retained initially. Two authors 
independently assessed retrieved abstracts and where necessary, the full text 
of these studies, to determine which satisfied the inclusion criteria. 
 
Data extraction and management 
Data extraction and assessment of the risk of bias were performed 
independently by the same authors using standardised data extraction forms. 
Studies reported in non-English language journals were translated before 
assessment. Where more than one publication of one study existed, only the 
publication with the most complete data was included. Where relevant 
outcomes were only published in earlier versions, these data were used. Any 
discrepancy between published versions was highlighted. Any further 
information required from the original author was requested by written 
correspondence and any relevant information obtained in this manner was 
included in the review. 
 
 
Assessment of risk of bias in included studies 
The following items were assessed using the risk of bias assessment tool 
(Higgins 2008) (see Appendix 2): 
 
 Was there adequate sequence generation? 
 
 Was allocation adequately concealed? 
 
 Was knowledge of the allocated interventions adequately prevented during the 
study? 
 
 Were incomplete outcome data adequately addressed? 
 
 Are reports of the study free of suggestion of selective outcome reporting? 
 Was the study apparently free of other problems that could put it at a risk of bias? 
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Measures of treatment effect 
For dichotomous outcomes (peritonitis - number, peritonitis - rate, death due to 
peritonitis, all-cause mortality, exit-site/tunnel infection - number, exit-site/tunnel 
infection - rate, catheter removal/replacement, technique failure, toxicity of 
antimicrobial treatments) results were expressed as risk ratios (RR) with 95% 
confidence intervals (CI). No continuous outcomes were identified. 
 
Unit of analysis issues 
Where data on the number of subjects with events (e.g. number of subjects 
with one or more episodes of peritonitis) were available, the RR was 
calculated as the ratio of the incidence of the event (one or more episodes) in 
the experimental treatment group over the incidence in the control group. 
Where data on the number of episodes were available the RR was calculated 
as the ratio of the rate of the outcome (e.g. the peritonitis rate) in the 
experimental treatment group (given by number of episodes of the outcome 
over total patient months on PD) over the rate in the control group. 
 
 
Dealing with missing data 
Where necessary, we contacted trialists to request missing patient data due to 
loss to follow- up and exclusion from study analyses in an effort to conduct 
intention-to-treat analyses. With the update, four authors responded to our 
requests. Where missing dichotomous data were few, and unlikely to affect 
the overall results, we analysed available data. 
 
 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
87  
 
Assessment of heterogeneity 
Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, 
with an alpha of 0.05 used for statistical significance and with the I² test 
(Higgins 2003). I² values of 25%, 50% and 75% correspond to low, medium 
and high levels of heterogeneity. 
Assessment of reporting biases 
The search strategy included searching major databases, conference 
proceedings and prospective trial registers without language restriction in an 
attempt to reduce publication bias related to failure of authors to publish 
negative results or inability to publish negative results in journals indexed in 
major databases. Insufficient studies were available to assess for publication 
bias using funnel plots. Where multiple publications of the same study were 
identified, data were included from the most recent publication, and 
preferably, the definitive publication. However, all publications were 
reviewed to identify outcomes not reported in the index publication in an 
attempt to reduce outcome reporting bias. 
 
Data synthesis 
Data were pooled using the random-effects model for dichotomous data. 
 
Subgroup analysis and investigation of heterogeneity 
Subgroup analysis was planned to explore potential sources of variability 
in observed treatment effect where possible (paediatric versus adult 
population, diabetic versus non- diabetic, time on PD before beginning of 
antimicrobial treatment). However, no subgroup analyses were performed 
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due to lack of available data from the included studies. 
 
Sensitivity analysis 
Sensitivity analysis was planned to investigate the effect of year of study and 
study performance. However, there were insufficient studies to do this. 
Summarising and interpreting results 
 
We used the GRADE approach to assess the quality of evidence for each of 
the key outcomes (Schunemann 2009). We used the GRADE profiler to 
import data from Review Manager 5.3 and create 'Summary of Findings' 
tables. 
 
For assessments of the overall quality of evidence for each outcome that 
included pooled data from RCTs, we downgraded the evidence from 'high 
quality' by one level for serious study limitations and by two levels for very 
serious study limitations. The evidence was appraised using the five GRADE 
considerations: risk of bias, imprecision of effect estimates, inconsistency, 
indirectness and potential publication bias. None were upgraded to moderate 
or high quality as most pooled estimates did not reveal a large magnitude of 
effect, there was potential for impact by confounders, and most did not show 
a strong dose-response gradient. The exception was the pooled estmate 
obtained for the comparison of the use of an antifungal agent versus 
placebo/no treatment for preventing fungal peritonitis, but the evidence was 
not upgraded from 'low' because only two studies contributed data for the 
outcome of fungal peritonitis and one of the studies had a high risk of bias. 
We used these assessments and the evidence for absolute benefit or harm of 
the interventions and the sum of available data on all important outcomes 
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from each study included for each comparison, to arrive at conclusions about 
the effectiveness of antimicrobial agents at preventing catheter-related 
infection or the need for catheter removal/replacement in PD patients. 
'Summary of Findings' tables consisted of the following clinically important 
outcomes identified in the selected trials: Peritonitis (number of patients with 
one or more episodes); Exit-site/tunnel infection (number of patients with one 
or more episodes); Catheter removal or replacement (number of patients); 
Fungal peritonitis (number of patients with one or more episodes). 
4.6 Results 
Description of studies 
See: Characteristics of included studies; Characteristics of excluded studies. 
 
 
Results of the search 
Search results are shown in Figure 1, Figure 2. Following full text review of 
the 57 potentially eligible reports, 22 studies (28 reports) were excluded and 
20 studies (29 reports) were identified as eligible for inclusion. Therefore, 20 
studies (29 reports) were added in this update; the original review had 19 
studies (23 reports). 
Included studies 
We included 39 studies in the review, 19 of which had been included in the 
original review. Of the 20 additional studies, 11 had been published since 
the search was done for the previous review and ten (Axelrod 1973; Cheng 
1999a; Cocksedge 1993; Fuchs 1990; Moore 1989; Ryckelynck 1987; 
Sharma 1971; SIPROCE 1997; Wadhwa 1995; Wadhwa 1997) had not been 
identified in previous searches. There was one four-arm trial (Swartz 1991), 
three three-arm trials (Fuchs 1990; Gadallah 2000; Sesso 1994), and the 
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remaining studies were two-arm trials. No cross over studies were 
identified. 
 
Of the 39 studies included, all (4374 participants) were parallel group studies. 
All participants were chronic PD patients treated in centre or in satellite 
facilities. Two studies (Axelrod 1973; Sharma 1971) reported the number of 
dialyses but not the number of patients in each group and hence, the data from 
these studies could not be added to the meta-analyses. Most studies included 
only adult patients; two studies (Blowey 1994; Mendoza-Guevara 2007) 
included only children and young adults on PD. Twenty-six studies 
(Bernardini 2005; Bernardini 1996; Chu 2008; Cocksedge 1993; Fuchs 
1990; Gadallah 2000; HONEYPOT Trial 2009; Lo 1996; Luzar 1990; Lye 
1992; MP3 Study 2008; Mupirocin SG 1996; Nolph 1985; Nunez-Moral 
2014; Perez-Fontan 1992; Poole-Warren 1991; Restrepo 2010; Sesso 1994; 
SIPROCE 1997; Swartz 1991; Wadhwa 1995; Wadhwa 1997; Waite 1997; 
Wikdahl 1997; Wong 2003; Zimmerman 1991) identified the proportion of 
patients who had diabetes mellitus. 
 
Most studies reported only some of the primary outcomes of interest to this 
review. The primary outcomes reported in the studies were as follows: 
peritonitis - number of patients (22 studies), peritonitis rate (14 studies), exit-
site/tunnel infection - number of patients (22 studies), exit-site/tunnel 
infection - rate (12 studies) and catheter removal/replacement (15 studies). 
Other outcomes reported included death due to peritonitis (2 studies), all-
cause mortality (13 studies), technique failure (3 studies) and toxicity of 
antimicrobial treatments (5 studies). No studies had data on peritonitis relapse 
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and only two had time to first peritonitis episode (HONEYPOT Trial 2009; 
MP3 Study 2008). 
Funnel plots to examine for publication bias were not done because there 
were insufficient studies. 
 
Oral or topical antibiotics versus placebo/no treatment 
In 7 trials (469 participants), patients were randomised to oral, or topical 
(exit site, nasal) or intraperitoneal prophylactic antibiotics versus placebo/no 
treatment (Blowey 1994; Churchill 1988; Low 1980; Sesso 1994; Swartz 
1991; Wong 2003; Zimmerman 1991). The duration of  follow-up ranged 
from 1 to 12 months. 
Oral or topical antibiotics versus other antibiotic 
Seven trials (640 participants) randomised patients to oral, or topical (exit 
site, nasal) or intraperitoneal antibiotics versus other antibiotics (Bernardini 
1996; Bernardini 2005; Chu 2008; Danguilan 2003; MP3 Study 2008; 
Perez-Fontan 1992; Sesso 1994) with follow-up ranging from 7.8 to 18 
months. 
Nasal antibiotic prophylaxis versus placebo/no treatment 
Three trials (338 participants) compared the use of nasal prophylactic 
antibiotics with placebo (Mupirocin SG 1996; Sesso 1994; Sit 2007). The 
duration of follow-up ranged from 7.8 to 18 months. 
Pre/peri-operative antibiotic prophylaxis versus placebo/no treatment or 
other antibiotic 
One trial (178 participants) assessed the use of vancomycin with cefazolin as 
perioperative intravenous prophylaxis head to head (Gadallah 2000) and four 
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trials (379 patients) compared the use of perioperative intravenous antibiotic 
prophylaxis against no antibiotic treatment (Bennet-Jones 1988; Gadallah 2000; 
Lye 1992; Wikdahl 1997). Follow-up periods ranged from 10 to 28 days. 
Topical disinfectants versus standard care or other active treatment 
(antibiotic or other disinfectant) 
Nine trials (1039 participants) evaluated the effect of topical disinfectants 
versus standard care or other intervention at the exit site on a range of 
outcomes (Cheng 1999a; HONEYPOT Trial 2009; Luzar 1990; Mendoza-
Guevara 2007; Nunez-Moral 2014; Wadhwa 1995;Wadhwa 1997; Waite 
1997; Wilson 1997). The duration of follow-up ranged from 6 to 24 months. 
Other interventions 
Other interventions included one trial (167 participants) which compared 
the use of an ultraviolet germicidal chamber to disinfect the spike and the 
solution bag outlet port versus no treatment (Nolph 1985) while another 
trial (50 participants) directed one group to soak their connectors in 
antiseptic before performing a bag exchange while the control group did 
not use antiseptic (Ryckelynck 1987). Three trials (140 participants) 
compared different dressing systems (Cocksedge 1993; Fuchs 1990; Moore 
1989) and one trial (195 participants) compared the addition of a silver ring 
device on the catheter versus no ring (SIPROCE 1997). 
One trial (124 participants) compared the antistaphylococcal vaccine 
Staphypan Berna against placebo (Poole-Warren 1991). 
 
Antifungal prophylaxis versus placebo/no treatment interventions 
Two trials (817 participants) compared the administration of an antifungal 
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agent with an antibiotic course against no treatment (Lo 1996; Restrepo 
2010). Follow-up periods ranged from 1 to 18 months. 
With the update, four trial authors responded to queries about study methods 
and/or requests for additional unpublished information (Ayliffe 1984; Chu 
2008; Danguilan 2003; HONEYPOT Trial 2009). 
Excluded studies 
Twenty-two studies (28 reports) were excluded after full text review. The 
characteristics of the excluded studies are shown in "Characteristics of 
excluded studies". Reasons for excluding studies included having a non-
randomised study design, focus of study was about treatment of PD-related 
infection not prevention, report was of a pharmacokinetics study, agent used 
in intervention was not an antimicrobial, and PD-related infection data was 
not readily available in the published report. 
 
Risk of bias in included studies 
The assessment of risk of bias is shown in Figure 3 and Figure 4. Figure 3 
shows relative proportional rankings of studies for each risk of bias 
indicator. Figure 4 shows the risk of bias items for individual studies. 
 
Allocation (selection bias) 
Randomisation of sequence generation was reported adequately in 19 
studies (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; Churchill 
1988; HONEYPOT Trial 2009; Low 1980; Luzar 1990; Mendoza-Guevara 
2007; MP3 Study 2008; Nolph 1985; Nunez-Moral 2014; Perez-Fontan 
1992; Restrepo 2010; SIPROCE 1997; Sit 2007; Swartz 1991; Waite 1997; 
Wilson 1997; Zimmerman 1991). Randomisation method was unclear in 15 
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studies and was not reported in 13 studies. Twelve studies reported 
allocation concealment adequately (Axelrod 1973; Bennet-Jones 1988; 
Bernardini 2005; Churchill 1988; HONEYPOT Trial 2009; Low 1980; 
Luzar 1990; MP3 Study 2008; Nolph 1985; Poole-Warren 1991; Sharma 
1971; SIPROCE 1997) and six studies did not report it adequately (Chu 
2008; Gadallah 2000; Lo 1996; Lye 1992; Moore 1989; Wikdahl 1997). 
Allocation concealment was unclear in 21 studies. 
 
Blinding (performance bias and detection bias) 
Only eight studies (Axelrod 1973; Bennet-Jones 1988; Bernardini 2005; 
Churchill 1988; Low 1980; MP3 Study 2008; Poole-Warren 1991; Sharma 
1971) reported methods of blinding for participants, investigators and 
outcome assessors. Blinding of participants was used in 9/38 (23.7%) 
trials, blinding of investigators in 9/38 (23.7%) trials, and outcome 
assessors were blinded in 9/38 (23.7%) trials. 
 
Incomplete outcome data (attrition bias) 
Outcomes data reporting was considered to be complete with a low risk of 
bias in 22 studies (Bennet-Jones 1988; Bernardini 1996; Bernardini 2005; 
Blowey 1994; Churchill 1988; Fuchs 1990; Gadallah 2000; Lo 1996; Low 
1980; Luzar 1990; Lye 1992; MP3 Study 2008; Mupirocin SG 1996; 
Nunez-Moral 2014; Perez-Fontan 1992; Poole-Warren 1991; Sit 2007; 
Swartz 1991; Waite 1997; Wikdahl 1997; Wilson 1997; Wong 2003). Eight 
studies (Axelrod 1973; Chu 2008; Danguilan 2003; HONEYPOT Trial 
2009; Nolph 1985; Sesso 1994; SIPROCE 1997; Zimmerman 1991) 
reported that from 9.2% to 77.7% of patients were excluded from analyses, 
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so were considered to be at high risk of bias. The risk of bias was unclear in 
9 studies because there was insufficient information provided to determine 
if data from all patients who entered the study were included in the analysis. 
 
Selective reporting (reporting bias) 
We identified 19 studies (Bernardini 1996; Bernardini 2005; Chu 2008; 
HONEYPOT Trial 2009; Luzar 1990; Lye 1992; MP3 Study 2008; 
Mupirocin SG 1996; Nunez-Moral 2014; Poole-Warren 1991; Sesso 1994; 
SIPROCE 1997; Swartz 1991; Wadhwa 1995; Wadhwa 1997; Wikdahl 
1997; Wilson 1997; Wong 2003; Zimmerman 1991) that were considered to 
have reported all outcomes based on the protocols described in the trial 
methods. Two studies (Axelrod 1973; Sharma 1971) reported outcomes 
incompletely so they could not be meta- analysed. It was unclear if outcomes 
were selectively reported in 11 studies because there was insufficient 
information provided to determine if data from all patients who entered the 
study were included in the analysis. 
Other potential sources of bias 
Nine studies (Axelrod 1973; Churchill 1988; HONEYPOT Trial 2009; 
Mupirocin SG 1996; Nolph 1985; Poole-Warren 1991; SIPROCE 1997; 
Waite 1997; Zimmerman 1991) reported receiving monetary support 
from pharmaceutical companies and 25 studies did not report study 
funding. 
 
Effects of interventions 
See: Summary of findings 1 Oral or topical or intraperitoneal antibiotics 
versus placebo/no treatment for preventing peritonitis in peritoneal dialysis 
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patients; Summary of findings 2 Nasal antibiotics versus no treatment for 
preventing peritonitis in peritoneal dialysis patients; Summary of findings 3 
Topical disinfectants versus standard care or other active treatment 
(antibiotic or other disinfectant) for preventing peritonitis in peritoneal 
dialysis patients; Summary of findings 4 Antifungal versus placebo/no 
treatment for preventing fungal peritonitis in peritoneal dialysis patients. 
In most studies, the primary outcomes were peritonitis (number of patients), 
peritonitis rate, exit site/tunnel infection (number of patients), exit site/tunnel 
infection rate, and catheter removal or replacement (number). Many studies 
only included one or two of these outcomes. Other outcomes included all-
cause mortality, time to first catheter-related infection, hospitalisation, death 
due to catheter-related infection, technique failure, local pruritus/rash and 
toxicity. 
Effect on PD catheter-related infections, catheter removal/replacement and 
all-cause mortality of oral or topical antibiotics compared with placebo/no 
treatment 
The oral antibiotic used was either ofloxacin, cephalexin, rifampin or 
cotrimoxazole and the topical antibiotic used was mupirocin ointment (exit 
site, nasal). There was no significant difference between oral or topical 
antibiotic prophylaxis and placebo/no treatment for the risk of peritonitis 
(Analysis 1.1.1 (4 trials, 241 patients): RR 0.87, 95% CI 0.58 to 1.32; 
Analysis 1.1.2 (1 trial, 154 patients): RR 0.55, 95% CI 0.22 to 1.40). There 
was low to moderate heterogeneity across these trials (I² = 33%). The risk 
of peritonitis outcome was assessed as low quality because of unclear or 
high risk of bias in 3 of 5 studies and because of wide confidence intervals 
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in all 5 studies due to small patient numbers. 
There was also no significant difference between the two interventions for 
the peritonitis rate (Analysis 1.2.1 (3 trials, 1440 patient-months): RR 0.68, 
95% CI 0.40 to 1.14), the risk of exit-site and tunnel infection (Analysis 
1.3.1 (3 trials, 191 patients): RR 0.45, 95% CI 0.19 to 1.04), the exit-
site/tunnel infection rate (Analysis 1.4.1 (2 trials, 939 patient-months): RR 
0.42, 95% CI 0.17 to 1.05), risk of catheter removal or replacement 
(Analysis 1.5.1 (5 trials, 395 patients): RR 0.82, 95% CI 0.46 to 1.46) and 
all-cause mortality (Analysis 1.6.1 (4 trials, 201 patients): RR 0.88, 95% CI 
0.41 to 1.89), with no significant heterogeneity across trials for any of these 
analyses (I2 = 0%). The risk of exit-site/tunnel infection outcome was 
assessed as low quality because of unclear or high risk of bias in all 3 studies 
and because of wide confidence intervals in all 3 studies due to small patient 
numbers. The risk of catheter removal/replacement outcome was also 
assessed as low quality because of unclear or high risk of bias in 3 of 5 
studies and because of wide confidence intervals in all 5 studies due to small 
patient numbers. 
 
Effect on PD catheter-related infections of oral or topical antibiotics 
compared with other antibiotic 
The use of antibiotic ointment prophylaxis (either sodium fusidate [exit site 
plus nasal] or mupirocin [exit site]) was compared with another antibiotic 
(either oral ofloxacin, oral rifampin or gentamicin cream [exit site]) in four 
trials. There was no significant difference between the interventions for the 
risk of peritonitis (Analysis 2.1 (4 trials, 314 patients): RR 1.28, 95% CI 
0.89 to 1.84). There was low heterogeneity across these trials (I² = 9%). 
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Similarly, there was no significant difference between topical antibiotic 
prophylaxis (either mupirocin ointment [exit site], sodium fusidate ointment 
[exit site plus nasal] or mupirocin cream [exit site]) compared with other 
antibiotic (either sodium fusidate ointment [exit site], oral ofloxacin or 
gentamicin cream [exit site]) for the risk of exit-site and tunnel infection 
(Analysis 2.3 (4 trials, 336 patients): RR 1.28, 95% CI 0.71 to 2.31). There 
was medium heterogeneity across these trials (I² = 56%). 
 
Effect on PD catheter-related infections and catheter removal/replacement of 
nasal antibiotic prophylaxis compared with placebo/no treatment 
There were no significant differences between nasal antibiotic prophylaxis 
and placebo/no treatment for the risk of peritonitis (Analysis 3.1 (3 trials, 
338 patients): RR 0.94, 95% CI 0.67 to 1.31), the peritonitis rate (Analysis 
3.2 (2 trials, 2797 patient-months): RR 0.67, 95% CI 0.16 to 2.77), the risk 
of exit-site and tunnel infection (Analysis 3.3 (3 trials, 338 patients): RR 
1.34, 95% CI 0.62 to 2.87), the exit-site and tunnel infection rate (Analysis 
3.4 (2 trials, 2796 patient-months): RR 0.91, 95% CI 0.29 to 2.92), and the 
number of patients with catheter removal or replacement (Analysis 3.5 (2 
trials, 289 patients): RR 0.92, 95% CI 0.48 to 1.78). There was no 
significant heterogeneity across the trials for any of these analyses. 
Although in one trial, there was a significant reduction in the exit-
site/tunnel infection rate when CAPD patients identified as S. aureus 
carriers (nasal) were treated with mupirocin ointment (nasal application, 
2/day for 5 days, every 1 month), there were no significant differences 
with any of the other primary outcomes of interest (Mupirocin SG 1996). 
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The risk of peritonitis and the risk of exit-site/tunnel infection outcomes were 
assessed as low quality because of unclear or high risk of bias in all 3 studies 
and because of wide confidence intervals in all 3 studies due to small patient 
numbers. The risk of catheter removal/replacement outcome was assessed as 
low quality because of unclear to high risk of bias in the 2 studies and 
because of wide confidence intervals in the 2 studies due to small patient 
numbers. 
 
Effect on early peritonitis and early exit-site infection of pre/peri-operative 
antibiotic prophylaxis compared with placebo/no treatment or other antibiotic 
Pre/peri-operative intravenous antibiotic prophylaxis compared with no treatment 
significantly reduced the risk of early peritonitis (less than one month from 
catheter insertion) in one study (Gadallah 2000) but there was no significant 
difference between the interventions in three other studies using different 
antibiotics (Analysis 4.1 (4 trials, 379 patients). The single 3-arm study (Gadallah 
2000) compared vancomycin with placebo, cefazolin with placebo and 
vancomycin with cefazolin and found the risk of peritonitis was significantly 
reduced by vancomycin compared with placebo (RR 0.08. 95% CI 0.01 to 0.61) 
and by vancomycin compared with cefazolin (RR 0.11, 95% CI 0.01 to 0.84); 
there was no significant difference between cefazolin compared with placebo. 
None of the antibiotic interventions made a significant difference to the risk of 
exit-site and tunnel infection (Analysis 4.2 (4 trials, 379 patients). When outcomes 
at more than one month after catheter insertion were considered, there was no 
significant difference between the interventions for the risk of peritonitis or exit-
site/tunnel infection. Because each trial used a different antibiotic intervention, it 
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is not possible to comment on heterogeneity across the trials. 
 
Effect on PD catheter-related infections, catheter removal/replacement and 
all-cause mortality of topical disinfectants compared with standard care or 
other active treatment (antibiotic or other disinfectant) 
Eight studies reported on the use of disinfectant at the exit site versus 
standard care or other active treatment. There was no significant difference 
between topical disinfection of the exit- site with povidone iodine ointment 
or solution or dry power spray compared with no treatment or soap and 
water on the risk of peritonitis (Analysis 5.1.1 (3 trials, 393 patients): RR 
0.81, 95% CI 0.52 to 1.26), exit-site/tunnel infection (Analysis 5.2.1 (4 
trials, 453 patients): RR 0.74, 95% CI 0.45 to 1.20), catheter removal or 
replacement (Analysis 5.4.1 (2 trials, 266 patients): RR 0.73, 95% CI 0.34 to 
1.55), or all-cause mortality (Analysis 5.5.1 (2 trials, 266 patients): RR 1.24, 
95% CI 0.54 to 2.84), with no significant heterogeneity across trials for any 
of these analyses. 
Topical disinfection of the exit-site with sodium hypochlorite solution 10% or 
sodium hypochlorite solution 5% or antibacterial honey was compared with 
standard care or standard care plus mupirocin ointment treatment nasally 
(only in S. aureus nasal carriers). There was no significant difference between 
the interventions for the risk of peritonitis (Analysis 5.1.2 (3 trials, 460 
patients): RR 0.84, 95% CI 0.62 to 1.13), exit-site/tunnel infection (Analysis 
5.2.2 (3 trials, 460 patients): RR 1.15, 95% CI 0.85 to 1.56), catheter removal 
or replacement (Analysis 5.4.2 (4 trials, 526 patients): RR 0.98, 95% CI 0.57 
to 1.69), or all-cause mortality (Analysis 5.5.2 (1 trial, 371 patients): RR 0.77, 
95% CI 0.40 to 1.51). There was low heterogeneity across trials for outcomes 
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with data from more than one trial. 
 
The risk of peritonitis outcome was assessed as low quality because of 
unclear allocation concealment and blinding in 4 of 6 studies and imprecision 
due to the small number of patients and events in 5 of 6 studies. The risk of 
exit-site/tunnel infection outcome was assessed as low quality because of 
unclear allocation concealment and blinding in 6 of 8 studies and imprecision 
due to the small number of patients and events in 7 of 8 studies. The risk of 
catheter removal/replacement outcome was assessed as low quality because 
of unclear allocation concealment and blinding in 5 of 7 studies and 
imprecision due to the small number of patients and events in 6 of 7 studies. 
 
Effect on PD-catheter-related infections and catheter 
removal/replacement of other interventions 
Seven studies reported on other interventions designed to reduce PD-related 
infections. There was no significant difference in the peritonitis rate with 
other interventions including: 
 use of a germicidal chamber for connection devices or soaking of the 
connector in antiseptic prior to bag exchange versus none (Analysis 6.1 
(2 trials, 1855 patient-months): RR 1.05,95% CI 0.74 to 1.51) 
 
 use of the Staphypan Berna antistaphylococcal vaccine (Analysis 9.1 (1 trial, 1099 
patient- months): RR 1.11, 95% CI 0.77 to 1.59). Staphypan Berna compared with 
placebo was also shown to make no significant difference to the exit-site and tunnel 
infection rate (Analysis 9.2 (1 trial, 1107 patient-months): RR 0.98, 95% CI 0.65 to 1.48). 
 
There was no significant difference between use of a silver ring on the PD 
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catheter versus none for the risk of peritonitis (Analysis 8.1 (1 trial, 195 
patients): RR 0.90, 95% CI 0.49 to 1.66), risk of exit-site/tunnel infection 
(Analysis 8.2 (1 trial, 195 patients): RR 1.26, 95% CI 0.84 to 1.90) or risk 
of catheter removal/replacement (Analysis 8.3 (1 trial, 195 patients): RR 
1.26, 95% CI 0.35 to 4.56). 
 
Three studies reported on the use of different dressing systems. There was 
no significant difference between the comparisons for the number of patients 
with one or more episodes of exit-site/tunnel infection (Analysis 7.1 (3 
trials, 140 patients) or the exit-site/tunnel infection rate (Analysis 7.2 (1 
trial, 679 patient-months). 
 
 
Effect on fungal peritonitis of antifungal prophylaxis compared with 
placebo/no treatment interventions 
The use of antifungal agents (oral fluconazole or oral nystatin) compared 
with no antifungal agent being given when a patient receives a course of 
antibiotics for bacterial peritonitis were reported in 2 studies. The antifungal 
intervention showed a significant reduction in the risk of fungal peritonitis 
(Analysis 10.1 (2 trials, 817 patients): RR 0.28, 95% CI 0.12 to 0.63). There 
was low heterogeneity across the two trials for this analysis. The risk of 
fungal peritonitis outcome was assessed as low quality because of unclear 
risk of bias in 1 study and high risk of bias in 1 study and imprecision due to 
the small number of events and patient numbers. 
One trial of oral nystatin in PD patients who were receiving treatment for 
bacterial peritonitis showed a significant reduction in the rate of fungal 
peritonitis due to Candida spp. with nystatin prophylaxis (Analysis 10.2 (1 
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trial, 6864 patient-months): RR 0.31, 95% CI 0.10 to 0.95). 
 
Adverse effects 
For the comparisons which included oral or topical antibiotics versus placebo/no 
treatment, two studies provided some information on adverse effects of therapy. 
They were reported in relation to the use of oral rifampin and sodium fusidate 
ointment (nasal and exit site). More patients reported adverse effects with oral 
rifampin therapy but the results did not achieve significance. Heterogeneity could 
not be determined (Analysis 1.8; 2 studies, 86 patients). 
For the studies which included oral or topical antibiotics versus other 
antibiotic, three studies reported on adverse effects of therapy. The 
antibiotics used were applied daily/routinely to the exit site and included 
Polysporin triple ointment, gentamicin cream and cyclic oral rifampin 
against mupirocin ointment or cream. There were fewer patients who 
reported adverse effects with mupirocin but the result was not significantly 
different. There was low heterogeneity of results (Analysis 2.8; 3 studies, 
419 patients: RR 0.54, 95% CI 0.21 to 1.39; I² = 40%). 
 
Three studies compared nasal antibiotics against placebo/no treatment and 
two of them reported information on adverse effects of therapy. The 
antibiotics used included mupirocin ointment (nasal) and sodium fusidate 
ointment (nasal and exit site) versus placebo ointment (nasal) or placebo 
tablets. More patients reported adverse effects with the antibiotic treatments 
but the results did not achieve significance. Heterogeneity could not be 
determined (Analysis 3.7; 2 studies, 289 patients). 
For the studies which included topical disinfectant versus standard care or 
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other active treatment at the exit site, four studies reported on adverse 
effects of therapy. The interventions that these reports related to were 
sodium hypochlorite solution, antibacterial honey and povidone iodine dry 
powder spray against povidone iodine solution, mupirocin ointment 
(nasal) or alcohol wipes. More patients reported adverse effects with use 
of the former agents and a statistically significant increase in pruritus 
occurred with topical disinfectants versus standard care. There was low 
heterogeneity of results (Analysis 5.7; 4 studies, 609 patients: RR 2.80, 
95% CI 1.21 to 6.48; I² = 44%). Antibiotic resistance was not adequately 
reported in the included studies (Table 3). 
 
 
Outcomes sought but not reported 
Very few studies reported on peritonitis relapse, development of antibiotic 
resistance (topical use), hospitalisation due to PD-related infections or 
peritonitis, time to first peritonitis episode, technique failure (transfer from 
PD to haemodialysis/transplant due to peritonitis), or death due to peritonitis. 
4.7 Discussion 
Summary of main results 
We identified 39 studies that compared antimicrobial agents with placebo/no 
treatment or other antimicrobial agent or standard care in CKD patients on 
PD. A range of antimicrobial agents were found and studies using antibiotic 
prophylaxis showed wide variability regarding the dose and duration of the 
interventions trialled. The duration of studies ranged from 1 month to 8 years. 
The quality of the evidence for all of the findings listed below was low. 
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Key findings are as follows: 
 
 
 The use of oral or topical antibiotic may reduce the risk of exit-
site/tunnel infection and may slightly reduce the risk of peritonitis.  
 It is uncertain whether the topical administration of antibiotic 
ointment to the anterior nares of PD patients (sodium fusidate or 
mupirocin ointment) reduces the risk of exit- site/tunnel infection or 
the risk of peritonitis. 
 Pre/peri-operative intravenous vancomycin appears to reduce the risk 
of early peritonitis in the first few weeks (< 1 month) following 
Tenckhoff catheter insertion but has an uncertain effect on the risk of 
exit-site/tunnel infection.The comparisons using other antibiotics (i.e. 
IV gentamicin; IV cefazolin plus gentamicin; IV cefuroxime plus 
cefuroxime intraperitoneal) did not reduce the risk of peritonitis or exit 
site/tunnel infection. 
 The use of topical disinfectant may lead to little or no difference 
in the risk of exit- site/tunnel infection but may slightly reduce 
the risk of peritonitis. 
 Oral antifungal prophylaxis (fluconazole or nystatin) with each 
antibiotic course given to a PD patient appears to reduce the risk of 
fungal peritonitis. 
 No intervention reduced the risk of catheter removal or replacement. 
 
 
None of the following interventions (oral or topical antibiotics versus 
placebo/no treatment; oral or topical antibiotics versus other antibiotic; nasal 
antibiotics versus placebo/no treatment; pre-peri-operative prophylaxis 
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versus placebo/no treatment or other antibiotic; topical disinfectants versus 
standard care or other active treatment; germicidal chamber versus none; 
silver ring system on catheter versus none) made a significant difference to 
mortality (all-cause). Neither of the following interventions (oral or topical 
antibiotics versus other antibiotic; topical disinfectants versus standard care 
or other active treatment) made a significant difference to the risk of 
technique failure. 
Heterogeneity among the studies was low except for the interventions 'oral or 
topical antibiotics versus placebo/no treatment' and 'oral or topical antibiotics 
versus other antibiotic'. 
Heterogeneity in the former comparison for the risk of peritonitis was 33% 
and was likely related to the variety of antibiotics used, the frequency of 
administration (daily, monthly, every 3 months), the route of administration 
(oral, topical) and the population studied (adults in Brazil, Canada, USA, 
Hong Kong). Heterogeneity in the latter comparison for the risk of exit-
site/tunnel infection was 56% and was probably related to the range of 
antibiotics used, the frequency of administration (twice daily, daily, every 2 
days, weekly), the route of administration (oral, topical) and the population 
studied (adults in the Philippines, Brazil, Hong Kong, USA). 
 
Overall completeness and applicability of evidence 
Ten studies reported on all three primary outcomes of interest (peritonitis, 
exit-site/tunnel infection, catheter removal/replacement); 16 studies 
reported on two primary outcomes of interest; 11 studies reported on one 
primary outcome of interest and two studies reported on primary outcomes 
in a way that was not usable (Axelrod 1973; Sharma 1971). Our meta- 
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analyses identified that use of oral or topical antibiotics may reduce the risk 
of exit-site/tunnel infection and the risk of peritonitis but did not appear to 
affect the exit-site/tunnel infection rate, the peritonitis rate or the risk of 
catheter removal/replacement. It is unclear if the use of nasal mupirocin in 
identified nasal carriers of S. aureus reduces the risk of exit-site/tunnel 
infection or peritonitis.The use of pre/peri-operative intravenous antibiotic 
at PD catheter insertion reduces the occurrence of early peritonitis (within 1 
month of insertion) with vancomycin being the most effective antibiotic to 
use. The use of topical disinfectant appears to lead to little or no difference 
in the risk of exit-site/tunnel infection but may slightly reduce the risk of 
peritonitis. The co-administration of antifungal agents with an antibiotic 
course appears to reduce the risk of fungal peritonitis developing in a PD 
patient. 
No RCT was found which had the comparison of routine courses of 
intranasal mupirocin versus daily exit-site mupirocin. Likewise, no RCT was 
found which compared S. aureus nasal carriage eradication at the time of PD 
catheter insertion versus no eradication of S. aureus nasal carriage. In 
addition, some outcomes were either not addressed (development of 
antibiotic resistance with topical use) or not often addressed (peritonitis 
relapse, hospitalisation rates due to PD-related infections or peritonitis, 
technique failure due to peritonitis). It should also be mentioned that for most 
comparisons there are only a few studies and small numbers of patients. 
 
Quality of the evidence 
Our review included 39 studies that involved 4374 participants, of whom all 
were either on peritoneal dialysis (CAPD, CCPD or APD) or were having 
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surgery to insert the Tenckhoff catheter prior to commencing peritoneal 
dialysis. Two studies had paediatric populations, two studies had a mix of 
adults and children, with the remainder having only adult participants. 
We found the quality of evidence for all outcomes to be of low quality mainly 
due to unclear or high risk of bias in a majority of studies and imprecise 
results because of small patient numbers and events. This means that further 
research is likely to have an important impact on our confidence in the 
estimates of effect and is likely to change those estimates. 
Of the 39 included studies, four were available only as abstracts; 18 reported 
adequate sequence generation, and 12 had adequate allocation concealment. 
Hence, allocation concealment was either unclear or inadequate in two-thirds 
of the studies. Studies that do not have adequate allocation concealment are 
felt to be at increased risk of bias (Moher 1998; Schulz 1995). Eight studies 
reported adequate blinding of participants and personnel, and 10 studies 
reported adequate blinding of outcome assessment. Therefore, blinding 
methodology was either unclear or inadequate in three-quarters of the 
studies. We found that 21 studies provided complete data reporting, and 10 
reported all primary outcomes. Nine of the included studies reported 
receiving some form of sponsorship from pharmaceutical companies, 6 
studies reported funding from an institute or government organisation and 25 
studies did not report any funding source. In this review, we did not observe 
a difference between studies that were sponsored by pharmaceutical 
companies and those that were not. Of the nine pharma-sponsored studies, 
six had adequate allocation concealment; of the six studies with partial or 
full funding from an institute/government organisation, five reported 
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adequate allocation concealment; and of the 25 studies that did not report a 
funding source, only three demonstrated adequate allocation concealment. 
Likewise, in terms of selective outcome reporting, five of the nine pharma-
sponsored studies reported expected outcomes; four of the six institute/ 
government-sponsored studies reported expected outcomes; and 10 of the 25 
studies without a declared funding source included all expected primary 
outcomes. 
For the comparison of oral or topical antibiotics versus placebo/no 
treatment, the variable quality of relevant studies and the small patient 
numbers, meant the quality of evidence was rated as low for the outcomes 
of peritonitis, exit-site/tunnel infection and catheter removal/replacement 
(Summary of findings table 1). For the comparison of nasal antibiotics 
versus placebo/no treatment, the variable quality of relevant studies and the 
small patient numbers, reduced the quality of evidence to low for the 
outcomes of peritonitis, exit- site/tunnel infection and catheter 
removal/replacement (Summary of findings table 2). With the comparison 
of topical disinfectants versus standard care or other active treatment, the 
unclear allocation in several studies and imprecision due to small patient 
numbers and events in several studies, meant the quality of evidence was 
rated as low for the outcomes of peritonitis, exit-site/tunnel infection and 
catheter removal/replacement (Summary of findings table 3). With the 
comparison of antifungal prophylaxis versus placebo/no treatment, the 
quality of evidence for the outcome of fungal peritonitis was considered to 
be low because of high risk of bias in one study and modest patient numbers 
and the limited number of studies reporting this outcome (Summary of 
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findings table 4). 
 
Potential biases in the review process 
Four of the included studies were available only as abstracts (4/38) but this 
was not considered a major source of bias. Since the original version of this 
review was published, the literature search has been run several times (up to 
April 2015), to increase the chance that all eligible studies published before 
that time have been included. Although the Cochrane Kidney and Transplant 
Specialised Register includes references of reports of studies identified by 
handsearching resources including conference proceedings, it is a possibility 
that relevant studies may have been added since our last search of the register. 
Some outcomes were reported in only a few studies, which increased the risk 
of the non- randomised selection of patients for the intervention or control 
group in a study. For example, the outcome of fungal peritonitis was reported 
in two studies (817 patients), with one study finding a significant difference 
between the fungal prophylaxis and control groups, while the second study 
did not have this finding. In addition, adverse effects were reported in only 
five studies. 
 
Agreements and disagreements with other studies or reviews 
A systematic review was performed as part of the HONEYPOT trial 
published in 2014. The authors systematically reviewed trials of topical 
antimicrobial prophylaxis for prevention of infections in peritoneal 
dialysis. Nine trials were identified using a search strategy that 
included electronic searches of Medline (through Ovid) and the 
Cochrane Central Register of Controlled Trials (Johnson 2014). Our 
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review included all of the studies included by Johnson 2014, as well as 
two studies not reported in that review (Chu 2008; Danguilan 2003). 
The 2014 review concluded that the evidence from the nine trials was 
inconclusive for nasal mupirocin, exit-site mupirocin and exit-site 
gentamicin prophylaxis. In the present review, we reached a similar 
conclusion, with some individual studies making a significant 
difference to the risk of exit-site/tunnel infection or the exit-site/tunnel 
infection rate but not having an effect on the other outcomes of 
peritonitis, catheter removal/replacement and technique failure. 
The Renal Association (UK) guidelines currently recommend that "topical 
antibiotic administration be used to reduce the frequency of S.aureus and 
Gram-negative exit-site infection and peritonitis" (Woodrow 2010). The 
suggested antibiotics are mupirocin ointment or gentamicin cream (the latter 
for patients with a known history of Pseudomonas infections). The 
International Society for Peritoneal Dialysis (ISPD) position statement on 
exit-site care to prevent peritonitis (Piraino 2011) states that "antibiotic 
protocols against S. aureus are effective in reducing the risk of S. aureus 
catheter infections" and that "all PD patients should use topical antibiotic 
either at the catheter exit-site or intranasally or both". The Kidney Health 
Australia-Caring for Australasians with Renal Impairment guidelines (Walker 
2014) recommend that "prophylactic therapy using mupirocin ointment be 
used, especially for S. aureus carriage (intranasally or at the exit site) to 
decrease the risk of S. aureus catheter exit site/tunnel infections and 
peritonitis" and suggest that the "PD catheter exit site be cleaned daily and a 
topical antimicrobial agent (either mupirocin or gentamicin) be applied". This 
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review found that the use of oral antibiotic or mupirocin ointment (at the exit 
site) may reduce the risk of exit-site/tunnel infection and the risk of 
peritonitis but was not seen to reduce the exit-site/tunnel infection rate, the 
peritonitis rate or the number of patients with catheter removal/replacement. 
The head to head comparison of application of mupirocin ointment or cream 
against gentamicin cream is based on two trials and shows that there is no 
significant difference between the effectiveness of mupirocin and gentamicin 
in terms of preventing exit-site/tunnel infection and peritonitis. It is unclear if 
the nasal application of mupirocin reduces the risk of exit-site/tunnel 
infection or the risk of peritonitis. 
The Renal Association (UK) guidelines state it is "recommended that 
initial catheter insertion be accompanied by antibiotic prophylaxis" and 
refer to the RCT evidence supporting the use of vancomycin (Wilkie 2010; 
Woodrow 2010). The ISPD position statement says that "prophylactic 
antibiotics administered at the time of insertion decrease the infection risk. 
A first-generation cephalosporin or vancomycin can be used, but suggested 
each program should weigh the potential benefit against the risk of 
vancomycin use (development of resistant organisms)" (Piraino 2011). The 
KHA-CARI guidelines say it is "recommended that intravenous antibiotic 
prophylaxis be used prior to peritoneal dialysis catheter insertion to reduce 
the risk of early peritonitis" and "vancomycin, cephalosporins and 
gentamicin have demonstrated effectiveness in reducing the risk of 
peritonitis" (Walker 2014). The inclusion of first generation cephalosporins 
is based on extrapolations from the results of pre-operative antibiotic trials 
in patients without chronic kidney disease. However, our study indicates 
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that the evidence supporting the use of first generation cephalosporins in 
PD patients undergoing Tenckhoff catheter insertion is scant. In the present 
review, we identified four RCTs of different pre-operative antibiotic 
prophylaxis regimens, including parenteral gentamicin, vancomycin, 
cephazolin and cefuroxime, with only two evaluating a first generation 
cephalosporin. One small trial involving 50 PD patients found that 
cephazolin and gentamicin were no better than no treatment (Lye 1992). 
The largest of the trials (265 patients) showed that cephazolin was inferior 
to vancomycin in preventing post-operative catheter-associated infections 
(7% versus 1%, respectively; P<0.05) (Gadallah 2000). However, the 
recommendation to use a first generation cephalosporin or vancomycin is 
understandable because of the risk of selecting for resistant organisms such 
as vancomycin-resistant enterococci and S. aureus (Hospital 1995) and the 
development of Clostridium difficile colitis (Wilkie 2010). Postoperative 
incidence of peritonitis in the control arms of three of the evaluated trials 
were high, ranging from 14% to 46% (Bennet-Jones 1988; Gadallah 2000; 
Wikdahl 1997) and the applicability of these data to PD units with lower 
infection rates following PD catheter insertion is unclear. 
The ISPD position statement suggests "most episodes of fungal peritonitis 
are preceded by courses of antibiotics" and "fungal prophylaxis during 
antibiotic therapy may prevent some cases of Candida peritonitis in 
programs that have high rates of fungal peritonitis" (Piraino 2011). The 
KHA-CARI guidelines recommend "oral antifungal prophylaxis should be 
considered when antibiotics are administered to patients undergoing 
peritoneal dialysis to reduce the risk of developing fungal peritonitis" 
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(Walker 2014). This review indicates that fluconazole reduced the risk of 
fungal peritonitis following antibiotic treatment and that nystatin reduced 
the rate of Candida peritonitis in PD patients. The authors of the 
fluconazole trial (Restrepo 2010) noted that a growing number of Candida 
strains were resistant to fluconazole during their trial, and this will limit its 
use. 
The ISPD no longer recommends that the exit-site be regularly disinfected 
with antibacterial soap or a medical antiseptic to keep the exit-site clean and 
reduce the numbers of resident bacteria. The current position statement states 
that "water and antibacterial soap are recommended by many centres. Use of 
an antiseptic to clean the exit site is preferred in some programs, but the 
agent must be non-cytotoxic" (Piraino 2011). The four trials in this review 
which compared the use of disinfectant against standard care did not show 
any benefit with the use of disinfectant (povidone-iodine 10% ointment; 
povidone-iodine 2.5% dry powder spray; povidone-iodine 20g/L solution; or 
sodium hypochlorite 10% solution) compared with standard care (povidone-
iodine 10% solution; alcohol chlohexidine hand wash and use of alcohol 
wipes; non-disinfectant soap and water; or pH neutral soap and water). Three 
of the studies did not report on adverse effects of the interventions and one 
study observed that skin rashes/pruritis occurred in 6% of patients following 
use of the povidone-iodine dry powder spray (Wilson 1997). The three trials 
in this review which looked at the use of disinfectant versus antibiotic or 
other disinfectant also did not show any benefit with the use of disinfectant 
(sodium hypochlorite 10% solution; sodium hypochlorite 5% solution; 
antibacterial honey 10 mg) compared with antibiotic (2% mupirocin 
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ointment) or other disinfectant (povidone iodine 10% solution). Adverse 
effects were reported in each of these studies. Sodium hypochlorite solution 
was associated with more irritation around the exit site than povidone iodine 
solution (Wadhwa 1995; Wadhwa 1997) and 5.9% of patients using 
antibacterial honey at the exit site in the HONEYPOT trial reported local 
reaction as the reason for withdrawing from the study whereas no patients in 
the control group reported this adverse effect (HONEYPOT Trial 2009). 
 
4.8 Authors' conclusions 
Implications for practice 
This update of a systematic review identified low quality evidence for the 
outcomes under consideration. Our findings are as follows: 
 
 The use of oral or topical antibiotic may reduce the risk of exit-
site/tunnel infection and may slightly reduce the risk of peritonitis. 
 It is uncertain whether the use of nasal antibiotic reduces the risk 
of exit-site/tunnel infection or the risk of peritonitis. 
 The use of pre/perioperative intravenous vancomycin appears to 
reduce the risk of early peritonitis but does not appear to reduce the 
risk of exit-site/tunnel infection. 
 The use of topical disinfectant may lead to little or no difference 
in the risk of exit- site/tunnel infection but may slightly reduce 
the risk of peritonitis. 
 Antifungal prophylaxis with oral nystatin/fluconazole appears to  
reduce the risk of fungal peritonitis occurring after a PD patient 
has had an antibiotic course. 
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Implications for research 
Many of the studies included in this review have significant methodological 
limitations, including lack of statistical power, and potential for bias. Further 
large randomised studies with sufficiently long follow-up periods are 
required. These need to assess patient-important outcomes such as adverse 
effects of the interventions given as well as quality of life. Studies need to be 
designed so they yield useful data on the key outcomes of exit-site/tunnel 
infection, peritonitis, catheter loss/replacement and technique failure due to 
infection. 
These studies should be large enough to enable subgroup analyses to 
determine which patients would benefit most from a prophylactic 
intervention and to clearly identify any harms associated with an intervention. 
There is a pressing need for more well-designed RCTs in this area, which 
adequately assess safety, as well as efficacy. 
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Table 4.1: Characteristics of included studies  
 
Axelrod 1973 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Random number table. "Patients were selected to receive 
placebo or antibiotic according to a random number list kept by 
the pharmacy..." 
Allocation 
concealment 
(selection bias) 
Low risk  
Central allocation (pharmacy) 
Blinding of 
participants and 
personnel 
(performance bias) 
Low risk  
Blinding, and unlikely that the blinding could have been broken.
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blinding, and unlikely that the blinding could have been broken. 
"We conducted a random double-blind trial of cephalothin 
sodium as the prophylactic agent." 
Methods Study design: parallel RCT 
Study duration/time frame: 2 months at Bronx VA Hospital; 12 months at 
Mt Sinai Hospital 
Participants Inclusion criteria 
 
Setting: 2 tertiary centres 
Country: USA 
Health status: Peritoneal dialysis patients 
Number: 36 patients (no numbers given for intervention and control 
group) 
Mean age: NS 
Sex (M/F): Bronx VA Hospital 24/0; Mt Sinai Hospital 3/9 
Proportion of diabetic patients (%): Bronx VA Hospital 8.3%; Mt Sinai 
Hospital 8.3% 
 
Exclusion criteria: NS 
Interventions Cephalothin added to 2 L bottle of dialysate (100 micrograms/mL) versus 
placebo solution added to 2 L bottle of dialysate 
Outcomes Peritonitis - number of dialyses 
Notes Funding source: Public Health Service grant and Eli Lilly & Company, 
Indianapolis. 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: 10 dialyses were excluded (no numbers given for 
intervention and control group breakdown) 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
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Incomplete outcome 
data (attrition bias) 
High risk 10/105 (9.5%) dialyses excluded from analysis because pre- 
dialysis serum showed antibiotic activity (9) and antibiotic had 
not been added to dialysate fluid (1). Data reported as no. 
episodes peritonitis/no. dialyses not no. episodes peritonitis/total 
patient-months on PD. 
Selective reporting 
(reporting bias) 
High risk Outcomes not reported as expected. Also, only 1 of 3 expected 
primary outcomes reported (peritonitis). 
Other bias High risk Partly funded by Eli Lilly & Company, Indianapolis. 
 
Bennet-Jones 
1988 
Methods Study design: parallel RCT 
Study duration/time frame: 28 days 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: UK 
Health status: All patients who were to undergo the insertion of a 
Tenckhoff catheter prior to starting CAPD 
Number: 27 patients randomised; IV gentamicin 13; no antibiotic 14 
Mean age ± SD: IV gentamicin 52.7 ± 18.6 years; no antibiotic 53.1 ± 
13.0 years 
Sex (M/F): IV gentamicin 8/5; no antibiotic 9/4 
Proportion of diabetic patients (%): 0% in either group 
 
Exclusion criteria 
 
Receiving any antibiotic in the previous 7 days; receiving vancomycin in 
the previous 3 weeks; history of gentamicin toxicity; any pre-existing 
hearing deficit 
Interventions Gentamicin (i.v.) 1.5 mg/kg at time of catheter placement versus none 
Outcomes Peritonitis - number of patients; exit-site/tunnel infection - number of 
patients 
Notes Funding source: None reported 
Follow-up period: 28 days 
Loss to follow-up: 0 
1 (7%) excluded from analysis in control group due to catheter removal 
Exclusions post-randomisation but pre-intervention: 0 
Stop or end point/s: review after 25 patients had completed 28 day follow- 
up period 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk  
Consecutively numbered sealed envelopes 
Allocation 
concealment (selection 
Low risk "Patients were randomised by being assigned consecutively 
numbered sealed envelopes, which contained either a 
bias)  prescription for gentamicin to be administered with the 
anaesthetic, or an instruction to the anaesthetist to give no 
antibiotic." 
Blinding of 
participants and 
personnel 
(performance bias) 
Low risk  
"Neither the surgeon nor physician knew whether or not the 
patient had received the antibiotic." 
Blinding of outcome 
assessment (detection 
bias) 
Low risk "Neither the surgeon nor physician knew whether or not the 
patient had received the antibiotic." Physician assessing 
outcomes did not know whether patient had received antibiotic 
or not. 
Incomplete outcome 
data (attrition bias) 
Low risk Only 1/27 (3.7%) patients not included in the analysis. 
Selective reporting 
(reporting bias) 
High risk 2 of 3 primary outcomes of interest reported (exit site infection, 
peritonitis). No report of adverse effects of intervention. 
Other bias Unclear risk No information provided about funding source. 
 
Bernardini 1996 
Methods Study design: parallel RCT 
Study duration/time frame: August 1992 - end September 1994 
Participants Inclusion criteria 
 
Setting: 2 tertiary centres 
Country: USA 
Health status: Adult CAPD and CCPD patients - prevalent and incident; 
no catheter infection or peritonitis; no antibiotics for at least 2 weeks prior 
to the study. 
Number: 82 patients randomised; oral rifampin 41; mupirocin ointment 41 
Mean age: NS 
Sex (M/F): oral rifampin 24/17; mupirocin ointment 20/21 
Proportion of diabetic patients (%): oral rifampin 27%; mupirocin 
ointment 41% 
 
Exclusion criteria 
 
Refusal to participate; contraindication to rifampin; patient on daily 
erythromycin therapy 
Interventions Mupirocin ointment (2%) daily application to exit site versus rifampin 
(oral) 300 mg x 2/day x 5 days, every 3 months 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
120  
Outcomes Peritonitis - rate; peritonitis - number of patients; catheter 
removal/replacement; adverse effects 
Notes Funding source: None reported 
Follow-up period: 1 year (mean) 
Loss to follow-up: NS 
Analysis was "intention to treat" 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: When patient ceased peritoneal dialysis or study ended. 
Additional data requested from authors: Further information on methods 
and more detailed results were obtained from the corresponding author. 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Study said to be randomised but no further information 
provided. 
Allocation concealment 
(selection bias) 
Unclear risk Study said to be randomised but no further information 
provided. 
Blinding of participants 
and personnel 
(performance bias) 
High risk Blinding not possible - topical antibiotic ointment vs oral 
antibiotic therapy. The outcome could be influenced by 
lack of blinding and knowledge of the interventions. 
Blinding of outcome 
assessment (detection 
bias) 
High risk "Catheter infections were defined as ... and were diagnosed 
by the peritoneal dialysis nurse and physician, who were 
not blinded to the patient's treatment arm." 
Incomplete outcome data 
(attrition bias) 
Low risk All patients included in analysis including patients who 
ceased therapy. 
Selective reporting 
(reporting bias) 
Low risk All pre-specified outcomes for this review were reported 
Other bias Unclear risk No information on funding provided 
 
Bernardini 2005 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: 3 tertiary centres 
Country: USA 
Health status: >=18 yrs age, on PD, able to give informed consent, already 
enrolled in a registry permitting data collection 
Number: 133 patients; gentamicin cream 67; mupirocin cream 66 
Mean age ± SD: gentamicin 54 ± 15; mupirocin 51 ± 15 years 
Sex (M/F): gentamicin 34/33; mupirocin 38/28 
Proportion of diabetic patients (%): gentamicin 40%; mupirocin 41% 
Exclusion criteria 
Allergy to either study cream; those in another interventional study; those 
with catheter infections or peritonitis in the past 30 days 
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Interventions Daily application of gentamicin cream (gentamicin sulfate 0.1%) versus 
mupirocin cream (mupirocin 2%) at exit site 
Outcomes Primary = P. aeruginosa and S.aureus catheter infection rate. 
Secondary = Gram-negative and Gram-positive peritonitis, overall catheter 
infection rate, overall peritonitis rate, causative organisms, catheter removal 
(due to infection), time to first catheter infection. 
Notes Funding source: National Kidney Foundation of Western Pennsylvania, 
National Kidney Foundation of Upstate New York, Paul Teschan Fund of 
Dialysis Clinic, Inc. 
Follow-up period: 8 months (median) 
 
 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Computer generated using a random number generator. 
"Randomization lists were computer generated using a 
random number generator." 
Allocation concealment 
(selection bias) 
Low risk "The sequence of allocation was known only by the 
investigators at the coordinating center." 
Blinding of participants and 
personnel (performance 
bias) 
Low risk "Investigators and patients were blinded to the cream 
used." 
Blinding of outcome 
assessment (detection bias) 
Low risk Outcome assessors were blinded to the cream used. 
Incomplete outcome data 
(attrition bias) 
Low risk All patients who received intervention included in 
analysis 
Selective reporting 
(reporting bias) 
Low risk All pre-specified outcomes for this review were reported
Other bias Low risk Supported by National Kidney Foundations of Western 
Pennsylvania and Upstate New York and by Paul 
Teschan Fund of Dialysis Clinic Inc 
 
 
 
 
 
 
 
 
 
 
 
 
Loss to follow-up: nil 
Analysis was "intention to treat" 
Exclusions post-randomisation but pre-intervention: 3 in mupirocin group 
(did not start PD) 
Stop or end point/s: stopped at 118 patient-years when a difference in 
peritonitis rates between the groups was found 
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Blowey 1994 
Methods Study design: parallel RCT 
Study duration/time frame: 1991 - 1993 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: USA 
Health status: no evidence of a dialysis-related infection in the preceding 
month; no antibiotic therapy in the preceding month; duration of dialysis 
of at least 3 months 
Number: 34 patients; positive for nasal S. aureus - Rifampin + bacitracin 
7; no treatment 8; negative for nasal S. aureus - no treatment 19 
Mean age (range): 11.5 years (8 mths-21 years) 
Sex (M/F): no details for intervention groups 
Proportion of diabetic patients: NS 
 
Exclusion criteria: NS 
Interventions Oral rifampin 20 mg/kg/day in 2 doses for 5 days + bacitracin (mupirocin) 
[nasal] 2 times/day x 7 days versus none 
Outcomes Peritonitis - number of patients; exit-site/tunnel infection - number of 
 patients 
Notes Funding source: None reported 
Follow-up period: 1 month 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Patients said to be randomised but no further information 
provided. 
Allocation concealment 
(selection bias) 
Unclear risk Patients said to be randomised but no further information 
provided. 
Blinding of participants 
and personnel 
(performance bias) 
High risk Blinding not done - oral antibiotic + topical antibiotic 
ointment vs no therapy. The outcome could be influenced 
by lack of blinding and knowledge of the interventions. 
Blinding of outcome 
assessment (detection 
bias) 
High risk Clinical assessment of outcome could be influenced by 
knowledge of treatment group. 
Incomplete outcome data 
(attrition bias) 
Low risk All patients completed the study 
Selective reporting 
(reporting bias) 
Unclear risk Only 2 of 3 primary outcomes of interest for this review 
were reported (exit site/tunnel infection, peritonitis) 
Other bias Unclear risk No information on funding provided 
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Cheng 1999a 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Hong Kong 
Health status: CAPD patients with infection-free exit sites 
Number: 66 patients; chlorhexidine soap 33; povidone iodine 33 
Mean age: NS 
Sex (M/F): NS 
Proportion of diabetic patients (%): NS 
 
Exclusion criteria: NS 
Interventions Use of chlorhexidine soap vs povidone iodine at exit site (daily) 
Outcomes Exit site infection - rate; catheter removal - number 
Notes Funding source: NS 
Follow-up period: chlorhexidine soap 17.2 ± 5 months; povidone iodine 
16.6 ± 6 months 
Loss to follow-up: NS 
 
 
 
Risk of bias 
table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Study said to be randomised but no information 
on method provided. 
Allocation concealment (selection 
bias) 
Unclear risk Study said to be randomised but no information 
on method provided. 
Blinding of participants and 
personnel (performance bias) 
High risk Lack of blinding could influence patient 
management 
Blinding of outcome assessment 
(detection bias) 
High risk Knowledge of interventions could influence 
outcome assessment 
Incomplete outcome data 
(attrition bias) 
Unclear risk Insufficient information to permit judgement. 
Abstract only available 
Selective reporting (reporting 
bias) 
Unclear risk Only 2 of 3 expected primary outcomes were 
reported (exit site infection, catheter removal) 
Other bias Unclear risk No information on funding provided 
 
 
 
 
 
 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
124  
Chu 2008 
Methods Study design: quasi RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Hong Kong 
Health status: Adult PD patient without any exclusion criteria 
Number: 95 patients; no details of initial randomised numbers; completed 
the study - gentamicin 43; mupirocin 38 
Mean age: gentamicin 57.6 years; mupirocin 61.2 years 
Sex (M/F): gentamicin 27/16; mupirocin 31/7 
Proportion of diabetic patients (%): gentamicin 41.9%; mupirocin 28.9% 
Exclusion criteria 
Active infection; ESI or peritonitis within the previous 4 weeks; allergy to 
either gentamicin or mupirocin; inability to apply the drug; inability to 
give consent. 
Interventions Daily application of gentamicin cream vs mupirocin ointment at the exit site
Outcomes Peritonitis - number of patients; peritonitis rate; exit site/tunnel infection - 
number of patients; exit site/tunnel infection rate; all-cause mortality 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: nil 
 
 
 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
High risk Alternate allocation. "The patients were assigned to either 
drug on a one-to-one alternate basis." 
Allocation concealment 
(selection bias) 
High risk Alternate allocation. "The patients were assigned to either 
drug on a one-to-one alternate basis." 
Blinding of participants 
and personnel 
(performance bias) 
High risk "Patients were not informed of which cream/ointment 
they were using. However the cream/ointment were not 
covered or blinded." (email from author) 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment 
Incomplete outcome data 
(attrition bias) 
High risk 14/95 (15%) withdrew from the study and were excluded 
from analysis. 
Excluded from analysis: 14 (14.7%) excluded from analysis for various 
reasons - do not know how many per intervention group. 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
Additional data requested from authors: Further information on methods 
were obtained from the corresponding author (KH Chu). 
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Selective reporting 
(reporting bias) 
Unclear risk Only 2 of 3 expected primary outcomes were reported 
(peritonitis, exit site/tunnel infection). 
Other bias Unclear risk No information on funding provided 
 
Churchill 1988 
Methods Study design: parallel RCT 
Study duration/time frame: 12 months 
Participants Inclusion criteria 
 
Setting: 4 tertiary centres 
Country: Canada 
Health status: CAPD patients aged 18 to 80 years 
Number: 105 patients; trimethoprim 160 mg/sulfamethoxazole 800 
mg/day 56; placebo 49 
Mean age: NS 
Sex (M/F): NS 
Proportion of diabetic patients (%): NS 
Exclusion criteria 
Allergy to either trimethoprim or sulfamethoxazole; elective 
transplantation; move from study area; unlikely to survive the study 
period; noncompliance; active tunnel infection; no previous peritonitis in 
patients who had been on CAPD for 18 months or more 
Interventions Trimethoprim 160 mg/sulfamethoxazole 800 mg/day x 12 months versus 
none 
Outcomes All-cause mortality, mortality due to peritonitis, peritonitis - number of 
patients, transfers to hemodialysis or transplantation, withdrawals, adverse 
reactions, response to peritonitis treatment, peritoneal catheter loss. 
Notes Funding source: Hoffman La Roche supplied the antibiotic (cotrimoxazole) 
and placebo tablets 
Follow-up period: 12 months 
Loss to follow-up: 20 in cotrimoxazole group (35.7%); 9 in placebo group 
(18.4%) 
Excluded from analysis: "Intention to treat" analysis was used. 
Exclusions post-randomisation but pre-intervention: 49 eligible patients 
refused to participate 
Stop or end point/s: 12 months from start of treatment 
Additional data requested from authors: Further information on methods 
and more detailed results were obtained from the corresponding author. 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Stratified or block randomisation 
Allocation concealment 
(selection bias) 
Low risk Central allocation by pharmacy 
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Blinding of participants and 
personnel (performance bias) 
Low risk Blinding, and unlikely that the blinding could have 
been broken 
Blinding of outcome 
assessment (detection bias) 
Low risk Blinding, and unlikely that the blinding could have 
been broken 
Incomplete outcome data 
(attrition bias) 
Low risk Intention to treat analysis for primary outcome 
Selective reporting (reporting 
bias) 
High risk 2 of 3 primary outcomes not reported (exit 
site/tunnel infection, catheter removal/replacement)
Other bias High risk Hoffman La Roche supplied the antibiotic 
(cotrimoxazole) and placebo tablets 
 
Cocksedge 1993 
Methods Study design: parallel RCT 
Study duration/time frame: 1 January 1988 to 31 December 1989 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Australia 
Health status: Current and new adult CAPD patients 
Number: 60 patients; shower and gauze 30; dressing pack and Fixomull 
30 
Mean age: NS (most patients were >60 years) 
Sex (M/F): NS 
Proportion of diabetic patients (%): 11.7% (7/60) - do not know how 
many per intervention group 
 Exclusion criteria: NS 
Interventions Shower and gauze versus dressing pack and Fixomull dressing at exit site 
Outcomes Exit site infection - rate, exit site infection - number of patients 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Sealed envelopes. "New patients to the program were asked 
to select a sealed envelope from a pack. Each envelope 
contained a card allocating the patient to either Method One 
or Method Two." 
Allocation concealment 
(selection bias) 
Unclear risk Do not know if the envelope was opaque or not. 
Blinding of participants 
and personnel 
(performance bias) 
High risk No blinding and the outcome is likely to be influenced by 
lack of blinding. 
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Blinding of outcome 
assessment (detection 
bias) 
High risk No blinding and knowledge of interventions could influence 
outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Unclear risk No details given re loss to follow up or any patient 
withdrawals. 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 expected primary outcomes are reported (exit 
site infection). No report of adverse effects of either 
intervention.
Other bias Unclear risk No report of funding source. 
 
Danguilan 2003 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Philippines 
Health status: New exit site infection-free CAPD patients 
Number: 100 patients; sodium fusidate 50; mupirocin 50 
Mean age: NS 
Sex (M/F): NS 
Proportion of diabetic patients (%): NS 
 
Exclusion criteria: NS 
Interventions Sodium fusidate ointment at exit site after dressing change versus 
mupirocin ointment at exit site after dressing change (weekly) 
Outcomes Exit site infection - number of patients; exit site infection - rate 
Notes Funding source: NS 
Follow-up period: 1.5 years 
Loss to follow-up: NS 
Excluded from analysis: nil. Intention-to-treat analysis used. 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
Additional data requested from authors: Further information on methods 
and results were obtained from the corresponding author (R Danguilan) 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Randomization method not stated. "One hundred patients 
were enrolled in the study... 50 patients were randomly 
assigned to each treatment group." 
Allocation concealment 
(selection bias) 
Unclear risk No details given re concealment of patient allocation. 
Blinding of participants 
and personnel 
(performance bias) 
High risk No blinding and the outcome is likely to be influenced by 
lack of blinding and knowledge of the interventions. 
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Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment. "Exit sites were 
monitored weekly during regular follow up." 
Incomplete outcome data 
(attrition bias) 
High risk Total of 22/100 dropouts from the study (22%). 
Proportion missing enough to have a clinically relevant 
effect. 
Selective reporting 
(reporting bias) 
Unclear risk Only 2 of 3 expected primary outcomes are reported (exit 
site infection, peritonitis) 
Other bias Unclear risk No report of funding source. 
 
Fuchs 1990 
Methods Study design: parallel RCT 
Study duration/time frame: 1 October 1987 to 31 December 1988 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: USA 
Health status: CAPD and APD patients over 18 years of age with well- 
healed non-inflamed exit sites; no previous exit site infection associated 
with the current catheter. 
Number: 51 patients; chlorhexidine gluconate 18; sodium hypochlorite 13;
povidone iodine 20 
Mean age: chlorhexidine gluconate 46 years; sodium hypochlorite 47 
years; povidone iodine 55 years 
Sex (M/F): chlorhexidine gluconate 7/11; sodium hypochlorite 7/6; 
povidone iodine 13/7. 
Proportion of diabetic patients (%): chlorhexidine gluconate 55.6%; 
 sodium hypochlorite 53.8%; povidone iodine 25% 
 
Exclusion criteria: NS 
Interventions Exit site cleaning with chlorhexidine gluconate and water versus sodium 
hypochlorite solution versus povidone-iodine solution 
Outcomes Exit site infection - number of patients 
Notes Funding source: NS 
Follow-up period: 15 months 
Loss to follow-up: NS 
Excluded from analysis: nil 
Exclusions post-randomisation but pre-intervention: nil 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Randomization method not stated. "Fifty-one patients 
were randomly assigned to one of three catheter exit site 
care regimens." 
Allocation concealment 
(selection bias) 
Unclear risk No details given re concealment of patient allocation. 
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Blinding of participants and 
personnel (performance 
bias) 
High risk No blinding and the outcome is likely to be influenced 
by lack of blinding and knowledge of the interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk Proportion missing not enough to have a clinically 
relevant effect. 2/13 (15.4%) in sodium hypochlorite 
group withdrew from the study. 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 expected primary outcomes is reported (exit 
site infection) 
Other bias Unclear risk No report of funding source. 
 
Gadallah 2000 
Methods Study design: parallel RCT 
Study duration/time frame: 8 years 
Participants Inclusion criteria 
	
Setting: Single tertiary centre 
Country: USA 
Health status: Patients undergoing permanent peritoneal dialysis catheter 
placement 
Number: 265 patients; IV vancomycin 90; IV cefazolin 88; no antibiotic 
87 
Mean age (range): IV vancomycin 46 (15-72) years; IV cefazolin 47 (20- 
81) years; no antibiotic 45 (19-76) years 
Sex (M/F): IV vancomycin 38/52; IV cefazolin 43/45; no antibiotic 38/49 
Proportion of diabetic patients (%): IV vancomycin 35.6%; IV cefazolin 
 34.1%; no antibiotic 32.2% 
	
Exclusion criteria: NS 
Interventions Vancomycin (i.v.) 1000 mg 12 h before catheter placement versus cefazolin 
(i.v.) 1000 mg 3 h before catheter placement versus no antibiotic treatment 
Outcomes Peritonitis - number of patients; exit site/tunnel infection - number of 
patients (within 14 days of date of catheter insertion) 
Notes Funding source: NS 
Follow-up period: 14 days 
Loss to follow-up: NS 
Excluded from analysis: Data for exit site/tunnel infection excluded from 
analysis (IV vancomycin 3; IV cefazolin 6; no antibiotic 8) 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
	
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
High risk Consecutive allocation of intervention - "first patient 
received vancomycin; second, cefazolin; third, neither; 
fourth, vancomycin; and so on." 
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Allocation concealment 
(selection bias) 
High risk Non-random, predictable sequence 
Blinding of participants and 
personnel (performance 
bias) 
High risk No blinding and the outcome is likely to be influenced 
by lack of blinding and knowledge of the interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk No missing data re peritonitis outcome. 
Selective reporting 
(reporting bias) 
Unclear risk 2 of 3 expected outcomes of interest are reported. 
Other bias Unclear risk No report of funding source. 
 
HONEYPOT Trial 2009 
Methods Study design: parallel RCT 
Study duration/time frame: 17 September 2008 to 16 June 2012 
Participants Inclusion criteria 
 
Setting: 26 tertiary centres 
Country: Australia; New Zealand 
Health status: Adults and children of all ages with end-stage kidney 
disease who were undergoing peritoneal dialysis. 
Number: 371 patients; antibacterial honey 186; intranasal mupirocin 185 
Mean age ± SD: antibacterial honey (adult) 61.2 ± 14.5 years; intranasal 
mupirocin (adult) 62.1 ± 14.6 years. 
Sex (M/F): antibacterial honey 108/78; intranasal mupirocin 116/69. 
Proportion of diabetic patients (%): antibacterial honey 34%; intranasal 
 mupirocin 28% 
Exclusion criteria: 
Exit site infection, tunnel infection or peritonitis in the preceding month; 
current or recent (within the preceding 4 weeks) treatment with an 
antibiotic administered by any route; nasal carriage of mupirocin-resistant
S. aureus; known hypersensitivity to or intolerance of honey or mupirocin; 
inability to provide informed consent; history of psychological illness or 
disorder that interfered with the ability to understand or comply with the 
requirements of the study. 
Interventions Daily topical exit-site application of antibacterial honey (10 mg) plus 
standard exit site care vs intranasal application of mupirocin ointment (2% 
mupirocin) (only in carriers of nasal S. aureus) plus standard exit site care. 
Mupirocin to be applied 2 x daily for 5 days, each month. 
Outcomes Primary = time to first episode of exit-site infection, tunnel infection or 
peritonitis, whichever came first. 
Secondary = time to first exit-site infection, time to first tunnel infection, 
time to first peritonitis, time to infection-associated catheter removal, death, 
and serious adverse events. 
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Notes Funding source: Baxter Healthcare; Queensland government; Comvita; 
Gambro 
Follow-up period: minimum of 12 months; maximum of 24 months. 
Loss to follow-up: 1 in honey group (0.5%); 3 in mupirocin group (1.6%) 
Excluded from analysis: nil 
Exclusions post-randomisation but pre-intervention: nil 
Stop or end point/s: Once 185 individuals per group had been followed up 
for at least 12 months. 
Additional data requested from authors: Further information about results 
were obtained from the biostatistician (E Pascoe). 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Minimization method. "Participants were randomly assigned in 
a 1:1 ratio by use of an adaptive allocation algorithm designed 
to minimise imbalance in treatment groups for the three 
variables." 
Allocation 
concealment 
(selection bias) 
Low risk Central allocation (web). "To ensure adequate concealment of 
allocation, the randomisation was done with a password- 
protected internet-based system." 
Blinding of 
participants and 
personnel 
(performance bias) 
High risk No blinding and the outcome is likely to be influenced by lack 
of blinding and knowledge of the interventions. "Blinding of 
investigators and patients is not possible because of the 
completely different characteristics of Medihoney and 
mupirocin ointment." 
Blinding of outcome 
assessment (detection 
bias) 
High risk No blinding and knowledge of the interventions could influence 
outcome assessment. "The trial was open label, but 
microbiology staff at the local laboratories were not informed of
  the treatment allocation." 
Incomplete outcome 
data (attrition bias) 
High risk Missing data not balanced between groups. 17/185 (9.2%) 
withdrew from control group; 54/186 (29%) withdrew from 
honey group. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes are reported. 
Other bias Unclear risk The study appears to be free of other sources of risk. Although 3 
of 4 funders are pharmaceutical companies, there is an explicit 
statement about their role on page 26 of the paper. 
 
Lo 1996 
Methods Study design: parallel RCT 
Study duration/time frame: 1 May 1991 to 30 April 1993 
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Participants Inclusion criteria 
 
Setting: 2 tertiary centres 
Country: Hong Kong 
Health status: All patients receiving CAPD 
Number: 397 patients; oral nystatin 199; control 198 
Mean age ± SD: 48.4 ± 14.5 years; control 48.5 ± 14.2 years 
Sex (M/F): Oral nystatin 86/113; control 98/100 
Proportion of diabetic patients (%): Oral nystatin 18.6%; control 15.2% 
 
Exclusion criteria: NS 
Interventions Nystatin 500,000 units x 4/day (whenever antibiotics were prescribed to 
patient) versus none 
Outcomes Peritonitis - number of patients, peritonitis - rate (due to Candida spp.) 
Notes Trial focusing on prophylaxis to prevent Candida peritonitis in CAPD 
patients receiving antibiotics for any indication 
Funding source: NS 
Follow-up period (mean ± SD): Oral nystatin 18.0 ± 7.6 months; control 
16.6 ± 8.5 months 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
High risk Patients were randomised according to odd or even 
identity numbers. 
Allocation concealment 
(selection bias) 
High risk A non-random, predictable sequence was used. 
Blinding of participants and 
personnel (performance bias) 
High risk No blinding and the outcome is likely to be 
influenced by lack of blinding and knowledge of the 
interventions.
Blinding of outcome High risk No blinding and knowledge of the interventions 
assessment (detection bias)  could influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk Intention to treat analysis for primary outcome. 
Selective reporting (reporting 
bias) 
Low risk The expected primary outcome is reported. 
Other bias Unclear risk No report of funding source. 
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Low 1980 
Methods Study design: parallel RCT 
Study duration/time frame: April to September 1979 
Participants Inclusion criteria 
 
Setting: 2 tertiary centres 
Country: Canada 
Health status: Patients receiving CAPD 
Number: 50 patients; oral cefalexin 25; placebo 25 
Mean age: NS 
Sex (M/F): NS 
Proportion of diabetic patients: NS 
 
Exclusion criteria: NS 
Interventions Cefalexin 500 mg x 2/day versus none 
Outcomes Peritonitis - number of patients; peritonitis - rate; catheter 
removal/replacement - number of patients 
Notes Funding source: National Institutes of Health 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Minimisation method used. 
Allocation concealment 
(selection bias) 
Low risk Allocation done by a third party 
Blinding of participants and 
personnel (performance bias) 
Low risk Blinding, and unlikely that the blinding could have 
been broken. 
Blinding of outcome 
assessment (detection bias) 
Low risk Blinding, and unlikely that the blinding could have 
been broken. 
Incomplete outcome data 
(attrition bias) 
Low risk No missing data. 
Selective reporting (reporting 
bias) 
Unclear risk 1 of 3 primary outcomes not reported (exit 
site/tunnel infection).
Other bias Low risk Study appears to be free of other sources of risk. 
  Funding was from a National Institutes of Health 
contract. 
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Luzar 1990 
Methods Study design: parallel RCT 
Study duration/time frame: May 1987 to September 1988 
Participants Inclusion criteria 
 
Setting: 8 tertiary centres 
Country: UK, France, Belgium 
Health status: New and current CAPD patients 
Number: 127 patients; povidone iodine 74; control 53 
Mean age: NS 
Sex (M/F): Povidone iodine 47/27; control 31/22 
Proportion of diabetic patients (%): Povidone iodine 17%; control 11% 
 
Exclusion criteria: Patients with any current infection. 
Interventions Povidone iodine (20 g/L) and nonocclusive dressing 2-3 times/week versus 
none (nondisinfectant soap and water) 
Outcomes All-cause mortality, peritonitis - rate, exit-site/tunnel infection - rate 
Notes Funding source: NS but lead author employed by Baxter R & D Europe, 
Belgium 
Follow-up period: 9.03 months per patient 
Loss to follow-up: 8 of 127 (6.3%) 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: 9 patients randomised 
to control group refused to do that type of exit site care 
Stop or end point/s: 1 year of follow-up per patient or until a significant 
difference in rate of exit-site infection. 
Four patients in Group 2 (soap and water) changed to Group 1 (povidone 
iodine and dressing). 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Random number table 
Allocation concealment 
(selection bias) 
Low risk Central allocation 
Blinding of participants and 
personnel (performance bias) 
High risk No blinding and the outcome is likely to be 
influenced by lack of blinding and knowledge of the 
interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk Proportion missing not enough to have a clinically 
relevant effect 
Selective reporting (reporting 
bias) 
Low risk 3 of 3 primary outcomes of interest are reported 
Other bias High risk Funding source not specified but seems to be Baxter 
Healthcare Corporation 
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Lye 1992 
Methods Study design: parallel RCT 
Study duration/time frame: 1 May 1989 to 31 May 1990 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Singapore 
Health status: Patients having CAPD catheters inserted 
Number: 66 patients; cefazolin + gentamicin 33; control 33 
Mean age ± SD: Cefazolin + gentamicin 56.2 ± 12.3 years; control 55.6 ± 
13.4 years 
Sex (M/F): Cefazolin + gentamicin 12/21; control 18/15 
Proportion of diabetic patients (%): Cefazolin + gentamicin 68%; control 
52% 
 
Exclusion criteria: 
 
Recognised infection at the time of surgery; antibiotic therapy in the week 
prior to surgery; vancomycin therapy in the 2 weeks before surgery; 
history of allergy to beta-lactam antibiotics and aminoglycosides 
Interventions Cefazolin (i.v.) 500 mg and gentamicin (i.v.) 80 mg 0.5-1.0 hour before 
catheter placement versus none 
Outcomes All-cause mortality, peritonitis - number of patients, exit-site/tunnel 
infection - number of patients (within 4 weeks of catheter insertion) 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
4 (16%) excluded from analysis in cefazolin + gentamicin group due to lack 
of effect of study antibiotics on MRSA bacteria; 3 (12%) excluded from 
analysis in control group for the same reason 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
High risk 
Alternate allocation 
Allocation concealment 
(selection bias) 
High risk Non-random, predictable sequence 
Blinding of participants and 
personnel (performance bias) 
High risk No blinding and the outcome is likely to be 
influenced by lack of blinding and knowledge of the 
interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
Low risk Missing data balanced across groups, and reasons 
similar 
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Selective reporting (reporting 
bias) 
Low risk 3 of 3 primary outcomes of interest are reported 
Other bias Unclear risk No report of funding source 
 
Mendoza-Guevara 2007 
Methods Study design: parallel RCT 
Study duration/time frame: 22 January 2004 to 15 March 2005 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Mexico 
Health status: Cyclic continuous PD patients that had been at least 3 
months on the PD program and free of peritonitis or exit-site infection for 
at least 1 month since the last episode. 
Number: 60 patients (paediatric); Amuchina 10% 30; pH neutral soap 30 
Median age (Q25-75): Amuchina 10% 12 (10-14) years; pH neutral soap 
12 (8.75-14.25) years 
Sex (M/F): Amuchina 10% 19/11; pH neutral soap 11/19 
Proportion of diabetic patients (%): NA 
 
Exclusion criteria: 
 
Patients on steroids; patients with cancer; HIV positive patients 
Interventions Use of Amuchina 10% (sodium hypochlorite) solution versus pH neutral 
soap for cleaning of exit site 
Outcomes Exit site infection - number of patients 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Random number tables. "Patients were assigned 1:1 in 
two groups, with only one treatment; the Rand 
Corporation tables were used for randomization." 
Allocation concealment 
(selection bias) 
Unclear risk No details of allocation method given 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Patient cleans own exit site - impossible to conceal 
intervention allocation. "The study was blind for the 
investigators and laboratory personnel." 
Blinding of outcome Low risk Blinding, and unlikely that the blinding could have been 
assessment (detection bias)  broken. "The study was blind for the investigators and 
laboratory personnel." 
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Incomplete outcome data 
(attrition bias) 
Unclear risk No details re missing data given 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 expected primary outcomes reported (exit site 
infection). 
Other bias Unclear risk No report of funding source 
 
Moore 1989 
Methods Study design: parallel quasi RCT 
Study duration/time frame: 1 October 1987 to 1 February 1988 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: USA 
Health status: Current CAPD patient (adult) 
Number: 29 patients; Blisterfilm 15; gauze 14 
Mean age (range): Blisterfilm 54 (30-75) years; gauze 59 (28-72) years 
Sex (M/F): NS 
Proportion of diabetic patients (%): NS 
Exclusion criteria: 
Patients with a history of exit-site infection 2 months prior to possible 
study admission 
Interventions Blisterfilm adhesive dressing versus gauze dressing at exit site 
Outcomes Exit site infection - number of patients 
Notes Funding source: NS 
Follow-up period: 4 months. 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
High risk Alternate allocation. "The numbering was consecutive so all 
participants were given an equal chance of being admitted to 
either group." "Odd numbers were admitted to the Blisterfilm 
group and even numbers admitted to the gauze group." 
Allocation 
concealment (selection 
bias) 
High risk Non-random, predictable sequence. However, allocation 
concealment not possible - the two dressings are of different 
sizes and types. 
Blinding of 
participants and 
personnel 
High risk No blinding and the outcome is likely to be influenced by lack 
of blinding and knowledge of interventions. 
(performance bias)   
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Blinding of outcome 
assessment (detection 
bias) 
High risk No blinding and knowledge of the interventions could 
influence outcome assessment. 
Incomplete outcome 
data (attrition bias) 
Unclear risk The published report states percentage of patients in each 
group that experienced exit-site infection but does not state 
actual patient numbers. No report of loss to follow-up, 
withdrawals etc. 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 expected primary outcomes of interest reported 
(exit-site infection) 
Other bias Unclear risk No report of funding source 
 
MP3 Study 2008 
Methods Study design: parallel RCT 
Study duration/time frame:NS 
Participants Inclusion criteria 
 
Setting: 3 tertiary centres 
Country: Canada 
Health status: Current or new PD patients; aged 18 years or more; have a 
PD catheter in situ; are medically stable. 
Number: 204 patients (adults); P3 ointment 103; mupirocin ointment 101 
Mean age ± SD: P3 ointment 59.36 ± 15.04 years; mupirocin ointment 
61.02 ± 13.66 years 
Sex (M/F): P3 ointment 63/37; mupirocin ointment 66/34 
Proportion of diabetic patients (%): P3 ointment 45.5%; mupirocin 
ointment 42% 
 
Exclusion criteria: 
 
Patients with acute renal failure; catheter-related infection at the time of 
recruitment or within the previous 3 months; use of an oral, intravenous or 
intraperitoneal antibiotic at the time of randomisation or within the 
previous 1 week; a known allergy to any component of P3 or mupirocin; 
or a scheduled date for living donor transplant surgery within 6 months of 
the study completion date. 
Interventions Application of Polysporin Triple (P3) antibiotic ointment (bacitracin 500 
U/g, gramicidin 0.25 mg/g, polymyxin B 10 000 U/g) at exit site when 
dressing is changed versus mupirocin ointment 
Outcomes Primary = Time to first catheter-related infection (ESI, tunnel infection, PD 
peritonitis). Secondary = catheter removal (catheter-related infection); 
hospitalization (catheter-related infection); death due to catheter-related 
infection; all-cause mortality; technique failure (i.e. transfer to HD) 
Notes Funding source: Kidney Foundation of Canada 
Follow-up period: Median (range): 18 (0.1-18) months 
Loss to follow-up: 2 from each group 
Excluded from analysis: Data for 3 patients from 1 site were excluded 
Exclusions post-randomisation but pre-intervention: nil 
Stop or end point/s: NS 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Computer random number generator. "All randomization is 
determined by a computer-generated random number list..." 
"...201 patients from two centers were randomly assigned to 
either mupirocin or P3 using stratified block randomization as 
per protocol." 
Allocation 
concealment 
(selection bias) 
Low risk Central allocation (pharmacy). "Randomization occurs centrally 
in coordination with the central clinical trials pharmacy... The 
ointments are placed in containers that are labeled only with the 
site investigator, study number, and expiry date." 
Blinding of 
participants and 
personnel 
(performance bias) 
Low risk Blinding, and unlikely that the blinding could have been broken. 
"The treatments resemble each other in odor, color, and 
consistency to allow for a double blinded controlled trial." 
"Neither the healthcare workers not the participants know which 
intervention the participant will receive." 
Blinding of outcome 
assessment 
(detection bias) 
Low risk  
Blinding, and unlikely that the blinding could have been broken. 
Incomplete outcome 
data (attrition bias) 
Low risk Missing data balanced across groups, and reasons similar. 
Selective reporting 
(reporting bias) 
Low risk Protocol is available and all pre-specified outcomes of interest to 
the review are reported in the pre-specified way. 
Other bias Low risk Funded by the Kidney Foundation of Canada. Study appears to 
be free of other sources of risk. 
 
Mupirocin SG 
1996 
Methods Study design: parallel RCT 
Study duration/time frame: up to 18 months 
Participants Inclusion criteria 
 
Setting: 9 centres 
Country: Europe 
Health status: Patients undergoing CAPD who were identified as S. aureus 
nasal carriers 
Number: 267 patients; mupirocin ointment 134; placebo ointment 133 
Mean age: Mupirocin ointment 60.3 years; placebo ointment 60.3 years 
Sex (M/F): Mupirocin ointment 81/53; placebo ointment 80/53 
Proportion of diabetic patients (%): Mupirocin ointment 17.2%; placebo 
ointment 22.6% 
 
Exclusion criteria: 
 
Patient negative for S. aureus nasal carriage; patient who had received 
antibiotics for a PD-related infection within the preceding month; patient 
with active exit site infection. 
Interventions Mupirocin (2%) nasal ointment 2/day x 5 days, every 1 month versus 
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 placebo 
Outcomes All-cause mortality, peritonitis - rate, exit-site/tunnel infection - number of 
patients, exit-site/tunnel infection - rate, catheter removal or replacement 
Notes Funding source: SmithKline Beecham, UK; Baxter Healthcare, USA 
Follow-up period: up to 18 months 
Loss to follow up: NS 
"Intention to treat" analysis used 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: 1413 patient-months in each group 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk  
No details given re randomisation method used. 
Allocation concealment 
(selection bias) 
Unclear risk Not stated. 
Blinding of participants and 
personnel (performance bias) 
Unclear risk Blinding, and unlikely that patients were aware of 
treatment group. Unclear if personnel were aware of 
patient treatment groups. 
Blinding of outcome 
assessment (detection bias) 
Unclear risk No details given re who did the outcome assessment 
and if they were blind to patient treatment group. 
Incomplete outcome data 
(attrition bias) 
Low risk Missing data balanced across groups, and reasons 
similar 
Selective reporting (reporting 
bias) 
Low risk 3 of 3 expected primary outcomes of interest are 
reported 
Other bias High risk Funding source: SmithKline Beecham, UK, and Baxter 
Healthcare, USA 
 
Nolph 1985 
Methods Study design: parallel RCT 
Study duration/time frame: 9 months 
Participants Inclusion criteria 
 
Setting: 10 tertiary centres 
Country: USA 
Health status: Patients with end stage renal disease being treated with 
CAPD. 
Number: 167 patients; test group 74; control 93 
Mean age ± SD: Test group 49 ± 14 years; control 49 ± 14 years 
Sex (M/F): Test group 50/24; control 49/44. 
Proportion of diabetic patients (%): Test group 16.2%; control 23.7% 
 
Exclusion criteria: NS 
Interventions Ultraviolet germicidal chamber for spike and bag outlet port versus none 
Outcomes All-cause mortality, peritonitis - number of patients, peritonitis - rate 
Notes Funding source: Travenol Laboratories Inc., USA 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Random number table. 
Allocation concealment 
(selection bias) 
Low risk Central allocation (Travenol Laboratories). 
Blinding of participants and 
personnel (performance 
bias) 
High risk No blinding and the outcome is likely to be influenced 
by lack of blinding and knowledge of the interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of the interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk 12.9% withdrew from control group; 24.3% withdrew 
from intervention group. Proportion missing enough to 
have a clinically relevant effect. 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 primary expected outcomes of interest is 
reported (peritonitis). 
Other bias High risk Funding source: Travenol Laboratories Inc., USA. 
 
Nunez-Moral 
2014 
Methods Study design: parallel RCT 
Study duration/time frame: 12 months 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Spain 
Health status: patients older than 18 years in PD program in which a 
peritoneal catheter had been implanted at least 6 weeks before; absence of 
infectious complications which had required either hospital admission or 
antibiotic treatment at least three months before entering the study; 
absence of known reaction or contingent polyhexanide intolerance; the 
patient or representatives had signed the informed consent form. 
Number: 60 patients; polyhexanide solution 30; control 30 
Mean age ± SD: Polyhexanide group 61 ± 15 years; control 60 ± 19 years 
Sex (M/F): Polyhexanide group 17/13; control 16/14 
Proportion of diabetic patients (%): Polyhexanide group 41%; control 
40% 
 
Exclusion criteria: Presence of exit-site infection at randomization time; 
history of bad adherence to treatment and/or medical advice; withdrawal of 
the informed consent. 
Interventions Use of polyhexanide solution at exit site versus standard care (0.9% saline 
Follow up period: 9 months 
Loss to follow up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
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 solution and povidone iodine solution) 
Outcomes All-cause mortality; exit site/tunnel infection - number of patients; exit 
site/tunnel infection - rate; catheter removal or replacement (due to 
infection) 
Notes Funding source: Nephrological Nursing Investigation Baxter award 2010 
Follow up period: 12 months 
Loss to follow up: nil 
Excluded from analysis: nil 
Exclusions post-randomisation but pre-intervention: nil 
Stop or end point/s: NS 
Additional data requested from authors: Further information on peritonitis 
data were requested from the corresponding author. 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Random number table. "Randomization was performed 
by means of a randomization code via random number 
table..." 
Allocation concealment 
(selection bias) 
Unclear risk Randomisation stated but no information on method used 
is available. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Insufficient information to permit judgement 
Blinding of outcome 
assessment (detection bias) 
Unclear risk Insufficient information to permit judgement 
Incomplete outcome data 
(attrition bias) 
Low risk No missing outcome data 
Selective reporting 
(reporting bias) 
Unclear risk Only 2 of 3 expected primary outcomes of interest 
reported fully. 
Other bias Unclear risk Disclosure states that "Part of these data belong to Baxter
S. L. funds as we received the Nephrological Nursing 
Investigation Baxter award 2010". 
 
Perez-Fontan 
1992 
Methods Study design: parallel RCT 
Study duration/time frame: 3 - 15 months 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Spain 
Health status: Patients undergoing CAPD and their assisting partners 
Number: 22 patients, 3 partners; mupirocin 12 patients, 1 partner; 
neomycin 10 patients, 2 partners 
Mean age ± SD: Mupirocin 51 ± 15 years; neomycin 48 ± 21 years 
Sex (M/F): Mupirocin 5/7; neomycin 5/5 
Proportion of diabetic patients (%): Mupirocin 25%; neomycin 20% 
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 Exclusion criteria: NS 
Interventions Mupirocin (2%) nasal ointment t.i.d. x 7 days versus neomycin sulphate 
(0.1%) nasal ointment t.i.d. x 7 days 
Outcomes Peritonitis - number of patients, peritonitis - rate, exit-site/tunnel infection - 
number of patients, exit site/tunnel infection - rate 
Notes Funding source: None reported 
Follow up period: 9.5 ± 3.3 months 
Loss to follow up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Stratified randomization method used. "Staph. aureus nasal 
carriers were assigned to one of two groups, randomized 
for age, time on CAPD and prevalence of diabetes." 
Allocation concealment 
(selection bias) 
Unclear risk No details given. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Insufficient information to permit judgement. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Insufficient information to permit judgement. 
Incomplete outcome data 
(attrition bias) 
Low risk Reasons for missing data not related to outcome. "Patients 
of Group 2 in whom eradication was not obtained after two 
neomycin cycles were treated with mupirocin." 
Selective reporting 
(reporting bias) 
Unclear risk 2 of 3 expected primary outcomes of interest are reported. 
Other bias Unclear risk No report of funding source. 
 
Poole-Warren 
1991 
Methods Study design: parallel RCT 
Study duration/time frame: 12 months 
Participants Inclusion criteria 
 
Setting: 8 tertiary centres 
Country: Australia and New Zealand 
Health status: Current CAPD patients stabilised on the therapy 
Number: 124 patients; Staphypan Berna 65; saline placebo 59 
Mean age ± SD: Staphypan Berna 54 ± 11 years; saline placebo 52 ± 14 
years 
Sex (M/F): Staphypan Berna 1/5; saline placebo 0/7 
Proportion of diabetic patients (%): Staphypan Berna 18.5%; saline 
placebo 15.3% 
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 Exclusion criteria: 
 
Current peritoneal infection; receipt of an antibiotic course within the 2 
week period prior to study enrolment; use of assist devices; use of 
disconnect systems. 
Interventions Staphypan Berna vaccine versus saline placebo 
Outcomes Peritonitis - number of patients, peritonitis - rate, exit-site/tunnel infection - 
number of patients, exit-site/tunnel infection - rate 
Notes Funding source: Baxter Healthcare Corporation, USA 
Follow-up period: 12 months 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: 43 patient years per treatment group 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Randomization method not stated. "Patients were randomly 
assigned by an independent third party to either the 
vaccinated group or the saline solution (SS) placebo 
administered group." 
Allocation concealment 
(selection bias) 
Low risk Central allocation (independent third party). "The assigned 
injection group was not known to either patient or staff 
immediately connected with the patient's care at any time 
during the study." 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Blinding, and unlikely that the blinding could have been 
broken. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blinding, and unlikely that the blinding could have been 
broken. 
Incomplete outcome 
data (attrition bias) 
Low risk Missing data balanced across groups, and reasons similar. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes of interest are reported. 
Other bias High risk Funding source: Baxter Healthcare Corporation, USA 
 
Restrepo 2010 
Methods Study design: parallel RCT 
Study duration/time frame: 1 June 2004 to 30 October 2007 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Colombia 
Health status: Chronic kidney disease patients stage 5 on PD (CAPD or 
APD) were included if they experienced peritonitis, exit-site infection or 
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 tunnel infection. 
Number: 340 patients; 226 patients with peritonitis; 114 patients with ESI 
or TI 
Mean age: 50.9 years (men); 47.9 years (women); unable to calculate 
mean age per intervention group 
Sex (M/F): Oral fluconazole 93/117; no oral fluconazole 116/94 
Proportion of diabetic patients (%): Oral fluconazole 33.3%; no oral 
fluconazole 37.1% 
 
Exclusion criteria: 
 
Allergy to fluconazole, imidazoles, or triazoles; hepatic disease; 
pregnancy; less than 18 years of age; more than 70 years of age; patients 
that did not wish to participate 
Interventions Oral fluconazole (200 mg every 48 hours) vs no oral fluconazole with an 
antibiotic course for a PD-related infection 
Outcomes Fungal peritonitis in the time period 30-150 days following the end of 
antibacterial treatment 
Notes Funding source: None reported 
Follow-up period: 30-150 days after the end of treatment 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: When 434 episodes of peritonitis had occurred 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Drawing of lots. "The randomization procedure was 
performed by drawing from a bag cards indicating whether 
the patient would or would not receive this treatment." 
Allocation concealment 
(selection bias) 
Unclear risk No details of allocation method stated. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Insufficient information to permit judgement. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Insufficient information to permit judgement. 
Incomplete outcome data 
(attrition bias) 
Unclear risk No details of missing data given. 
Selective reporting 
(reporting bias) 
Unclear risk The expected primary outcome is reported. However, 
adverse effects of antifungal use are not reported. 
Other bias Unclear risk No report of funding source. 
 
Ryckelynck 1987 
Methods Study design: parallel quasi RCT 
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 Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: 5 tertiary centres 
Country: France 
Health status: Current CAPD patients using Y-line systems 
Number: 50 patients; Antiseptic soak 24; no antiseptic 26 
Mean age: NS 
Sex (M/F): NS 
Proportion of diabetic patientsn (%): NS 
 
Exclusion criteria: NS 
Interventions Connector soaked in antiseptic prior to bag exchange versus no use of 
antiseptic 
Outcomes Peritonitis - rate 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk Randomisation method not stated. "24 patients using a 
single use Y-set and 26 using a reusable Y-set (O-set) 
were separately randomized into two groups." 
Allocation concealment 
(selection bias) 
Unclear risk Not stated 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Insufficient information to permit judgement. 
Blinding of outcome 
assessment (detection bias) 
Unclear risk Insufficient information to permit judgement. 
Incomplete outcome data 
(attrition bias) 
Unclear risk No details of missing data given. 
Selective reporting 
(reporting bias) 
High risk Only 1 of 3 expected primary outcomes is reported. 
Other bias Unclear risk No report of funding source. 
 
Sesso 1994 
Methods Study design: parallel RCT 
Study duration/time frame: January 1991 through June 1992 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: Brazil 
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 Health status: Continuing and new patients undergoing CAPD identified 
as S. aureus carriers 
Number: 31 patients; S. aureus nasal carriers - oral ofloxacin 9; sodium 
fusidate ointment 9; control 13 
Mean age ± SE: Oral ofloxacin 36.6 ± 4.6 years; sodium fusidate 46.1 ± 
3.8 years; control 42.1 ± 4.6 years 
Sex (M/F): Oral ofloxacin 6/3; sodium fusidate 6/3; control 9/4 
Proportion of diabetic patients (%): Oral ofloxacin 33.3%; sodium 
fusidate 11.1%; control 7.7% 
 
Exclusion criteria: 
 
Patients who had peritonitis or exit site infection within 1 month of the 
beginning of the study were excluded until being asymptomatic for at least 
1 month; patients who had received antimicrobial therapy within 78 hours 
before the start of the study; patients younger than 15 years. 
Interventions Ofloxacin 200 mg every 2 days over 5 days versus sodium fusidate (2%) 
ointment applied twice daily (nasal and exit site) x 5 days versus placebo 
tablets [all treatments repeated monthly] 
Outcomes All-cause mortality, peritonitis - number of patients, peritonitis - rate, exit- 
site/tunnel infection - number of patients, exit-site/tunnel infection - rate, 
catheter removal or replacement, nasal irritation 
Notes Funding source: Instituto Paulista de Estudos e Pesquisas em Nefrologia e 
Hipertensao 
Follow up period: 7.8 months (mean) 
Loss to follow up: 7 in oral ofloxacin group (77.8%); 4 in sodium fusidate 
group (44.4%); 7 in control group (53.9%) 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: June 1992 or date patient ceased CAPD, if earlier. 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk 
Randomisation method not stated. "Each carrier was then 
randomly assigned to one of the three groups". 
Allocation concealment 
(selection bias) 
Unclear risk Not stated. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Insufficient information to permit judgement. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Insufficient information to permit judgement. 
Incomplete outcome data 
(attrition bias) 
High risk 44.4% withdrew from sodium fusidate group; 77.7% 
withdrew from ofloxacin group; 53.8% withdrew from 
control group. Proportion missing enough to have a 
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  clinically relevant effect. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes of interest are reported. 
Other bias Low risk Supported by a grant from Instituto Paulista de Estudos e 
Pesquisas em Nefrologia e Hipertensao. Study appears to be 
free of other sources of risk. 
 
Sharma 1971 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: USA 
Health status: Peritoneal dialysis patients with acute or chronic renal 
failure. 
Number: 41 patients 
Age range: 11 to 75 years 
Sex (M/F): 22/19 (no details for each treatment group) 
Proportion of diabetic patients (%): NS 
 
Exclusion criteria: NS 
Interventions Oral neomycin 0.5 g in suspension every 12 hours vs placebo 
Outcomes Peritonitis - number of dialyses 
Notes Funding source: None reported 
Follow-up period: NS 
Loss to follow-up: Six dialyses excluded from analysis 
Excluded from analysis: 6 dialyses excluded (6.3%) 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk  
Randomisation method not stated. 
Allocation 
concealment (selection 
bias) 
Low risk  
Central allocation (pharmacy). 
Blinding of 
participants and 
personnel 
(performance bias) 
Low risk  
Blinding, and unlikely that the blinding could have been 
broken. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Blinding, and unlikely that the blinding could have been 
broken. 
Incomplete outcome Unclear risk No details of missing data given on a patient basis. 
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data (attrition bias)   
Selective reporting 
(reporting bias) 
High risk Outcomes not reported as expected - number of episodes 
peritonitis/number of dialyses not number of episodes 
peritonitis/total patient-months on dialysis. Also, only 1 of 3 
expected primary outcomes reported (peritonitis). 
Other bias Unclear risk No report of funding source. 
 
SIPROCE 1997 
Methods Study design: parallel RCT 
Study duration/time frame: 1 October 1994 to 1 April 1996 
Participants Inclusion criteria 
 
Setting: 10 dialysis centres (7 adult; 3 paediatric) 
Country: Germany 
Health status: All current patients on PD; new patients until December 
1995. 
Number: 195 patients; Silver ring 97; control group 98 
Mean age ± SD: Silver ring 44.74 ± 17.6 years; control group 47.01 ± 
18.5 years 
Sex (M/F): Silver ring 63/34; control group 52/46 
Proportion of diabetic patients (%): Silver ring 19.6%; control group 
21.4% 
 
Exclusion criteria: 
 
Patients with acute or chronic exit-site infections, sinus tract/tunnel 
infections, or peritonitis during the ascertainment period. 
Interventions Silver ring mounted on PD catheter versus no silver ring 
Outcomes Primary = first occurrence of exit-site infection. Exit site infection (number 
of patients), tunnel infection (number of patients), peritonitis (number of 
patients), catheter loss, all-cause mortality 
Notes Funding source: Supported in part by Baxter Deutschland GmbH, Ettlingen, 
Germany. 
Follow-up period: Silver ring 857 months; control group 937 months 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Stratified randomisation. "After informed consent had been 
obtained, the patients were stratified by diabetes mellitus 
status (types I and 
II) and randomly assigned by the coordinating study 
center (Berlin) to either the silver ring or 
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  the control group." 
Allocation 
concealment 
(selection bias) 
Low risk  
Central allocation (coordinating study centre). 
Blinding of 
participants and 
personnel 
(performance bias) 
High risk 
No blinding and the outcome is likely to be influenced by 
lack of blinding and knowledge of the interventions. 
Blinding of 
outcome 
assessment 
(detection bias) 
High risk  
No blinding and knowledge of the interventions could 
influence outcome assessment. 
Incomplete 
outcome data 
(attrition bias) 
High risk Proportion missing enough to have a clinically relevant 
effect. Dropouts: 29/97 (29.9%) in silver ring group; 
30/98 (30.6%) in control group. Withdrawals: 6/97 
(6.2%) in silver ring group; 0/98 (0%) in control group. 
Selective reporting 
(reporting bias) 
Low risk 
3 of 3 expected primary outcomes are reported. 
Other bias Unclear risk Supported in part by Baxter Deutschland GmbH, 
Ettlingen, Germany. 
 
Sit 2007 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Turkey 
Health status: Current CAPD patients (on CAPD for at least 6 months) 
Number: 49 patients; Mupirocin 25; control 24 
Mean age ± SD: Mupirocin 42.0 ± 12.1 years; control 37.5 ± 12.9 years 
Sex (M/F): Mupirocin 10/13; control 11/13 
Proportion of diabetic patients (%): NS 
Exclusion criteria: 
Patients who had been treated with intranasal mupirocin before 
randomisation; those with a known allergy to intranasal mupirocin; those 
with infection related to CAPD who were transferred to hemodialysis or 
transplantation. 
Interventions Intranasal mupirocin ointment applied to nares 2 x day for 5 days every 4 
weeks versus no ointment 
Outcomes Peritonitis - number of patients 
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Notes Funding source: None reported. 
Follow-up period: 12 months 
Loss to follow-up: NS 
Excluded from analysis: 2 (8%) excluded from analysis in mupirocin group 
due to renal transplantation (1) and death (1). 
Exclusions post-randomisation but pre-intervention: nil 
Stop or end point/s: When patient had been followed for 12 months. 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Coin toss. "Randomization was guided by the 
flip of a coin..." 
Allocation concealment (selection 
bias) 
Unclear risk Not stated 
Blinding of participants and 
personnel (performance bias) 
Unclear risk Insufficient information to permit judgement. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Insufficient information to permit judgement. 
Incomplete outcome data (attrition 
bias) 
Low risk Proportion missing not enough to have a 
clinically relevant effect. 
Selective reporting (reporting 
bias) 
Unclear risk 2 of 3 expected primary outcomes are reported 
(exit site/tunnel infection, peritonitis). 
Other bias Unclear risk No report of funding source. 
 
Swartz 1991 
Methods Study design: parallel RCT 
Study duration/time frame: Early 1987-1991 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: USA 
Health status: Patients beginning chronic PD with a new catheter 
Number: 59 patients; antibiotic prophylaxis 29; control 30 
Mean age ± SE: antibiotic prophylaxis 49 ± 3.4 years; control 51 ± 3.1 
years 
Sex (M/F): antibiotic prophylaxis 16/13; control 16/14 
Proportion of diabetic patients: antibiotic prophylaxis 34.5 (%); control 
33.3% 
 
Exclusion criteria: 
 
Patients beginning chronic PD with a new catheter but also: pediatric age 
group; extensive prior surgery; given general anesthesia; catheter 
placement incidental to another surgical procedure 
Interventions Trimethoprim/sulfamethoxazole (low dose) or cephalexin (250 mg) or 
clindamycin (300 mg) [3 days/week] versus none 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
152  
Outcomes All-cause mortality, peritonitis - rate, exit-site/tunnel infection - rate 
Notes Funding source: NS 
Follow-up period (mean ± SE): antibiotic prophylaxis 11.4 ± 1.3 months; 
control 12.3 ± 1.4 months 
Loss to follow-up: 2 of 29 in antibiotic prophylaxis group (6.9%) 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection 
bias) 
Low risk  
Random number table 
Allocation concealment (selection bias) Unclear risk Not stated. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk Insufficient information to permit 
judgement. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Insufficient information to permit 
judgement. 
Incomplete outcome data (attrition bias) Low risk Missing data balanced across groups, 
and reasons similar 
Selective reporting (reporting bias) Low risk 3 of 3 expected primary outcomes of 
interest are reported 
Other bias Unclear risk No report of funding source. 
 
Wadhwa 1995 
Methods Study design: parallel quasi RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: USA 
Health status: PD patients (presume they were current) 
Number: 50 patients; Amuchina 10% 25; povidone iodine 10% 25 
Mean age: Amuchina 10% 59 years; povidone iodine 10% 53 years 
Sex (M/F): NS 
Proportion of diabetic patients (%): Amuchina 10% 48%; povidone iodine 
10% 32% 
 
Exclusion criteria: NS 
Interventions Application of Amuchina 10% (sodium hypochlorite) vs povidone iodine 
10% solution at exit site 
Outcomes Exit site infection - number of patients; peritonitis - number of patients; 
catheter removal - number of patients 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
153  
 
 
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Randomisation method not stated. "Fifty PD patients were 
prospectively randomized to perform daily exit site care with 
soap and water followed by Amuchina 10% or Povidone 
Iodine 10% solution." 
Allocation concealment 
(selection bias) 
Unclear risk Not stated. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Not stated. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Not stated. 
Incomplete outcome 
data (attrition bias) 
Unclear risk Insufficient information to permit judgement. No details re 
missing data provided. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes are reported (exit site 
infection, peritonitis, catheter loss). 
Other bias Unclear risk No report of funding source. 
 
Wadhwa 1997 
Methods Study design: parallel quasi RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single centre 
Country: USA 
Health status: PD patients (presume they were current) 
Number: 39 patients; Amuchina 5% 18; povidone iodine 10% 21 
Mean age: Amuchina 5% 55 years; povidone iodine 10% 60 years 
Sex (M/F): NS 
Proportion of diabetic patients (%): Amuchina 5% 27.8%; povidone 
iodine 10% 28.6% 
 
Exclusion criteria: NS 
Interventions Application of Amuchina 5% (sodium hypochlorite) vs povidone iodine 
10% solution at exit site 
Outcomes Exit site infection - number of patients; peritonitis - number of patients; 
catheter removal - number of patients 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: NS 
Excluded from analysis: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Randomisation method not stated. "Thirty nine PD patients 
were prospectively randomized to perform daily exit site care 
with soap and water followed by Amuchina 5% or povidone 
iodine 10% solution." 
Allocation concealment 
(selection bias) 
Unclear risk Not stated. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Not stated. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Not stated. 
Incomplete outcome 
data (attrition bias) 
Unclear risk Insufficient information to permit judgement. No details re 
missing data provided. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes are reported (exit site 
infection, peritonitis, catheter loss). 
Other bias Unclear risk No report of funding source. 
 
Waite 1997 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Canada 
Health status: Patients with ESKD requiring PD catheter insertion 
Number: 117 patients; povidone iodine ointment 61; standard care 56 
Mean age ± SD: povidone iodine ointment 54.4 ± 15.1 years; standard 
care 53.2 ± 14.5 years 
Sex (M/F): povidone iodine ointment 33/28; standard care 30/26 
Proportion of diabetic patients (%): povidone iodine ointment 31.2%; 
standard care 35.7% 
 
Exclusion criteria: NS 
Interventions Povidone iodine (10%) ointment 3.5 g at every dressing change versus none
Outcomes All-cause mortality, peritonitis - number of patients, exit-site/tunnel 
infection - number of patients, catheter removal or replacement 
Notes Funding source: Purdue-Frederick, Toronto, Canada 
Follow-up period: 6 months. 
Loss to follow-up: NS 
3 (2.5%) excluded from analysis due to withdrawal (2) and failure to have 
PD catheter inserted (1) - group allocation NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Random number table 
Allocation concealment 
(selection bias) 
Unclear risk Not stated. 
Blinding of participants and 
personnel (performance 
bias) 
Unclear risk  
Insufficient information to permit judgement. 
Blinding of outcome 
assessment (detection bias) 
Low risk "Investigators assessing response (presence or absence 
of infection) were blinded to the treatment received by 
the individual patients". 
Incomplete outcome data 
(attrition bias) 
Low risk Proportion missing not enough to have a clinically 
relevant effect 
Selective reporting 
(reporting bias) 
Unclear risk 2 of 3 expected primary outcomes of interest are 
reported. 
Other bias High risk Funding source: Purdue-Frederick 
 
Wikdahl 1997 
Methods Study design: parallel RCT 
Study duration/time frame: 27 months 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Sweden 
Health status: New peritoneal dialysis patients 
Number: 38 patients; cefuroxime 18; control 20 
Mean age: Cefuroxime 56 (33-84) years; control 61 (34-84) years 
Sex (M/F): Cefuroxime 12/6; control 15/5 
Proportion of diabetic patients (%): Cefuroxime 33.3%; control 35% 
 
Exclusion criteria: NS 
Interventions Cefuroxime (i.v.) 1.5 g 0.5-2.0 hr before surgery + 250 mg i.p. in first 
dialysis bag versus none 
Outcomes Peritonitis - number of patients, exit-site/tunnel infection - number of 
patients (within 10 days of catheter insertion) 
Notes Funding source: NS 
Follow-up period: 10 days post surgery 
Loss to follow-up: NS 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: 6 months after catheter insertion 
Additional data requested from authors: Further information on methods 
and more detailed results were obtained from the corresponding author. 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation (selection 
bias) 
Unclear risk Closed envelopes used but insufficient 
details given 
Allocation concealment (selection bias) High risk Envelopes without all safeguards
Blinding of participants and personnel 
(performance bias) 
Unclear risk Not stated. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Not stated. 
Incomplete outcome data (attrition bias) Low risk No missing data. 
Selective reporting (reporting bias) Low risk 3 of 3 expected primary outcomes of 
interest are reported. 
Other bias Unclear risk No report of funding source. 
 
Wilson 1997 
Methods Study design: parallel RCT 
Study duration/time frame: NS 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: UK 
Health status: All patients in the peritoneal dialysis program 
Number: 149 patients; povidone iodine spray 77; no spray 72 
Mean age (range): Povidone iodine spray 53 (18-82) years; no spray 51 
(21-76) years 
Sex (M/F): Povidone iodine spray 55/22; no spray 43/29 
Proportion of diabetic patients (%): NS 
 
Exclusion criteria: NS 
Interventions Povidone iodine (2.5%) dry powder spray at exit site at every dressing 
change versus none 
Outcomes All-cause mortality, peritonitis - number of patients, exit-site/tunnel 
infection - number of patients, catheter removal or replacement, technique 
failure due to infection, local pruritus/rash 
Notes Funding source: NS. 
Follow-up period: 12 months 
Loss to follow-up: 1 in spray group (1.3%), 3 in control group (4.2%) 
Withdrawals: 5 in spray group (6.5%) (adverse events) 
1 (1.3%) excluded from analysis in povidone iodine spray group due to 
missing results 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: 12 months or until a significant difference was found 
between groups 
Additional data requested from authors: Further information on methods 
and more detailed results were obtained from the corresponding author. 
 
 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
157  
Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Random number table 
Allocation concealment (selection bias) Unclear risk Not stated. 
Blinding of participants and personnel 
(performance bias) 
Unclear risk Not stated. 
Blinding of outcome assessment 
(detection bias) 
Unclear risk Not stated. 
Incomplete outcome data (attrition 
bias) 
Low risk Proportion missing not enough to have a 
clinically relevant effect 
Selective reporting (reporting bias) Low risk 3 of 3 expected primary outcomes of 
interest are reported 
Other bias Unclear risk No report of funding source. 
 
Wong 2003 
Methods Study design: parallel RCT 
Study duration/time frame: 5 months 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: Hong Kong SAR, China 
Health status: current CAPD patients 
Number: 154 patients; mupirocin 73; control 81 
Mean age ± SD: mupirocin 60 ± 12 years; control 59 ± 13 years 
Sex (M/F): mupirocin 32/41; control 47/34 
Proportion of diabetic patients (%): mupirocin 26%; control 33.3% 
Exclusion criteria: 
Presence of significant mental disorder; presence of a significant skin 
problem; antibiotic treatment within 1 month of the start of the study; 
regular daily mupirocin ointment prophylaxis at the catheter exit site 
already prescribed before the start of the study; active exit site infection or 
peritonitis; ill health; use of any exit site dressing method other than 10% 
povidone iodine. 
Interventions Application of mupirocin ointment to exit site 1 x day after routine exit-site 
dressing versus usual daily exit-site care 
Outcomes Exit site infection - number of patients, exit site infection - rate, peritonitis - 
number of patients, peritonitis - rate 
Notes Funding source: NS 
Follow-up period: NS 
Loss to follow-up: 1 withdrawal (not stated which intervention group) 
Excluded from analysis: 5 (6.4%) from mupirocin group; 7 (8.0%) from 
control group 
Exclusions post-randomisation but pre-intervention: NS 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Randomisation method not stated. "Patients not excluded 
were randomized into two groups." No description of 
sequence generation. 
Allocation concealment 
(selection bias) 
Unclear risk No description of sequence generation. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk  
Not stated. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk  
Not stated. 
Incomplete outcome data 
(attrition bias) 
Low risk Missing data balanced across groups, and reasons similar. 
Outcome data for tunnel infection not reported - this is ok 
as this infection is the least frequent one in PD patients. 
Selective reporting 
(reporting bias) 
Low risk 3 of 3 expected primary outcomes are reported (exit site 
infection, peritonitis, catheter loss). 
Other bias Unclear risk No report of funding source. 
 
Zimmerman 1991 
Methods Study design: parallel RCT 
Study duration/time frame: 1 September 1987 - 31 May 1989 
Participants Inclusion criteria 
 
Setting: Single tertiary centre 
Country: USA 
Health status: Adults who had completed at least 6 months of peritoneal 
dialysis 
Number: 64 patients; rifampin 32; control 32 
Mean age ± SEM: Rifampin 53 ± 3 years; control 55 ± 4 years 
Sex (M/F): Rifampin 17/15; control 24/8 
Proportion of diabetic patients (%): Rifampin 43.8%; control 37.5% 
 
Exclusion criteria: NS 
Interventions Rifampin 300 mg x 2/day x 5 days, every 3 months versus none 
Outcomes Peritonitis - number of patients, peritonitis - rate, catheter removal or 
replacement, toxicity 
Notes Funding source: Baxter Healthcare 
Follow-up period (mean ± SEM): Rifampin 10.2 ± 1.2 months; control 12.0
± 1.3 months 
Loss to follow-up: NS 
Withdrawals: Rifampin 4/32 (12.5%); nil in control group 
Excluded from analysis: NS 
Exclusions post-randomisation but pre-intervention: NS 
Stop or end point/s: NS 
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Risk of bias table 
Bias Authors' judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Random number table 
Allocation concealment 
(selection bias) 
Unclear risk No details of allocation method given. 
Blinding of participants and 
personnel (performance bias) 
High risk No blinding and the outcomes are likely to be 
influenced by lack of blinding and knowledge of the 
interventions. 
Blinding of outcome 
assessment (detection bias) 
High risk No blinding and knowledge of the interventions could 
influence outcome assessment. 
Incomplete outcome data 
(attrition bias) 
High risk 12.5% in rifampin group withdrew; 0% in control 
group withdrew. Proportion missing enough to have a 
clinically relevant effect. 
Selective reporting (reporting 
bias) 
Low risk Protocol not available but all expected outcomes of 
interest are reported. 
Other bias High risk Funding source: Baxter Healthcare 
 
 
Table 4.2: Characteristics of excluded studies 
 
Al Hwiesh 2008 
Reason for exclusion Not an RCT. A cohort study 
Ayliffe 1984 
 
Reason for exclusion Not an RCT 
Casey 2000 
 
Reason for exclusion Not an RCT. A cohort study 
Cavdar 2004 
 
Reason for exclusion Not an intervention of interest 
Churchill 1989 
 
Reason for exclusion Not an intervention of interest 
Crabtree 2003 
 
Reason for exclusion Not an intervention of interest 
de Fijter 1989 
 
Reason for exclusion Treatment study not prevention. Not an RCT 
 
 
Stop or end point/s: NS 
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de Fijter 1992a 
Reason for exclusion Pharmacokinetics study not prevention 
Fong 1993 
 
Reason for exclusion Preliminary results of an ongoing study. Not an RCT. No reply from 
authors to query email 
Gadallah 2000c 
 
Reason for exclusion Urokinase is not an antimicrobial agent. Treatment study not prevention 
Klaus 2002 
 
Reason for exclusion It is an RCT but peritonitis data is not readily available. No reply from 
authors to query email 
Maiorca 1983 
 
Reason for exclusion Not an intervention of interest 
Munoz 1989 
 
Reason for exclusion Not an RCT. No control group 
Naylor 1997 
 
Reason for exclusion Small pilot study 
Plum 1997a 
 
Reason for exclusion Treatment study not prevention 
Read 1985 
 
Reason for exclusion Not an RCT. No control group 
Rodriguez-
Perez 1989 
 
Reason for exclusion Not an intervention of interest 
Ryckelynck 
1988 
 
Reason for exclusion Not an RCT. No control group 
Stegmayr 1991 
 
Reason for exclusion Not an RCT. A cohort study with consecutive interventions 
Thomae 1982 
 
Reason for exclusion Study only went for 84 hours. Of the 7 patients, 3 had previously had 
peritonitis 
Trooskin 1990 
 
Reason for exclusion Not an intervention of interest 
Verger 1987 
 
Reason for exclusion Not an intervention of interest 
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Table 4.3: Summary of findings tables 
 
1 Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for 
Preventing peritonitis in peritoneal dialysis patients 
Oral or topical or intraperitoneal antibiotics versus placebo/no treatment for preventing 
peritonitis in peritoneal dialysis patients 
Patient or population: Patients with CKD on peritoneal dialysis 
Settings: Tertiary settings 
Intervention: Oral or topical or intraperitoneal antibiotics versus placebo/no treatment 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments
Assumed 
risk 
Corresponding risk
Control Oral or topical or 
intraperitoneal 
antibiotics versus 
placebo/no 
treatment 
Peritonitis 
(number of 
patients with one 
or more 
episodes) 
Study population RR 0.82
(0.57 to 
1.19) 
395 
(5 studies) 
⊕⊕⊝⊝
low1,2 
 
360 per 
1000 
295 per 1000 
(205 to 428) 
Moderate 
385 per 
1000 
316 per 1000 
(219 to 458)
Exit-site/tunnel 
infection 
(number of 
patients with one 
or more 
episodes) 
Study population RR 0.45
(0.19 to 
1.04) 
191 
(3 studies) 
⊕⊕⊝⊝
low2 
 
176 per 
1000 
79 per 1000 
(34 to 184) 
Moderate 
231 per 
1000 
104 per 1000 
(44 to 240) 
Catheter 
removal or 
replacement 
(number of 
patients) 
Study population RR 0.82
(0.46 to 
1.46) 
395 
(5 studies) 
⊕⊕⊝⊝
low1,2 
 
115 per 
1000 
94 per 1000 
(53 to 168) 
Moderate 
156 per 
1000 
128 per 1000 
(72 to 228) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in 
footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
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Footnotes 
1  Unclear or high risk of bias in 3 of 5 studies 
2  Wide confidence intervals due to small patient numbers 
 
2 Nasal antibiotics versus placebo/no treatment for preventing peritonitis in 
peritoneal dialysis patients 
Nasal antibiotics versus no treatment for preventing peritonitis in peritoneal dialysis patients 
Patient or population: Patients with CKD on peritoneal dialysis 
Settings: Tertiary settings 
Intervention: Nasal antibiotics versus placebo/no treatment 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments
Assumed 
risk 
Corresponding 
risk 
Control Nasal antibiotics 
versus placebo/no 
treatment 
Peritonitis 
(number of 
patients with one 
or more episodes) 
Study population RR 0.94
(0.67 to 
1.31) 
338 
(3 studies) 
⊕⊕⊝⊝	
low¹,² 
 
294 per 
1000 
276 per 1000 
(197 to 385) 
Moderate 
331 per 
1000 
311 per 1000 
(222 to 434)
Exit site/ tunnel 
infection (number 
of patients with 
one or more 
episodes) 
Study population RR 1.34
(0.62 to 
2.87) 
338 
(3 studies) 
⊕⊕⊝⊝	
low¹,² 
 
165 per 
1000 
221 per 1000 
(102 to 473) 
Moderate 
188 per 
1000 
252 per 1000 
(117 to 540)
Catheter removal 
or replacement 
(number of 
patients) 
Study population RR 0.92
(0.48 to 
1.78) 
289 
(2 studies) 
⊕⊕⊝⊝	
low¹,² 
 
103 per 
1000 
95 per 1000 
(49 to 183) 
Moderate 
265 per 
1000 
244 per 1000 
(127 to 472) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in 
footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
Very low quality: We are very uncertain about the estimate. 
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GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Footnotes 
¹ Unclear risk of bias for allocation concealment in largest study (Mupirocin SG 1996) 
² Wide confidence intervals due to small patient numbers 
Abbreviations: CI - confidence interval; RR - risk ratio; GRADE - Grading of 
Recommendations Assessment, Development and Evaluation 
3 Topical disinfectants versus standard care or other active treatment (antibiotic 
or other disinfectant) for preventing peritonitis in peritoneal dialysis patients 
Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant) for preventing peritonitis in peritoneal dialysis patients 
Patient or population: Patients with CKD on peritoneal dialysis 
Settings: Tertiary settings 
Intervention: Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant) 
Outcomes Illustrative comparative risks* 
(95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments
Assumed 
risk 
Corresponding risk 
Control Topical disinfectants 
versus standard care 
or other active 
treatment (antibiotic 
or other 
disinfectant) 
Peritonitis 
(number of 
patients with 
one or more 
episodes) 
Study population RR 0.83
(0.65 to 
1.06) 
853 
(6 studies) 
⊕⊕⊝⊝
low1,2 
 
235 per 
1000 
195 per 1000 
(153 to 250) 
Moderate 
152 per 
1000 
126 per 1000 
(99 to 161)
Exit site/tunnel 
infection 
(number of 
patients with 
one or more 
episodes) 
Study population RR 0.97
(0.74 to 
1.27) 
913 
(7 studies) 
⊕⊕⊝⊝
low1,2 
 
238 per 
1000 
230 per 1000 
(176 to 302) 
Moderate 
222 per 
1000 
215 per 1000 
(164 to 282)
Catheter 
removal or 
replacement 
(number of 
Study population RR 0.89
(0.57 to 
1.38) 
792 
(6 studies) 
⊕⊕⊝⊝
low1,2 
 
97 per 
1000 
86 per 1000 
(55 to 134) 
Moderate 
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patients) 93 per 
1000 
83 per 1000 
(53 to 128) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in 
footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
 
Footnotes 
1  Unclear allocation in several studies 
2  Imprecision due to small number of patients and events in several studies 
4 Antifungal versus placebo/no treatment for preventing peritonitis in 
peritoneal dialysis patients 
Antifungal versus placebo/no treatment for preventing fungal peritonitis in peritoneal dialysis 
patients 
Patient or population: Patients with CKD on peritoneal dialysis 
Settings: Tertiary settings 
Intervention: Antifungal versus placebo/no treatment during antibiotic course 
Outcomes Illustrative comparative 
risks* (95% CI) 
Relative 
effect 
(95% 
CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments
Assumed 
risk 
Corresponding 
risk 
Control Antifungal versus 
placebo/no 
treatment 
Fungal 
peritonitis 
(number of 
patients with 
one or more 
episodes) 
Study population RR 0.28 
(0.12 to 
0.63) 
817 
(2 studies) 
⊕⊕⊝⊝	
low1,2 
 
64 per 
1000 
18 per 1000 
(8 to 40) 
Moderate 
64 per 
1000 
18 per 1000 
(8 to 40) 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in 
footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in 
the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; 
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
Very low quality: We are very uncertain about the estimate. 
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Footnotes 
1  High risk of bias in one study (Lo 1996) 
2  Imprecision due to small number of events and studies 
 
Table 4.4: Additional tables 
 
1 Comparisons in original review and updated review 
Comparisons in original review Comparisons in updated review 
Oral antibiotics versus none Oral or topical antibiotics versus placebo/no treatment 
Nasal antibiotics versus none Oral or topical antibiotics versus other antibiotic 
Peri-operative IV prophylaxis versus 
none Nasal antibiotics versus no treatment 
Peri-operative IV prophylaxis head-to-
head 
Pre/peri-operative IV prophylaxis versus none or head-to- 
head 
Topical disinfectants versus none Topical disinfectants versus standard care or other active treatment (antibiotic or other disinfectant) 
Germicidal chamber versus none Germicidal chamber versus none 
Antistaphylococcal vaccine 
(Staphypan) versus placebo Dressing systems (any) 
Antibiotic prophylaxis head-to-head 
agents Silver ring system on catheter versus none 
 Antistaphylococcal vaccine (Staphypan) versus placebo 
 Antifungal versus placebo/no treatment 
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2 Guidelines on antimicrobial interventions to prevent peritonitis in PD 
Guideline Country Year Recommendation 
Kidney-Disease 
Outcomes Quality 
Initiative 
United 
States of 
America 
 
NA 
 
No guideline 
 
 
 
 
 
 
 
 
 
The Renal 
Association 
 
 
 
 
 
 
 
 
 
 
United 
Kingdom 
 
 
 
 
 
 
 
 
 
 
April 2008
July 2010 
Guideline 3.1 - PD Access: Implantation Protocol. 
 
Recommended that renal units have clear protocols 
for peri-operative catheter care including the use of 
antibiotic prophylaxis (1A). 
 
Guideline 5.1.4 - PD Infectious Complications: 
Prevention Strategies 
 
Recommended that initial catheter insertion be 
accompanied by antibiotic prophylaxis (1B). 
 
Guideline 5.1.5 - PD Infectious Complications: 
Prevention Strategies 
 
Recommended that invasive procedures be 
accompanied by antibiotic prophylaxis and 
emptying the abdomen of dialysis fluid for a period 
commensurate with the procedure (1C). 
 
Guideline 5.1.6 - PD Infectious Complications: 
   Prevention Strategies 
 
Recommended that topical antibiotic administration 
be used to reduce the frequency of S. aureus and 
Gram-negative exit-site infection and peritonitis 
(1A). 
Canadian Society of 
Nephrology Canada NA No guideline 
European Renal Best 
Practice Europe NA No guideline 
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International Society 
for Peritoneal 
Dialysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
July 2010 
November 
2011 
Guideline 3.1: Implantation Protocol (1A) 
 
Recommended that renal units have clear protocols 
for perioperative catheter care, including the use of 
antibiotic prophylaxis. 
Recommended that perioperative catheter care 
protocol include screening for methicillin-resistant 
S. aureus (MRSA) and nasal carriage of S. aureus. 
Recommended that prophylactic antibiotics be 
administered to reduce the risk of catheter-site 
infection, peritonitis and wound sepsis and there is 
randomised controlled trial (RCT) evidence for the 
use of vancomycin. 
 
Position Statement: Catheter Placement to Prevent 
Catheter Infections and the Related Peritonitis 
Episodes 
 
Prophylactic antibiotics administered at the time of 
insertion decrease the infection risk. A first- 
generation cephalosporin or vancomycin can be 
used, but suggested each program should weigh the 
potential benefit against the risk of vancomycin use 
(development of resistant organisms). 
There is no data on the effectiveness of obtaining 
nose cultures before catheter insertion, and treating 
patients positive for S. aureus nasal carriage. 
 
Position Statement: Exti-Site Care to Prevent 
Peritonitis 
 
Antibiotic protocols against S. aureus are effective 
in reducing the risk of S. aureus catheter infections. 
All PD patients should use topical antibiotic either at 
the catheter exit-site or intranasally or both. 
Topical antibiotic ointments (as opposed to 
antibiotic creams) should not be used at the exit site 
of polyurethane catheters. 
 
Position Statement: Prevention of Fungal Peritonitis 
    
Most episodes of fungal peritonitis are preceded by 
courses of antibiotics. 
Fungal prophylaxis during antibiotic therapy may 
prevent some cases of Candida peritonitis in 
programs that have high rates of fungal peritonitis. 
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Kidney Health 
Australia-Caring for 
Australasians with 
Renal Impairment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Australia/ 
New 
Zealand 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
February 
2014 
Guideline 6. Prophylactic Antibiotics for Insertion of 
PD Catheters 
 
Recommended that intravenous antibiotic 
prophylaxis be used prior to peritoneal dialysis 
catheter insertion to reduce the risk of early 
peritonitis. 
Vancomycin, cephalosporins and gentamicin have 
demonstrated effectiveness in reducing the risk of 
peritonitis. 
 
Guideline 8. Treatment of Peritoneal Dialysis- 
Associated Fungal Peritonitis 
 
Oral antifungal prophylaxis should be considered 
when antibiotics are administered to patients 
undergoing peritoneal dialysis to reduce the risk of 
developing fungal peritonitis. 
Prophylactic antifungals should be administered 
before gynaecological procedures. 
 
Guideline 10. Prophylaxis for Exit Site/Tunnel 
Infections Using Mupirocin 
 
Recommended that prophylactic therapy using 
mupirocin ointment be used, especially for S. aureus 
carriage (intranasally or at the exit site) to decrease 
the risk of S. aureus catheter exit site/tunnel 
infections and peritonitis. 
Suggested that clean the PD catheter exit site daily 
and apply a topical antimicrobial agent (either 
mupirocin or gentamicin). 
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3 Other outcomes analysed 
Outcome analysed Number of studies Number of patients RR (95% CI) 
Oral antibiotic prophylaxis 
Pruritus 1 64 3.00 (0.13 to 71.00) 
Diarrhoea 1 64 0.09 (0.01 to 1.58) 
Nausea 1 64 9.00 (0.50 to 160.59) 
Allergy 1 64 5.00 (0.25 to 100.20) 
Nasal antibiotic prophylaxis 
Nasal irritation 1 15 2.10 (0.10 to 44.40) 
Rhinitis 1 267 0.74 (0.27 to 2.09) 
Headache 1 267 0.99 (0.14 to 6.94) 
Diarrhoea 1 267 1.65 (0.40 to 6.78) 
Nausea 1 267 0.99 (0.14 to 6.94) 
Vomiting 1 267 2.98 (0.61 to 14.94) 
Pruritus 1 267 1.49 (0.25 to 8.77) 
Topical disinfectants 
Technique failure 1 149 0.19 (0.01 to 3.83) 
Pruritus 1 149 10.29 (0.58 to 182.92) 
 
 
 
 
 
Table 4.5: Data and analyses tables 
1 Oral or topical antibiotics versus placebo/no treatment 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Peritonitis (number of 
patients with one or more 
episodes) 
5 395 Risk Ratio (M-H, Random, 
95% CI) 
0.82 [0.57, 1.19] 
1.1.1 Oral antibiotic versus 
placebo 
4 241 Risk Ratio (M-H, Random, 
95% CI) 
0.87 [0.58, 1.32] 
1.1.2 Mupirocin ointment 
versus standard care 
1 154 Risk Ratio (M-H, Random, 
95% CI) 
0.55 [0.22, 1.40] 
1.2 Peritonitis rate 
(episodes/total patient- 
months on PD) 
3 1440 Risk Ratio (M-H, Random, 
95% CI) 
0.68 [0.40, 1.14] 
1.2.1 Any systemic 
antibiotic versus placebo/no 
treatment (excluding 
nystatin) 
3 1440 Risk Ratio (M-H, Random, 
95% CI) 
0.68 [0.40, 1.14] 
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1.3 Exit-site/tunnel infection 
(number of patients with one 
or more episodes) 
3 191 Risk Ratio (M-H, Random, 
95% CI) 
0.45 [0.19, 1.04] 
1.3.1 Any systemic 
antibiotic versus placebo/no 
treatment 
3 191 Risk Ratio (M-H, Random, 
95% CI) 
0.45 [0.19, 1.04] 
1.4 Exit-site/tunnel infection 
rate (episodes/total patient- 
months on PD) 
2 939 Risk Ratio (M-H, Random, 
95% CI) 
0.42 [0.17, 1.05] 
1.4.1 Any systemic 
antibiotic versus placebo/no 
treatment 
2 939 Risk Ratio (M-H, Random, 
95% CI) 
0.42 [0.17, 1.05] 
1.5 Catheter removal or 
replacement (number of 
patients) 
5 395 Risk Ratio (M-H, Random, 
95% CI) 
0.82 [0.46, 1.46] 
1.5.1 Any systemic 
antibiotic versus placebo/no 
treatment 
5 395 Risk Ratio (M-H, Random, 
95% CI) 
0.82 [0.46, 1.46] 
1.6 Mortality (all-cause) 4 201 Risk Ratio (M-H, Random, 
95% CI) 
0.88 [0.41, 1.89] 
1.6.1 Any systemic 
antibiotic versus placebo/no 
treatment 
4 201 Risk Ratio (M-H, Random, 
95% CI) 
0.88 [0.41, 1.89] 
1.7 Mortality due to 
peritonitis 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.7.1 Oral antibiotic versus 
placebo 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.8 Adverse effects 2  Risk Ratio (M-H, Random, No totals 
   95% CI)  
1.8.1 Diarrhoea 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.8.2 Nausea 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.8.3 Pruritis (generalised) 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.8.4 Nasal irritation 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
1.8.5 Allergy 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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2 Oral or topical antibiotics versus other antibiotic 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Peritonitis (number 
of patients with one or 
more episodes) 
4 314 Risk Ratio (M-H, Random, 
95% CI) 
1.28 [0.89, 1.84] 
2.1.1 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1 18 Risk Ratio (M-H, Random, 
95% CI) 
0.25 [0.03, 1.82] 
2.1.2 Mupirocin ointment 
versus rifampin (oral) 
1 82 Risk Ratio (M-H, Random, 
95% CI) 
1.25 [0.67, 2.33] 
2.1.3 Mupirocin 
ointment/cream versus 
gentamicin cream (topical) 
2 214 Risk Ratio (M-H, Random, 
95% CI) 
1.39 [0.93, 2.07] 
2.2 Peritonitis rate 
(episodes/total patient- 
months on PD) 
5  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.2.1 Mupirocin ointment 
versus polysporin triple 
ointment (exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.2.2 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.2.3 Mupirocin ointment 
versus neomycin sulphate 
ointment (nasal) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.2.4 Mupirocin ointment 
versus rifampin (oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.2.5 Mupirocin ointment 
versus gentamicin cream 
(exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.3 Exit-site/tunnel infection 
(number of patients with one 
4 336 Risk Ratio (M-H, Random, 
95% CI) 
1.28 [0.71, 2.31] 
or more episodes)     
2.3.1 Mupirocin ointment 
versus sodium fusidate 
ointment (topical) 
1 100 Risk Ratio (M-H, Random, 
95% CI) 
0.91 [0.42, 1.95] 
2.3.2 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1 22 Risk Ratio (M-H, Random, 
95% CI) 
2.41 [0.76, 7.62] 
2.3.3 Mupirocin 
ointment/cream versus 
gentamicin cream (topical) 
2 214 Risk Ratio (M-H, Random, 
95% CI) 
1.19 [0.41, 3.46] 
2.4 Exit-site/tunnel infection 
rate (episodes/total patient- 
months on PD) 
3  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.4.1 Mupirocin ointment 
versus polysporin triple 
ointment (exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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2.4.2 Mupirocin ointment 
versus gentamicin cream 
(exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.4.3 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.5 Catheter removal or 
replacement (number 
of patients) 
4  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.5.1 Mupirocin ointment 
versus polysporin triple 
ointment (exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.5.2 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.5.3 Mupirocin ointment 
(exit site) versus rifampin 
(oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.5.4 Mupirocin cream 
versus gentamicin 
cream (exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.6 Mortality (all-cause) 4  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.6.1 Mupirocin ointment vs 
polysporin triple ointment 
(exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.6.2 Sodium fusidate 
ointment versus ofloxacin 
(oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.6.3 Mupirocin ointment 
versus rifampin (oral) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.6.4 Mupirocin ointment 
versus gentamicin cream 
(exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.7 Technique failure 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.7.1 Mupirocin ointment 
versus polysporin triple 
ointment (exit site) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
2.8 Adverse effects 3 419 Risk Ratio (M-H, Random, 
95% CI) 
0.54 [0.21, 1.39] 
2.8.1 Nausea 1 82 Risk Ratio (M-H, Random, 
95% CI) 
0.09 [0.01, 1.59] 
2.8.2 Pruritus (local) 2 337 Risk Ratio (M-H, Random, 
95% CI) 
0.65 [0.29, 1.49] 
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3 Nasal antibiotics versus placebo/no treatment 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
3.1 Peritonitis (number of 
patients with one or more 
episodes) 
3 338 Risk Ratio (M-H, Random, 
95% CI) 
0.94 [0.67, 1.31] 
3.2 Peritonitis rate 
(episodes/total patient- 
months on PD) 
2 2797 Risk Ratio (M-H, Random, 
95% CI) 
0.67 [0.16, 2.77] 
3.3 Exit site and tunnel 
infection (number of patients 
with one or more episodes) 
3 338 Risk Ratio (M-H, Random, 
95% CI) 
1.34 [0.62, 2.87] 
3.4 Exit site and tunnel 
infection rate (episodes/total 
patient-months on PD) 
2 2796 Risk Ratio (M-H, Random, 
95% CI) 
0.91 [0.29, 2.92] 
3.5 Catheter removal or 
replacement (number of 
patients) 
2 289 Risk Ratio (M-H, Random, 
95% CI) 
0.92 [0.48, 1.78] 
3.6 Mortality (all-cause) 3 338 Risk Ratio (M-H, Random, 
95% CI) 
0.89 [0.53, 1.47] 
3.7 Adverse effects 2 1624 Risk Ratio (M-H, Random, 
95% CI) 
1.28 [0.70, 2.32] 
3.7.1 Headache 1 267 Risk Ratio (M-H, Random, 
95% CI) 
0.99 [0.14, 6.94] 
3.7.2 Diarrhoea 1 267 Risk Ratio (M-H, Random, 
95% CI) 
1.65 [0.40, 6.78] 
3.7.3 Nausea 1 267 Risk Ratio (M-H, Random, 
95% CI) 
0.99 [0.14, 6.94] 
3.7.4 Vomiting 1 267 Risk Ratio (M-H, Random, 
95% CI) 
2.98 [0.61, 14.49] 
3.7.5 Pruritis 1 267 Risk Ratio (M-H, Random, 
95% CI) 
1.49 [0.25, 8.77] 
3.7.6 Nasal irritation/rhinitis 2 289 Risk Ratio (M-H, Random, 
95% CI) 
0.93 [0.30, 2.94] 
4 Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
4.1 Peritonitis (number of 
patients with one or more 
episodes) 
4  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.1.1 Vancomycin versus 
placebo 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.1.2 Cefazolin versus 
placebo 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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4.1.3 IV gentamicin versus 
no antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.1.4 IV cefazolin + 
gentamicin versus no 
antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.1.5 IV cefuroxime + 
cefuroxime (intraperitoneal) 
versus no antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.1.6 Vancomycin versus 
cefazolin 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2 Exit site/tunnel infection 
(number of patients with one 
or more episodes) 
4  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.1 Vancomycin versus 
placebo 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.2 Cefazolin versus 
placebo 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.3 IV gentamicin versus 
no antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.4 IV cefazolin + 
gentamicin versus no 
antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.5 IV cefuroxime + 
cefuroxime (intraperitoneal) 
versus no antibiotics 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.2.6 Vancomycin versus 
cefazolin 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.3 Catheter removal or 
replacement (number of 
patients) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
4.4 Mortality (all-cause) 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
5 Topical disinfectants versus standard care or other active treatment (antibiotic or 
other disinfectant) 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
5.1 Peritonitis (number of 
patients with one or more 
episodes) 
6 853 Risk Ratio (M-H, Random, 
95% CI) 
0.83 [0.65, 1.06] 
5.1.1 Disinfectant versus 
standard care 
3 393 Risk Ratio (M-H, Random, 
95% CI) 
0.81 [0.52, 1.26] 
5.1.2 Disinfectant versus 
other active treatment 
(antibiotics, other 
disinfectant) 
3 460 Risk Ratio (M-H, Random, 
95% CI) 
0.84 [0.62, 1.13] 
5.2 Exit site/tunnel infection 
(number of patients with one 
or more episodes) 
8 973 Risk Ratio (M-H, Random, 
95% CI) 
1.00 [0.75, 1.33] 
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5.2.1 Disinfectant versus 
standard care 
4 453 Risk Ratio (M-H, Random, 
95% CI) 
0.74 [0.45, 1.20] 
5.2.2 Disinfectant versus 
other active treatment 
(antibiotics, other 
disinfectant) 
4 520 Risk Ratio (M-H, Random, 
95% CI) 
1.19 [0.89, 1.60] 
5.3 Exit site/tunnel infection 
rate (episodes/total patient- 
months on PD) 
2 1752 Risk Ratio (M-H, Random, 
95% CI) 
1.25 [0.31, 4.93] 
5.3.1 Disinfectant versus 
other active treatment 
(antibiotics, other 
disinfectant) 
2 1752 Risk Ratio (M-H, Random, 
95% CI) 
1.25 [0.31, 4.93] 
5.4 Catheter removal or 
replacement (number of 
patients) 
7 852 Risk Ratio (M-H, Random, 
95% CI) 
0.89 [0.57, 1.38] 
5.4.1 Disinfectant versus 
standard care 
2 266 Risk Ratio (M-H, Random, 
95% CI) 
0.73 [0.34, 1.55] 
5.4.2 Disinfectant versus 
other active treatment 
(antibiotics, other 
disinfectant) 
5 586 Risk Ratio (M-H, Random, 
95% CI) 
0.98 [0.57, 1.69] 
5.5 Mortality (all-cause) 4 697 Risk Ratio (M-H, Random, 
95% CI) 
0.88 [0.53, 1.44] 
5.5.1 Disinfectant versus 
standard care 
2 266 Risk Ratio (M-H, Random, 
95% CI) 
1.24 [0.54, 2.84] 
5.5.2 Disinfectant versus 
other active treatment 
(antibiotics, other 
disinfectant) 
2 431 Risk Ratio (M-H, Random, 
95% CI) 
0.73 [0.39, 1.35] 
5.6 Technique failure 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
5.7 Pruritus (local) 4 609 Risk Ratio (M-H, Random, 
95% CI) 
2.80 [1.21, 6.48] 
 
6 Germicidal chamber versus none 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
6.1 Peritonitis rate 
(episodes/total patient- 
months on PD) 
2 1855 Risk Ratio (M-H, Random, 
95% CI) 
1.05 [0.74, 1.51] 
6.2 Mortality (all-cause) 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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7 Dressing systems (any) 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
7.1 Exit site/tunnel infection 
(number of patients with one 
or more episodes) 
3  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.1.1 Chlorhexidine 
gluconate plus water versus 
povidone-iodine solution 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.1.2 Sodium hypochlorite 
solution versus povidone- 
iodine solution 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.1.3 Shower plus gauze 
versus dressing pack plus 
fixomull 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.1.4 Blisterfilm versus 
gauze 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.2 Exit site/tunnel infection 
rate (episodes/total patient- 
months on PD) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
7.2.1 Shower plus gauze 
versus dressing pack plus 
fixomull 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
8 Silver ring system on catheter versus none 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
8.1 Peritonitis (number of 
patients with one or more 
episodes) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
8.2 Exit site/tunnel infection 
(number of patients with one 
or more episodes) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
8.3 Catheter removal or 
replacement (number of 
patients) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
8.4 Mortality (all-cause) 1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
9 Antistaphylococcal vaccine (Staphypan) versus placebo 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
9.1 Peritonitis rate 
(episodes/total patient- 
months on PD) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
9.2 Exit site/tunnel infection 
rate (episodes/total patient- 
months on PD) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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10 Antifungal versus placebo/no treatment 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
10.1 Fungal peritonitis 
(number of patients with one 
or more episodes) 
2 817 Risk Ratio (M-H, Random, 
95% CI) 
0.28 [0.12, 0.63] 
10.2 Fungal peritonitis rate 
(episodes/total patient- 
months on PD) 
1  Risk Ratio (M-H, Random, 
95% CI) 
No totals 
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Appendices 
 
Table 4.6: Electronic search strategies 
Database searched Search terms 
 
 
 
 
CENTRAL 
peritoneal next dialysis 
PERITONEAL DIALYSIS (MeSH explode)) 
pd or capd or ccpd 
#1 or #2 or #3 
PERITONITIS (MeSH) 
periton* 
#5 or #6 
#4 and #7 
 
 
 
 
MEDLINE 
exp Peritoneal Dialysis/ 
peritoneal dialysis.tw. 
(PD or CAPD or CCPD).tw. 
or/1-3 
Peritonitis/ 
peritonitis.tw. 
(periton$ and infect$).tw. 
or/8-10 
and/4,7,11 
 
 
 
 
 
EMBASE 
peritoneal dialysis/ 
continuous ambulatory peritoneal dialysis/ 
(PD or CAPD or CCPD).tw. 
peritoneal dialysis.tw. 
or/1-4 
exp Peritonitis/ 
Catheter Infection/ 
peritonitis.tw. 
infect$.tw. 
. or/6-9 
. and/5,10 
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Table 4.7: Risk of bias assessment tool 
Potential source of bias Assessment criteria 
Random sequence 
generation 
Selection bias (biased 
allocation to interventions) 
due to inadequate 
generation of a randomised 
sequence 
Low risk of bias: Random number table; computer random number 
generator; coin tossing; shuffling cards or envelopes; throwing dice; 
drawing of lots; minimisation (minimisation may be implemented 
without a random element, and this is considered to be equivalent to 
being random). 
High risk of bias: Sequence generated by odd or even date of birth; date 
(or day) of admission; sequence generated by hospital or clinic record 
number; allocation by judgement of the clinician; by preference of the 
participant; based on the results of a laboratory test or a series of tests; 
by availability of the intervention. 
Unclear: Insufficient information about the sequence generation process 
to permit judgement. 
Allocation concealment 
Selection bias (biased 
allocation to interventions) 
due to inadequate 
concealment of allocations 
prior to assignment 
Low risk of bias: Randomisation method described that would not allow 
investigator/participant to know or influence intervention group before 
eligible participant entered in the study (e.g. central allocation, 
including telephone, web-based, and pharmacy-controlled, 
randomisation; sequentially numbered drug containers of identical 
appearance; sequentially numbered, opaque, sealed envelopes). 
High risk of bias: Using an open random allocation schedule (e.g. a list 
of random numbers); assignment envelopes were used without 
appropriate safeguards (e.g. if envelopes were unsealed or non-opaque 
or not sequentially numbered); alternation or rotation; date of birth; case 
record number; any other explicitly unconcealed procedure. 
Unclear: Randomisation stated but no information on method used is 
available. 
Blinding of participants 
and  personnel 
Performance bias due to 
knowledge of the allocated 
interventions by participants 
and personnel during the 
study 
Low risk of bias: No blinding or incomplete blinding, but the review 
authors judge that the outcome is not likely to be influenced by lack of 
blinding; blinding of participants and key study personnel ensured, and 
unlikely that the blinding could have been broken. 
High risk of bias: No blinding or incomplete blinding, and the outcome 
is likely to be influenced by lack of blinding; blinding of key study 
participants and personnel attempted, but likely that the blinding could 
have been broken, and the outcome is likely to be influenced by lack of 
blinding. 
Unclear: Insufficient information to permit judgement 
Blinding of outcome 
assessment 
Detection bias due to 
knowledge of the allocated 
interventions by outcome 
assessors. 
Low risk of bias: No blinding of outcome assessment, but the review 
authors judge that the outcome measurement is not likely to be 
influenced by lack of blinding; blinding of outcome assessment ensured, 
and unlikely that the blinding could have been broken. 
High risk of bias: No blinding of outcome assessment, and the outcome 
measurement is likely to be influenced by lack of blinding; blinding of 
outcome assessment, but likely that the blinding could have been 
broken, and the outcome measurement is likely to be influenced by lack 
of blinding. 
Unclear: Insufficient information to permit judgement 
Incomplete outcome data Low risk of bias: No missing outcome data; reasons for missing 
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Attrition bias due to 
amount, nature or handling 
of incomplete outcome data. 
outcome data unlikely to be related to true outcome (for survival data, 
censoring unlikely to be introducing bias); missing outcome data 
balanced in numbers across intervention groups, with similar reasons for 
missing data across groups; for dichotomous outcome data, the 
proportion of missing outcomes compared with observed event risk not 
enough to have a clinically relevant impact on the intervention effect 
estimate; for continuous outcome data, plausible effect size (difference 
in means or standardised difference in means) among missing outcomes 
not enough to have a clinically relevant impact on observed effect size; 
missing data have been imputed using appropriate methods. 
High risk of bias: Reason for missing outcome data likely to be related 
to true outcome, with either imbalance in numbers or reasons for 
missing data across intervention groups; for dichotomous outcome data, 
the proportion of missing outcomes compared with observed event risk 
enough to induce clinically relevant bias in intervention effect estimate; 
for continuous outcome data, plausible effect size (difference in means 
or standardized difference in means) among missing outcomes enough 
to induce clinically relevant bias in observed effect size; ‘as-treated’ 
analysis done with substantial departure of the intervention received 
from that assigned at randomisation; potentially inappropriate 
application of simple imputation. 
Unclear: Insufficient information to permit judgement 
Selective reporting 
Reporting bias due to 
selective outcome reporting 
Low risk of bias: The study protocol is available and all of the study’s 
pre-specified (primary and secondary) outcomes that are of interest in 
the review have been reported in the pre-specified way; the study 
protocol is not available but it is clear that the published reports include 
all expected outcomes, including those that were pre-specified 
(convincing text of this nature may be uncommon). 
High risk of bias: Not all of the study’s pre-specified primary outcomes 
have been reported; one or more primary outcomes is reported using 
measurements, analysis methods or subsets of the data (e.g. sub-scales) 
that were not pre-specified; one or more reported primary outcomes 
were not pre-specified (unless clear justification for their reporting is 
provided, such as an unexpected adverse effect); one or more outcomes 
of interest in the review are reported incompletely so that they cannot be 
entered in a meta-analysis; the study report fails to include results for a 
key outcome that would be expected to have been reported for such a 
study. 
Unclear: Insufficient information to permit judgement 
Other bias 
Bias due to problems not 
covered elsewhere in the 
table 
Low risk of bias: The study appears to be free of other sources of bias. 
High risk of bias: Had a potential source of bias related to the specific 
study design used; stopped early due to some data-dependent process 
(including a formal-stopping rule); had extreme baseline imbalance; has 
been claimed to have been fraudulent; had some other problem. 
Unclear: Insufficient information to assess whether an important risk of 
bias exists; insufficient rationale or evidence that an identified problem 
will introduce bias. 
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Figure 4.1: Study flow diagram (updated) 
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Figure 4.2: Study flow diagram (original) 
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Figure 4.3: Risk of bias graph: review authors’ judgements about each risk of bias 
item presented as percentages across all included studies 
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Figure 4.4: Risk of bias summary: review authors’ judgements about each risk of bias 
item for each included study 
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Figure 4.4: Risk of bias summary: review authors’ judgements about each risk of bias 
item for each included study (continued) 
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Figure 4.5: Analysis 1.1 Comparison 1 – Oral or topical antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of 
patients with one or more episodes) 
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Figure 4.6: Analysis 1.2 Comparison 1 – Oral or topical antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate 
(episodes/total patient- months on PD) 
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Figure 4.7: Analysis 1.3 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 3 Exit-site/tunnel 
infection (number of patients with one or more episodes) 
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Figure 4.8: Analysis 1.4 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 4 Exit-site/tunnel 
infection rate (episodes/total patient-months on PD) 
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Figure 4.9: Analysis 1.5 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or 
replacement (number of patients) 
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Figure 4.10: Analysis 1.6 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause) 
 
 
 
 
 
 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
192 
 
 
Figure 4.11: Analysis 1.7 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 7 Mortality due to 
peritonitis 
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Figure 4.12: Analysis 1.8 Comparison 1 - Oral or topical antibiotics versus placebo/no treatment, Outcome 8 Adverse effects 
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Figure 4.13: Analysis 2.1 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 1 Peritonitis (number of 
patients with one or more episodes) 
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Figure 4.14: Analysis 2.2 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 2 Peritonitis rate 
(episodes/total patient-months on PD) 
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Figure 4.15: Analysis 2.3 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 3 Exit-site/tunnel infection 
(number of patients with one or more episodes) 
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Figure 4.16: Analysis 2.4 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 4 Exit-site/tunnel infection 
rate (episodes/total patient-months on PD) 
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Figure 4.17: Analysis 2.5 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 5 Catheter removal or 
replacement (number of patients) 
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Figure 4.18: Analysis 2.6 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 6 Mortality (all-cause) 
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Figure 4.19: Analysis 2.7 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 7 Technique failure 
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Figure 4.20: Analysis 2.8 Comparison 2 - Oral or topical antibiotics versus other antibiotic, Outcome 8 Adverse effects 
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Figure 4.21: Analysis 3.1 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 1 Peritonitis (number of patients 
with one or more episodes) 
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Figure 4.22: Analysis 3.2 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 2 Peritonitis rate (episodes/total 
patient-months on PD) 
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Figure 4.23: Analysis 3.3 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 3 Exit site and tunnel infection 
(number of patients with one or more episodes) 
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Figure 4.24: Analysis 3.4 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 4 Exit site and tunnel infection 
rate (episodes/total patient-months on PD) 
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Figure 4.25: Analysis 3.5 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 5 Catheter removal or 
replacement (number of patients) 
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Figure 4.26: Analysis 3.6 Comparison 3 - Nasal antibiotics versus placebo/no treatment, Outcome 6 Mortality (all-cause) 
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Figure 4.27: Analysis 3.7 Comparison 3 - Nasal antibiotics versus placebo/no 
treatment, Outcome 7 Adverse effects 
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Figure 4.28: Analysis 4.1 Comparison 4 – Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 
1 Peritonitis (number of patients with one or more episodes) 
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Figure 4.29: Analysis 4.2 Comparison 4 - Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 
2 Exit site/tunnel infection (number of patients with one or more episodes) 
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Figure 4.30: Analysis 4.3 Comparison 4 - Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 
3 Catheter removal or replacement (number of patients) 
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Figure 4.31: Analysis 4.4 Comparison 4 - Pre/peri-operative prophylaxis versus placebo/no treatment or other antibiotic, Outcome 
4 Mortality (all- cause) 
 
 
Chapter 4: Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 
213 
 
Figure 4.32: Analysis 5.1 Comparison 5 – Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 1 Peritonitis (number of patients with one or more episodes) 
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Figure 4.33: Analysis 5.2 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 2 Exit site/tunnel infection (number of patients with one or more episodes) 
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Figure 4.34: Analysis 5.3 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 3 Exit site/tunnel infection rate (episodes/total patient-months on PD) 
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Figure 4.35: Analysis 5.4 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 4 Catheter removal or replacement (number of patients) 
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Figure 4.36: Analysis 5.5 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 5 Mortality (all-cause) 
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Figure 4.37: Analysis 5.6 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 6 Technique failure 
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Figure 4.38: Analysis 5.7 Comparison 5 - Topical disinfectants versus standard care or other active treatment (antibiotic or other 
disinfectant), Outcome 7 Pruritus (local) 
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Figure 4.39: Analysis 6.1 Comparison 6 – Germicidal chamber versus none, Outcome 1 Peritonitis rate (episodes/total patient-
months on PD) 
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Figure 4.40: Analysis 6.2 Comparison 6 - Germicidal chamber versus none, Outcome 2 Mortality (all-cause) 
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Figure 4.41: Analysis 7.1 Comparison 7 – Dressing systems (any), Outcome 1 Exit site/tunnel infection (number of patients with one 
or more episodes) 
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Figure 4.42: Analysis 7.2 Comparison 7 – Dressing systems (any), Outcome 2 Exit site/tunnel infection rate (episodes/total patient-
months on PD) 
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Figure 4.43: Analysis 8.1 Comparison 8 – Silver ring system on catheter versus none, Outcome 1 Peritonitis (number of patients 
with one or more episodes) 
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Figure 4.44: Analysis 8.2 Comparison 8 – Silver ring system on catheter versus none, Outcome 2 Exit site/tunnel infection (number 
of patients with one or more episodes) 
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Figure 4.45: Analysis 8.3 Comparison 8 - Silver ring system on catheter versus none, Outcome 3 Catheter removal or replacement 
(number of patients) 
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Figure 4.46: Analysis 8.4 Comparison 8 - Silver ring system on catheter versus none, Outcome 4 Mortality (all-cause) 
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Figure 4.47: Analysis 9.1 Comparison 9 – Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 1 Peritonitis rate 
(episodes/total patient- months on PD) 
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Figure 4.48: Analysis 9.2 Comparison 9 - Antistaphylococcal vaccine (Staphypan) versus placebo, Outcome 2 Exit site/tunnel 
infection rate (episodes/total patient-months on PD) 
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Figure 4.49: Analysis 10.1 Comparison 10 – Antifungal versus placebo/no treatment, Outcome 1 Fungal peritonitis (number of 
patients with one or more episodes) 
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Figure 4.50: Analysis 10.2 Comparison 10 - Antifungal versus placebo/no treatment, Outcome 2 Fungal peritonitis rate 
(episodes/total patient-months on PD) 
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Chapter 5: Infection prophylaxis in peritoneal dialysis 
patients: results from an Australia/New Zealand survey 
 
5.1 Abstract 
 
Background: Clinical practice guidelines exist to reduce the rates of 
peritoneal dialysis (PD) - related infections, a common complication of PD 
in end-stage kidney disease patients. We describe the clinical practices used 
by Australian and New Zealand nephrologists to prevent PD-related 
infections in PD patients. 
Methods: A survey of PD practices in relation to the use of antibiotic 
and antifungal prophylaxis in PD patients was conducted of practising 
nephrologists identified via the Australia and New Zealand Society of 
Nephrology (ANZSN) membership in 2013. 
Results: Of 333 nephrologists approached, 133 (39.9%) participated. 
Overall, 127 (95.5%) nephrologists prescribed antibiotics at the time 
of Tenckhoff catheter insertion, 85 (63.9%) routinely screened for 
nasal S. aureus carriage, with 76 (88.4%) reporting they treated S. 
aureus carriers with mupirocin ointment. Following Tenckhoff 
catheter insertion, 79 (59.4%) prescribed mupirocin ointment at the 
exit site or intranasally, and 93 (69.9%) nephrologists routinely 
prescribed a course of oral antifungal agent whenever their PD patients 
were given a course of antibiotics. 
Conclusions: Although the majority of nephrologists prescribe 
antibiotics at the time of Tenckhoff catheter insertion, less than 70%  
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routinely prescribe mupirocin ointment and/or prophylactic antifungal 
therapy. This variation in practice in Australia and New Zealand may 
contribute to the disparity in PD-related infection rates that is seen 
between units. 
Key words: Antibiotic prophylaxis; antifungal agents; kidney failure, 
chronic; peritoneal dialysis; practice guideline. 
5.2 Introduction 
 
Peritoneal dialysis (PD) is an effective home-based dialysis modality 
suitable for many patients with end-stage kidney disease (ESKD). 
Recurrent or severe exit-site infections (ESIs) and peritonitis are frequent 
complications which often result in Tenckhoff catheter removal and PD 
technique failure (1, 2). Up to one-third of all PD peritonitis episodes 
result in hospitalization and 5 - 10% of cases lead to death (3, 4). Hence, 
reducing PD-related infections may be both cost-saving and lead to 
reduced morbidity and mortality in PD patients. 
Peritoneal dialysis technique survival in Australia and New Zealand (ANZ) is 
lower than in most other developed countries (5). From 2002 - 2005, the 
median technique survival in Australia was 
1.8 years while in New Zealand it was 2.4 years (5). In comparison, Thailand 
had a reported median technique survival of 3.4 years (1995 - 2005) and 
Mexico a median technique survival of 4.0 years (1985 - 1997) (5). Peritonitis 
rates in ANZ are significantly greater than those reported in many other 
countries. According to the International Society for Peritoneal Dialysis 
(ISPD) guidelines, the PD peritonitis rate should not exceed 0.36 episodes per 
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patient-year (6). As reported in the 2013 ANZDATA Registry Report, the 
overall peritonitis rate in Australia was 0.50 episodes per patient-year while in 
New Zealand it was 0.57 episodes per patient-year for the period 1 January to 
31 December 2012 (7). These rates are worse than the revised ISPD minimum 
peritonitis rate of 0.36 episodes per patient-year (6). The majority of ANZ PD 
units do not meet the revised minimum peritonitis rate (7). 
With regard to infection prophylaxis, the appropriate use of antibiotics at the 
time of and after Tenckhoff catheter insertion, care of exit sites and the 
judicious use of prophylactic antifungal agent are essential to reduce the risk 
of PD-related infections and associated technique failure. Post-operative 
infection after catheter placement has been shown to be reduced by the use 
of intravenous antibiotic administration prior to or at the time of Tenckhoff 
catheter insertion (8). Exit-site colonisation and infection is one of the 
recognized ways for peritonitis to start (9). The development of ESI places 
patients at increased risk of developing peritonitis, with this association 
being present up to 60 days after initial diagnosis (10). Episodes of fungal 
peritonitis are known to be frequently preceded by a course of antibiotics 
and patients taking prolonged or frequent courses are most at risk. It has 
been shown that fungal prophylaxis during antibiotic therapy may prevent 
cases of Candida and other fungal peritonitis (6). Fungal peritonitis is 
associated with significant morbidity and mortality, a high likelihood of 
Tenckhoff catheter removal and high rates of permanent transfer to 
hemodialysis due to peritoneal membrane injury (11). 
Although both ISPD and the local KHA-CARI guidelines explicitly 
recommend appropriate prophylactic antibiotic and antifungal use to reduce 
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PD-related infections, a survey of Australian and New Zealand nephrologists 
conducted in 2009 showed that many failed to adhere to these guidelines, 
with 14 of 30 PD units (47%) reporting the absence of a local protocol that 
included prophylaxis against exit-site infections (12). A study which looked 
at Australian registry data found that antifungal prophylaxis during treatment 
for bacterial peritonitis was only given in 7% of peritonitis episodes (11). 
There is substantial variation in the peritonitis rates between PD units in 
Australia and New Zealand (7,13,14), with the lack of consistency in PD 
program management or guideline implementation being blamed (5,15). 
With continuing high rates of PD-related peritonitis being reported, it is 
therefore imperative to determine if nephrologists are adhering to best 
practice guidelines. 
Guideline implementation in PD units is dependent on the actions of the 
treating physician, PD nursing staff, and/or those in charge of the PD 
program. There is little data on the current antimicrobial prophylactic 
practices in place at PD units in Australia and New Zealand. We therefore 
designed a self- administered survey to elicit information about current 
practice in ANZ PD units around the topic of PD-related infection 
prevention. 
5.3 Methods 
 
Survey instrument 
 
Draft survey questions were developed by a project officer and piloted 
among several nephrologists in Australia and New Zealand. Revisions 
were made in response to the comments received. 
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The survey was composed of 4 parts. The first assessed current practice in 
relation to the use of prophylactic antibiotics at Tenckhoff catheter insertion; 
the second, the use of prophylactic antibiotics to prevent exit-site/tunnel 
infection; the third asked about the concurrent use of antifungal agents when 
a PD patient is given a course of antibiotics; the fourth asked for details 
regarding the type of Tenckhoff catheter inserted, the specialty of the 
operator and the surgical technique used. Demographic details of the 
respondents were also collected (gender, age, years of practice in nephrology, 
place of residence, location of current practice/s). These aspects of infection 
prevention in PD patients were chosen because of their importance in 
reducing peritonitis incidence and there are evidence-based guideline 
recommendations on which to base practice. The questions about access 
surgery were included as it was felt that practice was changing, and the 
survey provided an opportunity to gather this data. 
Participants 
 
The link for the web-based survey was emailed to all members of the 
Australian and New Zealand Society of Nephrology (ANZSN) through the 
ANZSN office in June 2013. A cover letter invited consultant nephrologists 
caring for PD patients to participate, explained the aims of the survey and 
gave instructions on how to access the survey. Reminder emails were sent 1, 3 
and 4 weeks after the initial email. A further email was sent to nephrologists 
listed in the KHA-CARI database in August 2013 to obtain more responses. 
The survey ended in September 2013. 
Statistical analyses 
 
The proportions of respondents who gave antibiotic prophylaxis at 
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Tenckhoff catheter insertion, who screened and treated nasal S. aureus 
carriers, who used antibiotic prophylaxis at the exit site, and who gave 
antifungal prophylaxis whenever a PD patient received an antibiotic course 
were calculated. The type of antibiotic, duration of treatment and use of 
other cleaning agents was also calculated. Data relating to Tenckhoff 
catheter insertion practices were also categorized and calculated. 
 
5.4 Results 
 
We report data obtained in relation to the first 3 parts of the survey. One 
hundred and thirty-three (39.9%) of the 333 actively practising nephrologists 
responded to all questions in the survey. For Australia, data from 44/68 
(64.7%) centres covering 2894/3358 (86.2%) patients were received. Of 
these, 15 were large-size units with >60 PD patients, 15 were medium-size 
units with >30 but <60 PD patients, and 14 were small-size units with <30 PD 
patients. For the key questions about prophylactic practice, nephrologists 
working at large centres contributed an average of 51.3% of the responses. 
For New Zealand, responses were received from 11/12 centres with prevalent 
PD patients, covering 819/849 patients (96.5%). Three of the centres could be 
classified as large-size units with >100 PD patients, 4 were medium-size units 
with >40 but <100 PD patients and 4 were small-size units with ≤40 PD 
patients. For the key prophylaxis questions, nephrologists at large centres 
contributed 43.8% of the responses. Chi-squared analysis of the responses to 
the 3 key questions according to unit size found no significant difference 
between the practices at units according to size, with the exception of the data 
for New Zealand regarding the use of mupirocin. For this practice, there was 
greater use of mupirocin at medium- and small-size units than at large-size 
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units.  
The baseline characteristics of nephrologists participating in the survey are 
shown in Table 1. Over 70% were men with 65% aged less than 50 years. 
Almost 30% have over 20 years of clinical experience. 
Responses to the questions about the use of antibiotic prophylaxis and the 
screening and treatment of nasal S. aureus carriers are detailed in Table 2. 
Overall, 95.5% of all respondents give antibiotics at catheter insertion, 63.9% 
screen for nasal S. aureus, 88.4% treat identified S. aureus carriers, and 
59.4% apply mupirocin ointment intranasally or at the exit site on a regular 
basis. Responses to the questions regarding the use of antifungal prophylaxis 
are shown in Table 3. A total of 69.9% of respondents give antifungal 
prophylaxis to PD patients when they are prescribed an antibiotic course. 
Respondents’ prophylaxis practices at catheter insertion 
 
The prophylactic antibiotic most commonly given at the time of Tenckhoff 
catheter insertion was a cephalosporin (88.7%) followed by vancomycin 
(22.6%), with some stating that vancomycin is used when a patient has 
previously screened positive for methicillin-resistant 
S. aureus (MRSA) or is allergic to penicillin. 
 
Respondents’ prophylaxis practices to prevent exit-site/tunnel 
infections 
 
Eighty-five respondents (63.9%) reported that they swab to detect nasal 
carriage of S. aureus and 76 (88.4%) said they treated anyone identified as a 
nasal S. aureus carrier. The length of antibiotic treatment given varied 
widely, with the most common treatment length being for 3- 7 days (23 
respondents [31.9%]) followed by 2 weeks (13 respondents [18.1%]). 
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Seventy-nine respondents (59.4%) stated that exit-site care to prevent S. 
aureus colonization at the exit site included the use of mupirocin ointment. 
Other practices included antibacterial wash (43 respondents [32.3%]), use of 
betadine wipes (31 respondents [23.3%]), and soap 
and water (36 respondents [27.1%]). Others (27 respondents [20.3%]) 
used nothing, saline wash or medicated honey. 
Respondents’ prophylaxis practices to prevent fungal peritonitis 
 
Ninety-three individuals (69.9%) reported that they routinely give 
antifungal prophylaxis with an antibiotic course in PD patients. The 
duration of treatment varied, with 55 (59.1%) saying they give the 
antifungal for the same length of time as the antibiotics and 37 (39.8%) 
saying that they give it for 3 days longer than the antibiotic course. 
 
5.5 Discussion 
 
Adherence to international and national guidelines to prevent PD-related 
infections has been shown to reduce the rates of technique failure and 
infection-related morbidity (16, 17). In Australia and New Zealand in 2012, 
PD peritonitis rates varied between 1.0 and 0.1 episodes per patient-year, 
with 21 of 62 (33.9%) centers with peritonitis rates above the recommended 
minimum rate of 0.36 episodes per patient-year. Our survey of 133 practising 
nephrologists in Australia and New Zealand showed a wide variation in 
clinical practice, with approx. 30 - 40% not adhering to published guidelines, 
particularly regarding the screening of patients for 
S. aureus nasal carriage, the use of mupirocin ointment either nasally or at 
the exit site, and the use of antifungal prophylaxis with an antibiotic 
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course, which are likely to contribute to the higher rates of PD-related 
infections observed in the 2 countries. The guideline recommendations 
chosen as the focus of this survey are either based on the findings of 
randomized controlled trials (RCTs) or a systematic review of all relevant 
RCTs.  
The KHA-CARI guidelines published in 2004 recommended that antibiotic 
prophylaxis using a first generation cephalosporin should be administered at 
the time of PD catheter insertion to reduce the risk of PD-related infections, 
including catheter-site infection, peritonitis, and wound sepsis (18). The 
guidelines also recommended that vancomycin not be prescribed routinely 
because of the potential for developing resistant microorganisms (18). There 
was a slight amendment to the 2004 KHA-CARI guidelines in August 2013, 
which suggested that a single intravenous dose of vancomycin, 
cephalosporin, or gentamicin can be prescribed prior to PD catheter 
insertion, although vancomycin should be used cautiously to avoid the 
emergence of vancomycin-resistant enterococci and S. aureus (19). The 
ISPD guidelines, published in 2011, provided similar recommendations to 
those of the 2013 KHA-CARI guidelines (6). Ninety-five per cent of survey 
respondents stated that antibiotic was given with PD catheter insertion with 
24.4% being given prior to surgery and 72.4% being given intra-operatively. 
Cephalosporin was the antibiotic most frequently used (88.7%) followed by 
vancomycin (22.6%). Nearly 46% of respondents reported using 
vancomycin in PD patients who were screened positive for methicillin-
resistant S. aureus (MRSA) and nearly 32% of respondents prescribed this 
in patients with penicillin allergy. These behaviours broadly reflect the 
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guideline recommendations but only one quarter of respondents stated that 
the prophylactic antibiotic is given before PD catheter surgery. There is 
evidence supporting the administration of antibiotic in the 2 hours before 
surgery commences rather than at the same time as surgery is performed, 
which ensures the attainment of high concentrations of antibiotics in the 
wound during the operation (20-23). 
Nasal carriage of S. aureus is considered to be a strong risk factor for the 
development of ESI and peritonitis (24). The 2004 KHA-CARI guidelines 
stated that the prophylactic use of mupirocin ointment, particularly in S. 
aureus nasal carriers, is recommended to decrease the risk of S. aureus 
catheter exit-site/tunnel infections and peritonitis (18). The updated KHA- 
CARI guidelines recommend that mupirocin ointment be used intranasally or 
topically at the exit site to reduce the risk of S. aureus catheter exit-site/tunnel 
infections and peritonitis (19). The ISPD guidelines recommend that all PD 
patients use topical antibiotic at the catheter exit site and/or intranasally (6). 
The survey responses show that 63.9% perform nasal swabs to identify 
patients/carers/staff who are S. aureus carriers and almost 90.0% treated those 
patients who were identified as S. aureus nasal carriers. It is unclear from our 
survey what the rationale is for why 10% of clinicians do not treat S. aureus 
nasal carriers after a positive result. However, this preventive approach to 
reduce S. aureus ESI and peritonitis has often been criticised for the lack of 
proven cost-effectiveness, being difficult to implement in clinical practice and 
for its potential to promote S. aureus resistance (25,26). Duration of treatment 
for those who screen positive varied widely, ranging from 3 - 7 days (31.9%), 
which is in line with published recommendations, to 3 months (20.8%) (27). 
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The survey responses reveal that 59.4% instruct patients to routinely apply 
mupirocin ointment either intranasally or to the exit site in addition to using 
various cleansing/antiseptic agents while 20.3% of respondents said they use 
‘other’ means of caring for the exit site. The majority of respondents 
prescribed antiseptics and/or antibiotics but 7 (5.3%) do not routinely use any 
agents. There is RCT evidence supporting the use of mupirocin at the exit site 
and its ability to reduce the incidence or rates of ESI and peritonitis attributed 
to S. aureus or Gram-positive organisms (17,28). A recent systematic review 
confirmed the ability of mupirocin applied intranasally to significantly reduce 
the risk of ESI and peritonitis due to S. aureus, based on three RCTs (29). 
Intranasal mupirocin was also found to reduce the risk of ESI by 46% but did 
not reduce the risk of peritonitis due to all organisms (29). When this survey 
was conducted, some units were participating in the HONEYPOT trial and 
had been randomized to have their patients apply medicated honey at the exit 
site or to use nasal mupirocin prophylaxis in identified S. aureus carriers 
(30,31). Participation in this trial would explain some of the 40.6% of 
respondents who report they do not instruct patients to use mupirocin 
ointment at the exit site. The use of topical antiseptics for chronic exit-site 
care and the application of mupirocin only in PD patients identified as S. 
aureus carriers is common in some countries (32). It has been suggested that 
this approach is likely to reflect the concerns of clinicians and nurses of the 
emergence of bacterial resistance to mupirocin or aminoglycosides in general 
and the positive selection of other pathogenic organisms such as 
Pseudomonas spp., when topical antibiotic is used routinely in long-term 
patients. 
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Both the ISPD and KHA-CARI guidelines recommend the routine 
prophylactic use of antifungal agent such as nystatin to prevent fungal 
peritonitis occurring when a PD patient is prescribed a course of antibiotics. 
The KHA-CARI guideline recommendations on antifungal prophylaxis 
published in 2004 state that the use of oral nystatin should be considered at 
the time of antibiotic administration to PD patients (18). The updated 
guideline continues these recommendations (19). They also suggest that oral 
nystatin is preferred to fluconazole as prophylaxis because of the risk of 
development of resistance to fluconazole with increased exposure. The ISPD 
guidelines outline that most episodes of fungal peritonitis are preceded by 
courses of antibiotics and that fungal prophylaxis during antibiotic therapy 
may prevent some cases of peritonitis due to Candida spp. in programs that 
have high rates of fungal peritonitis (6). Our survey results show that almost 1 
in 3 nephrologists do not routinely give an antifungal agent when a PD patient 
receives an antibiotic course. The evidence supporting these 
recommendations comes from a number of observational studies and 2 RCTs 
(33,34) which have shown benefit in terms of reducing episodes of fungal 
peritonitis. The trial by Lo et al. (33) investigated whether Candida peritonitis 
(CP) was prevented when continuous ambulatory PD (CAPD) patients in 
Hong Kong were given oral nystatin concomitant with antibiotic therapy. The 
treatment group (199 patients) received nystatin tablets 500,000 units 4 times 
a day whenever antibiotics were prescribed while the control group (198 
patients) received only their antibiotic therapy. At 2 years, the probability of 
being free of CP was higher in the antifungal treatment vs control group 
(0.974 vs 0.915; p < 0.05). The authors concluded that giving oral nystatin 
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prophylaxis with each antibiotic prescription reduced the CP rate in patients. 
The trial conducted by Restrepo et al. (34) in Colombia assessed whether 
giving oral fluconazole whenever a PD patient was treated for bacterial 
peritonitis, exit-site infection, or tunnel infection could prevent the 
development of fungal peritonitis. Patients in the treatment group received 
oral fluconazole (200 mg every 48 hours) for the entire time that they 
received therapeutic antibiotics by any oute. In those patients who received 
oral fluconazole, 3 occurrences of fungal peritonitis were found within 30 – 
150 days following the end of antibiotic therapy. In contrast, the group that 
received no antifungal therapy had 15 occurrences of fungal peritonitis over 
the same timeframe. For patients treated for bacterial peritonitis, the 
difference between the 2 groups regarding the development of secondary 
fungal peritonitis was significant (p = 0.0051). The authors concluded that in 
patients treated for bacterial peritonitis, the administration of fluconazole 
during the period they received antibiotics significantly reduced the 
appearance of secondary fungal peritonitis.  
The ISPD guideline recommendations are less defined than are the 
KHA-CARI recommendations and emphasize that the use of antifungal 
therapy should be modified by local microbiology. The fact that we found 
nearly 1 in 3 nephrologists do not use antifungal prophylaxis may reflect a 
lack of awareness of the guideline recommendations or a belief that the local 
rates of fungal peritonitis are low and prophylaxis is not warranted. However, 
this response represents an improvement in antifungal prescribing having  
previously been reported that 92% of peritonitis episodes in Australian 
patients did not receive antifungal prophylaxis (5). 
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Our study has several limitations. Firstly, our response rate of 39.9% was low 
but similar to the response rates reported by other similar surveys (12, 35-
37). The response rate might have been impoved by the inclusion of PD 
nurses in the survey. Secondly, the responses given may only represent how 
nephrologists would ideally practice. Only an audit of practice could reliably 
ascertain actual practice. Thirdly, those who completed the survey may be 
more interested in the care of PD patients than non-respondents and hence, be 
a self-selected group whose practice might be significantly different to the 
rest of the ANZ nephrology community. Fourthly, 73% of respondents were 
in the 41 to 60 age group and it may be that the responses of younger 
nephrologists are under-represented. Lastly, we did not include a question 
asking why nephrologists choose not to follow a guideline recommendation. 
It is known that there are many reasons for physician non-adherence to 
guideline recommendations, including lack of awareness, lack of familiarity, 
disagreement with a recommendation, perceived lack of self-efficacy, lack of 
faith in achievement of the desired outcome, the inertia of previous practice, 
and external barriers, which can be guideline-related, patient-related or 
environmental in nature (38).  
A strength of the study is that the sample of nephrologists was mostly 
obtained via the Australia and New Zealand Society of Nephrology 
database, so is representative of the practising nephrologists in 
Australia and New Zealand. 
In Australia and New Zealand, there is a wide variation in clinical practice to 
prevent PD- related infections, with most variation occurring around the use 
of mupirocin to prevent exit-site infection and the co-administration of an 
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antifungal agent with an antibiotic course. Despite wide dissemination, 
guidelines on their own have a limited effect on changing clinical practice 
(39,40). It has been shown that multifaceted interventions that target a 
number of barriers to change are more likely to be effective than a single 
intervention in changing clinical behavior (41). One approach to improve 
PD practice involves the setting up of quality improvement collaboratives 
where groups of preofessionals from several centers learn fom and motivate 
each other to achieve a common objective (42-44). These often involve the 
delivery of a care bundle based on the guidance. Other means of improving 
practice include the publishing of comparative PD outcomes (e.g. by 
nephrology registries), the use of multidisciplinary team-based meetings 
with a focus on quality improvement (45), the performance of a root-cause 
analysis to each peritonitis episode to identify aspects that need 
improvement (46), and the sharing of clinical practice routines by those units 
that have excellent peritonitis rates so that others may benefit from their 
experience (6). The findings of this study show that practice varies widely 
between centers and the 2 countries involved in the survey and we outline 
some of the means by which the gap between health services research and 
health care delivery might be reduced.  
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Table 5.1: Baseline characteristics of survey respondents (n=133) 
 
 
Characteristic  n % 
Gender Women 39 29.3 
 Men 94 70.7 
Age group (years) 30-40 28 21.1 
 41-50 59 44.4 
 51-60 38 28.6 
 61-70 8 6.0 
Length of specialist 
nephrology practice 
(years) 
1-5 13 9.8 
 6-10 29 21.8 
 11-15 33 24.8 
 16-20 19 14.3 
 >20 39 29.3 
Country of residence Australia 101 75.9 
 New Zealand 32 24.1 
Location of work* City 138 90.8 
 Rural 14 9.2 
 
 
*Numbers are not additive as some individuals work in more than one location 
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Table 5.2: Practice patterns for antibiotic prophylaxis and nasal screening and treatment 
in PD patients 
 
 
Practice patterns for antibiotic prophylaxis at Tenckhoff catheter insertion (n = 133) 
Characteristic Response n % 
Give antibiotic 
at catheter 
insertion 
Yes 127 95.5 
Timing of 
antibiotic 
administration 
Prior to surgery 31 24.4 
 At time of 
surgery 
92 72.4 
 Other* 4 3.2 
Antibiotic given Vancomycin 30 22.6 
 Cephalosporin 118 88.7 
 Gentamicin 7 5.3 
 Penicillin 1 0.8 
 None 4 3.0 
 Other 6 4.5 
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Table 5.2: Practice patterns for antibiotic prophylaxis and nasal screening and treatment 
in PD patients (continued) 
Practice patterns for the screening (n = 133) and treatment (n = 86) of nasal S. aureus 
carriers 
Characteristic Response n % 
Swab for nasal 
S. aureus 
Yes 85 63.9 
Treat identified 
carriers 
Yes 76 88.4 
Length of 
antibiotic 
treatment (n = 
72) 
Single dose 1 1.3 
 3-7 days 23 31.9 
 2 weeks 13 18.1 
 3-6 weeks 10 13.9 
 3 months 15 20.8 
 Other 10 13.9 
Practice patterns for care of the exit site (n = 133) 
Characteristic Response n % 
Exit site care 
practice 
Mupirocin 
ointment† 
79 59.4 
 Antibacterial 
wash 
43 32.3 
 Betadine wipes 31 23.3 
 Soap and water 36 27.1 
 Other 27 20.3 
*Both times are used, depending on who is inserting the catheter; 
†includes nasal or exit site application 
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Table 5.3: Practice patterns for antifungal prophylaxis in PD patients 
 
Practice patterns for antifungal prophylaxis with an antibiotic course (n = 133) 
and length of treatment (n = 93) 
Characteristic Response n % 
Give antifungal 
agent 
Yes 93 69.9 
Duration of 
treatment 
Same duration as 
the antibiotics 
55 59.1 
 For 3 days longer 
than the 
antibiotics 
37 39.8 
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Chapter 6: Patients’ perspectives on the prevention and 
treatment of peritonitis in peritoneal dialysis: a semi-
structured interview study 
 
6.1 Abstract 
 
Background: Peritoneal dialysis (PD) is recommended for adults with 
residual kidney function and without significant comorbidities. However, 
peritonitis is a serious and common complication that is associated with 
hospitalization, pain, catheter loss and death. This study aims to describe 
the beliefs, needs, and experiences of PD patients about peritonitis, to 
inform the training, support, and care of these patients. 
Methods: Qualitative semi-structured interviews were conducted with 29 
patients from 3 renal units in Australia who had previous or current 
experience of PD. The interviews were conducted between November 2014 
and November 2015. Transcripts were analyzed thematically. 
Results: We identified 4 themes: constant vigilance for prevention 
(conscious of vulnerability, sharing responsibility with family, demanding 
attention to detail, ambiguity of detecting infection, ineradicable 
inhabitation, jeopardizing PD success); invading harm (life-threatening, 
wreaking internal damage, debilitating pain, losing control and dignity); 
incapacitating lifestyle interference (financial strain, isolation and 
separation, exacerbating burden on family); and exasperation with 
hospitalization (dread of hospital admission, exposure to infection, gruelling 
follow-up schedule, exposure to harm). 
Conclusions: Patients perceived that peritonitis could threaten their health, 
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treatment modality, and lifestyle, which motivated vigilance and attention to 
hygiene. They felt a loss of control due to debilitating symptoms including 
pain, having to be hospitalized, and were uncertain about how to monitor for 
signs of peritonitis. Providing patients with education about the causes and 
signs of peritonitis and addressing their concerns about lifestyle impact, 
financial impact, hospitalization, and peritonitis-related anxieties may 
improve treatment satisfaction and outcomes for patients requiring PD. 
6.2 Introduction 
 
Although incidence rates of peritonitis have decreased substantially with 
technological advances in peritoneal dialysis (PD), peritonitis rates in many 
countries still exceed 0.4 episodes per patient year (1, 2). Worldwide, 
peritonitis is the direct cause of 4% of deaths in patients on PD and is a 
“contributing factor” in at least 16% of deaths on PD. Furthermore, 
peritonitis is a leading cause of hospitalization and technique failure in PD 
whereby patients must transfer to hemodialysis (3-10). 
To minimize the risk of peritonitis, patients are required to perform an 
exchange following the procedure they have been taught, paying 
attention to aseptic technique and ensuring excellent hand hygiene. They 
also need to clean and care for their exit site as taught and assess the exit 
site regularly for any signs of infection. They need to be aware that 
severe constipation or diarrhea can lead to peritonitis and take steps to 
prevent the occurrence of constipation, and they should also be aware 
that certain medical procedures can lead to peritonitis and that they need 
to be given antibiotics with these procedures (11).  All of these demands 
on the patient can interfere with lifestyle and cause anxiety. 
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A systematic review of qualitative studies of the perspectives of adults on 
PD found that PD can offer a sense of control, independence, self-efficacy, 
and freedom but patients also reported impaired self-esteem, physical 
incapacitation, and reduced social functioning (12). However, there were 
limited data specifically about peritonitis and comparisons between 
automated PD (APD) and continuous ambulatory PD (CAPD) were sparse. 
This study aims to describe patients’ beliefs, needs, and experiences about 
peritonitis in PD. An understanding of their beliefs and attitudes can inform 
strategies to help and empower patients in preventing peritonitis. Awareness 
of their concerns and needs when receiving treatment for peritonitis can 
inform support structures and lead to better treatment and health outcomes. 
6.3 Methods 
 
We used the Consolidated Criteria for Reporting Qualitative Health 
Research (COREQ) to report this study (13). 
Participants and setting 
 
Participants were eligible for interview if they were English-speaking, over 
18 years of age, able to give informed voluntary consent, and had previous or 
current experience with PD. Purposive sampling was used to include 
participants with a range of ages, gender, experiences of APD and CAPD, 
and peritonitis episodes. Participants were recruited from Princess Alexandra 
Hospital, Brisbane; Westmead Hospital, Sydney; and Monash Medical 
Centre, Melbourne. Ethics approval was obtained from all 3 sites. 
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Data collection 
 
We developed the interview guide after a review of the literature based on a 
systematic review of patients’ experiences of PD and discussion among the 
research team (Table S1). Face-to-face interviews were performed by the 
primary investigator (DC) between November 2014 and November 2015. DC 
is a researcher with training in public health and interest in PD. Recruitment 
ceased once theoretical saturation was observed in the concurrent analysis, 
when little or no new data was obtained after 3 consecutive interviews. All 
interviews were recorded digitally and transcribed verbatim. 
 
Data analysis 
 
The transcripts were imported into HyperRESEARCH (Version 2.8.3; 
Research Ware Inc., MA, US) to facilitate thematic analysis. The principles 
of grounded theory were followed (i.e. the development of a theory or 
explanation grounded in the data collected) (14). Each transcript was 
reviewed line by line by DC and meaningful segments of text were 
highlighted and given an appropriate code according to the concepts that 
had been identified inductively in the data. Similar concepts were grouped 
into themes. The coding was reviewed by AT who also read the interview 
transcripts. A schema was developed to show conceptual relationships 
between the themes. The preliminary concepts were discussed among the 
study authors (investigator triangulation). DC revised the coding structure 
until it included all concepts about patient beliefs and experiences regarding 
peritonitis. 
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6.4 Results 
 
Twenty-nine patients from 3 Australian states participated (88% response 
rate). Non-participation (n = 4) was due to refusal or inability to set a suitable 
interview time after 3 attempts. The average duration of the interview was 40 
minutes, which was conducted in person (n = 27) or via Skype (n = 2). The 
participant demographic characteristics are shown in Table 1.  
We identified 4 major themes: constant vigilance for prevention, invading 
harm, incapacitating lifestyle interference, and exasperation with 
hospitalization. The themes and related subthemes are described in the 
following section with illustrative quotations provided in Table 2. A thematic 
schema showing the patterns and relationships among themes is provided in 
Figure 1. 
 
Constant vigilance for prevention 
 
Conscious of vulnerability: Peritonitis was “always in the back of your mind” 
and represented a threat to participants’ health and lives. Participants who had 
experienced peritonitis were fearful of recurrence and felt particularly 
susceptible during a bag exchange or when they made a mistake as “germs 
could get in.” Those who had not had peritonitis were “mindful” of the 
possibility of peritonitis because they had seen other patients with peritonitis. 
For some, they felt “panic” during the first few times they did an exchange. 
Sharing responsibility with family: Some participants stressed family 
members had to be “educated as much as we are” so that their family 
would not be overwhelmed. Participants wanted to be able to depend on 
them for help. Others felt that their family members demonstrated a lack 
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of care and consideration “because they just don’t understand how 
important it is.” 
Demanding attention to detail: The cleaning demands of doing an exchange 
were rigorous, such that patients felt it “just drives you insane.” They were 
careful to “follow all of the instructions.” Some deliberately did an exchange 
in a slow methodical manner, some timed how long they washed their hands 
for, turned off anything that would move air around the room (e.g. fan, heater, 
air conditioner) and closed the windows and doors before they commenced an 
exchange. Others checked the dates of their dialysate bags, gauze and any 
other items they used. Participants were careful to not “have shortcuts” and to 
avoid becoming “careless or [overly] confident with their cleaning” as this 
could result in peritonitis. One man felt under siege and that the attention to 
detail required was overwhelming – “It could be anything … can’t wear a 
fleecy shirt. A bit of fleece gets in there, you’re finished.” 
Ambiguity of detecting infection: Participants had trouble identifying the first 
signs of peritonitis and thought instead that they had the flu or that they had 
gastrointestinal problems. Some experienced only localized pain which they 
realized later was due to peritonitis. One participant recounted that their 
general practitioner diagnosed a lower bowel infection but did not suspect 
peritonitis. Women noticed that their bags became cloudy during ovulation 
and menstruation, and panicked and went to hospital. 
Ineradicable inhabitation: After experiencing peritonitis, some believed that 
they “never fully clear the germs” and would always be prone to peritonitis. 
Even after antibiotics, they believed the cause of the infection remained in 
their system. Others said it had taken “a long time” to get rid of the infection. 
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Some participants who had a spontaneous infection, believed the peritonitis 
was caused by “a bug that just kind of happens” and that “the peritoneum … 
reacts to it [the fluid] and it gives you peritonitis.” 
 
Jeopardizing PD success: Participants wanted to remain on PD because it 
suited their lifestyle and offered more freedom and did not require 
cannulation. Aware that peritonitis could cause PD failure, patients were 
“worried” about being forced to go onto hemodialysis. Some hoped that they 
could “still do dialysis this way once [the peritonitis] cleared up.” Some had 
been warned that if they had 3 episodes of peritonitis, the decision could be 
made “to take you off peritoneal dialysis … and they will have to put a 
fistula in.” 
Invading harm 
 
Life-threatening: Some were worried that they could die from peritonitis. 
Others were fatalistic, saying “If you die, you die because of my problem” 
while some said they felt so sick at the time that they thought “I just need 
to die.” 
Wreaking internal damage: Some participants anticipated that peritonitis 
would cause their “internal lining” to be “scarred” and “damaged.” They 
spoke of being “hit” with peritonitis and said that following peritonitis 
“everything changes” and that physically, they were “tender.” 
Debilitating pain: Although they had been told that peritonitis could be 
painful, participants were unprepared for the pain which they described as 
“enormous”, “massive”, “crumpling” and like “labour pain.” They became 
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unable to function as they were “hunched over” and “couldn’t do anything” 
and could “hardly move” or talk. They described the pain as quickly coming 
on and escalating rapidly to an “unbelievable” level. 
Losing control and dignity: When going through a peritonitis episode, 
unpredictable occurrences such as falling unconscious in public, being 
unable to get off the toilet in the ward without assistance, and vomiting in 
public caused participants to feel embarrassed. Participants spoke of having 
“no control over your body” and the humiliation of other patients in the 
ward “knowing what’s going on.” For example, one participant who was 
very constipated because of peritonitis threw up faeces. 
 
Incapacitating lifestyle interference 
Financial strain: Having peritonitis meant that participants were unable to 
work or could only work part-time. For some, their partner had to take time 
off work. Some could not work for more than 1 month, 1 participant shut 
down their business, and others were concerned about being able to pay their 
mortgage. The accumulating cost of frequent hospital appointments to receive 
treatment for peritonitis also caused financial burden. 
Isolation and separation: Being in hospital meant a disruption to normal 
family life and some participants were placed in isolation, so they could not 
interact with their family. Participants with young children worried about how 
others such as elderly parents were coping with caring for the children and 
realized their children would be “missing” them. 
Exacerbating burden on family: Participants had to call on others such as a 
parent, spouse or ex-spouse to help them when they experienced a peritonitis 
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episode because they were too unwell to perform normal tasks. Family 
members helped in a variety of ways – calling the hospital for advice when 
the episode first started, driving the patient to hospital, bringing home-cooked 
food to the hospital each evening, visiting the patient each day, caring for the 
patient’s children, and helping to organize treatment at home for those who 
did not have to be hospitalized. 
 
Exasperation with hospitalization 
 
Dread of hospital admission: The thought of going to hospital “depressed” 
participants and was described as “a big price” to pay for making a mistake. 
Some participants had periods when they were in hospital “nearly every 
second month” and once there, they would be there for “a couple of weeks 
again.” They saw the hospital system as an impersonal one and that they 
were never consistently seen by one doctor. 
Exposure to infection: Some were concerned about the perceived lack of 
knowledge regarding PD among general hospital staff. For example, 1 
participant had a Tenckhoff catheter inserted on an emergency basis and was 
told by a ward nurse post-operation that she could go for a walk but later 
learned from the PD nurse that this could cause leakage. Another participant 
who was admitted to hospital with peritonitis believed “a doctor could’ve 
even infected me – he didn’t even wash his hands.” 
Gruelling follow-up schedule: Managing treatment for peritonitis was 
confronting for some as they had to inject antibiotics into a dialysis bag. 
Participants had to go to hospital every 2 days for about 2 weeks to have a 
blood test to find out if they needed to continue with the antibiotic treatment 
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and this “took a lot of time” out of their normal routine and was “a little 
frustrating” and “inconvenient” but was accepted by participants as 
unavoidable. 
Receiving inattentive care: Some felt they received inadequate care from 
hospital staff. Some experienced intense pain the first time they were hooked 
up to the APD machine, and blamed staff for a lack of monitoring. Another 
patient was given treatment for high blood pressure but staff left him 
unattended, which led to him blacking out and “even though I had buzzed no 
one had come.” 
6.5 Discussion 
 
Peritonitis was an ever-present concern for patients on PD as it meant they 
would be in pain, vomiting, possibly embarrassed, needing to go to hospital, 
calling on family or friends for help, and unable to go to work. 
Some participants felt that family members should be informed about the 
process and demands involved in doing PD so that they could depend on 
their support in preventing and managing peritonitis. Patients found the 
cleaning routine around doing an exchange to be demanding, more so for 
those on CAPD compared with APD because of the need to connect and 
disconnect more often. When peritonitis occurred, patients experienced 
panic, incapacitating pain, and felt embarrassed because they lost bodily 
control and normal function. Those who were hospitalized expressed 
concerns about finances and placing extra responsibilities on family 
members. Participants who received out-of-hospital treatment felt burdened 
by frequent visits to the renal unit, the need to inject antibiotics into dialysis 
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bags, and the costs associated with travel to and from the clinic. Many 
participants had difficulty identifying the symptoms of peritonitis. Changes 
to the management and the provision of additional support to patients could 
help them to cope with the challenges they encounter when they have 
peritonitis. 
The systematic review of qualitative studies on patients’ experiences of PD 
found that some patients regarded PD as onerous and a disruptive intrusion. 
However, there were limited data specifically on peritonitis (12). More 
recent studies on patient and family perspectives on PD have shown that 
patients and family members were aware of the threat of peritonitis, took 
measures to prevent infection, were uncertain of how to manage a crisis, and 
some could not recognize the symptoms of peritonitis (15). The procedures 
required to prevent infection were described as “daunting and time-
consuming” and peritonitis was associated with fear and uncertainty (16). 
Patients’ fear of PD-associated peritonitis, placing a burden on family 
members, and lack of confidence in their ability to maintain proper PD self-
care at home have been shown to be barriers to choosing PD as a dialysis 
modality (17). These were identified in our study. However, our study 
highlights that patients want family members to be better educated about PD 
and its requirements, some patients are unclear about the causes of 
peritonitis and do not believe the treatment they receive is fully effective, 
patients were strongly motivated to make PD work for them, they were 
unprepared for the level of pain they experienced and loss of bodily control. 
For those who could not work and especially those who were self-employed, 
they were worried about finances. Patients with young children were most 
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concerned about the separation that hospitalization brought and many 
patients spoke of the added responsibility that fell on family members when 
they had peritonitis. We also found that patients dreaded the idea of having 
to go to hospital, felt they were exposed to inferior treatment and possible 
infection when in hospital, and found the outpatient treatment schedule to be 
time-consuming and inconvenient. 
In our study, we achieved theoretical saturation and conducted investigator 
triangulation to ensure that the analysis captured the range and depth of the 
data collected. However, there are some potential limitations. The 
transferability of the findings beyond Australia is uncertain but the similarity 
of our results with studies conducted in the UK suggests broad relevance to 
other settings. We did not interview non-English speaking participants to 
avoid cultural and linguistic misinterpretation. In addition, we did not 
explicitly ask participants if they would prefer hemodialysis to PD, so it is 
possible that our sample was biased towards remaining on PD.  
Some participants in this study could not identify the symptoms of 
peritonitis and some thought the treatment they were given for 
peritonitis did not eradicate the cause. The International Society for 
Peritoneal Dialysis (ISPD) guidelines recommend that retraining 
occur 3 months after initial training and routinely after that (at least 
once/year), after hospitalization, after peritonitis or catheter 
infection, and after change in dexterity, vision, or mental acuity (11). 
More frequent retraining for patients could help clear up some of the 
misconceptions they have, reinforce what the symptoms of 
peritonitis are, and check whether the patient is performing an 
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exchange as they were taught. A home visit by a PD nurse to see 
how the patient functions in their own environment has been 
recommended but only some of the participants in this study had 
received a home visit (18). The desire expressed for family members 
to be educated about the process of PD and the causes of peritonitis 
could be accommodated by allowing family members to attend 
training with the patient or if this is not practical, to perhaps attend a 
day specifically designed for families of patients on PD. 
Some participants had very mild symptoms when they experienced peritonitis 
because the infection was detected early. Others had a very different 
experience, with the peritonitis episode making a major intrusion into their 
life. Being unable to work for a few weeks and travel costs to and from 
hospital caused financial strain. Parents with young children in particular, had 
to ask family and friends for help and some participants reported being 
disappointed with the lack of family assistance that occurred. We suggest that 
child care associated with the hospital be offered to patients who need to 
attend clinic or be hospitalized because of peritonitis and do not have anyone 
they can immediately call on. It would also help patients if access to free or 
low-cost parking at the unit/hospital could be provided during the treatment 
period. 
We found that many participants reluctantly went to hospital when they 
experienced peritonitis and the dread was intense for those patients who had 
repeat episodes of peritonitis. Various reasons for this response to hospitalization 
have been given and they include reality of the individual’s mortality, dealing 
with an altered level of dependency, grieving for losses (self or lifestyle) and fear 
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of recurrent problems (19). There was a perceived lack of knowledge about PD 
displayed by general hospital staff and some patients felt they were potentially 
exposed to infection. We suggest it would be an improvement if an experienced 
PD nurse or physician could be on call and visit patients when they are admitted 
to general wards or the intensive care unit (ICU). When undergoing treatment out 
of hospital for peritonitis, some units gave participants the antibiotics and 
instructions on how to inject them into the dialysis bag. 
Participants said they found this process confronting and that they were not 
confident of doing it correctly. More practical support for antibiotic pre-
administration is needed. In addition, having to go to the hospital or renal 
unit every 2 days for 2 weeks was time-consuming for patients and it would 
be an improvement if patients who are working could attend for tests and bag 
collection before and after normal work hours. Table 3 outlines our 
suggestions for clinical practice. 
Our findings have yielded insights into the perspectives of adult PD 
patients about peritonitis. Further research could be conducted which 
explores the effect of giving patient education and retraining on an 
ongoing basis (e.g. every 6 months) rather than in response to an event 
such as hospitalization, after peritonitis, or catheter infection. 
Conclusions 
Patients were highly motivated to remain on PD but many found the cleaning 
demands and instructions around doing an exchange to be overwhelming. 
Some participants were unclear about the symptoms of peritonitis and others 
were confused about the causes of peritonitis. Peritonitis impacted 
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participants physically, socially and financially as it affected their ability to 
work and perform normal tasks. Participants wanted to avoid hospitalization, 
reported suboptimal care when in hospital, and for those who were treated out 
of hospital for peritonitis, found the frequent trips to the renal unit or hospital 
to be inconvenient and time- consuming. Understanding the experiences and 
needs of PD patients who have had peritonitis can be used to inform strategies 
for patient-centered health care. Understanding the beliefs of patients about 
peritonitis and their knowledge of symptoms can also help inform training 
strategies aimed at educating patients on this topic. 
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Table 6.1: Participant demographic and clinical characteristics (n=29) 
 
Characteristic N % 
Age (years) [SD]   
30-39 [1.1] 5 17 
40-49 [3.2] 9 33 
50-59 [1.4] 5 17 
60-69 [2.2] 6 20 
70-79 [ 1 .6] 3 10 
80-89 1 3 
Sex   
Male 18 62 
Female 11 38 
Marital status   
Married/living with partner 17 59 
Divorced/separated 5 17 
Single 5 17 
Widowed 2 7 
Ethnicity   
Anglo-Saxon (White) 15 52 
Asian 11 38 
Aboriginal 1 3 
Mediterranean 1 3 
Pacific Islander 1 3 
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Table 6.1 (continued) 
 
Current renal replacement therapy   
APD 13 45 
CAPD 7 24 
HD* 7 24 
Transplant* 2 7 
Previous renal replacement therapy†   
APD 6 22 
CAPD 17 63 
HD 3 11 
Transplant 1 4 
Time on PD (months)   
0-12 7 24 
13-24 10 35 
25-36 4 14 
37-48 2 7 
49-60 1 3 
≥61 5 17 
Number of peritonitis episodes   
0 8 27 
1 13 45 
2 4 14 
>2 4 14 
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SD = standard deviation; APD = automated peritoneal dialysis; CAPD = continuous ambulatory peritoneal 
dialysis; HD = hemodialysis; PD = peritoneal dialysis; RRT = renal replacement therapy. 
% may not total 100 due to rounding. *Time since on PD=3-31 months; mean=11.8 months. †Not all patients 
have had a previous RRT and some have had more than 1.  
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Table 6.2: Illustrative quotations 
 
 
Themes Quotations
Constant vigilance for prevention
Conscious of vulnerability I wouldn't say I'm concerned about it, but it's in the back of your mind that you've got to make sure you're very careful. 
(Female, 70s, APD) 
Scared me in a sense that, at the back of my mind I was thinking I’m going to get it again. So that's what I said, when I do my 
bags, I'm so careful now just to make sure nothing goes wrong. (Male, 40s, CAPD) 
You were always worried you might get peritonitis because you talk to people who get three or four or five episodes a year 
and they appear to do everything right. I did everything as close as I could to right. That’s always in the back of your mind. 
(Male, 60s, HD and CAPD) 
Sharing responsibility with 
family 
One thing I missed that's very important is to have your partner in there. They should be educated as much as we are... Yeah 
because they are part of your life. They are the people who look after you away from hospital and they should have the 
knowledge and understanding of your sickness and what should be done. (Male, 40s, CAPD) 
But also, say for example, if they've got a carer looking after them, it doesn't help either, because the carer's got to be trained 
properly, or the children, because they just don't understand how important it is. (Male, 50s, Transplant and CAPD) 
See, my daughter and my grandkids - they had no idea - none whatsoever. I understand that. Maybe they should be involved 
with the training, to recognise something that shouldn't be there. I believe maybe they should come to the dialysis centre and 
speak to them. (Male, 60s, HD and CAPD) 
Demanding attention to 
detail 
Well as far as doing PD the hygiene level has to be really - maybe 110 per cent, you really have to wash your hands and 
prepare the dialysis everything should be - we close the house in the winter we have to switch off all the heating and 
everything. (Male, 40s, CAPD) 
Every day and wash the hands, get it ready. Do this. Do that. Wash the hands again.  Disinfect the hands.  I know I've got to 
do it all and it's basically what's keeping me alive. But it's just doing it day after day, just drives you insane. (Male, 50s, APD) 
It's not about going home, and just putting two chords together, it's not. It's hard, you've got to open up boxes, and you got to 
clean your area, you got to clean [your bench], you got to attach yourself, wash your hands to [unattach] yourself. It is time 
consuming, it's just full on, absolutely full on. (Female, 40s, HD, CAPD and APD) 
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Ambiguity of detecting 
infection 
I thought, I've eaten something funny maybe, I don't know. Within a couple of hours I was in crippling pain hunched over. I 
decided to come home from work. I drove past both Westmead and Blacktown hospital to get home. Didn't think anything of 
it. I got home and I just thought I'd eaten something bad or something I don't know what it was. (Male, 30s, HD and APD) 
I thought it was just a tummy bug from something I ate initially because the pain from what I’d learnt about peritonitis wasn’t, 
the pain I had was localised and it could’ve been a lower bowel infection which my GP thought it might be as well. (Male, 
40s, APD and CAPD) 
The only thing is that every time my period nearly comes, I get this cloudiness of the bags. I'm not really sure if this is from 
the period or if I'm having peritonitis. I'm getting confused. (Female, 40s, APD and CAPD) 
Ineradicable inhabitation I always think that, once you've got it you never fully clear the germs out of your system. I'm not a doctor but my theory is 
having spent so much time on dialysis and talking to other people, if you get it once you never really completely get rid of it 
so you've always got that slight chance of getting it again. (Male, 30s, HD and APD) 
I don't know whether I've got this right but they said, because she's had the Tenckhoff catheter in for so long when you first 
put that warm fluid into you because you haven't had anything in for so long, it's just the peritoneum goes, oh, oh, I can't 
handle this and it just, maybe, reacts to it and it gives you peritonitis. (Female, 50s, CAPD) 
But I don't think I got rid of it for a long time and it was really ugly. (Male, 40s, HD, CAPD and APD) 
Jeopardising peritoneal 
dialysis success 
Any infection within my peritoneal cavity because that could stop me from having this style of dialysis. I don’t want to go 
onto hemodialysis. In conjunction with that I must admit it was the same thought I hope I don’t die and I hope I can still do 
dialysis this way once it’s cleared up. (Male, 40s, APD and CAPD) 
My most - greatest fear was that I would go off the stomach PD and onto the arm PD, because I wouldn't - I would - don't 
want - didn't want to go onto the arm PD. (Male, 50s, Transplant and CAPD) 
No, when I first started on PD, because that first day I got it, the nurses came out and we did one bag exchange together and 
then my next exchange I had peritonitis. I guess that for me was a big thing because I really didn't want to go on haemo. I 
really wanted to make the PD work. (Female, 30s, Transplant, CAPD and APD) 
  
Chapter 6: Patients’ perspectives on the prevention and treatment of peritonitis in peritoneal dialysis: a semi-structured interview study 
 
310  
Invading harm
Life-threatening I was worried because they had said that people have died from peritonitis. So yeah, I was quite scared. I was thinking - well 
first of all I was in so much pain I just wanted it to go away, then when they confirmed I had peritonitis I was thinking, I hope 
I don't die. I hope it's not that bad. (Male, 30s, HD and APD) 
That was my first thought because I know how serious it can be. That was my first thought, I hope I don’t die from this. 
(Male, 40s, APD and CAPD) 
Yeah, I'm scared. Am I going to die? (Female, 40s, APD and CAPD) 
Wreaking internal damage Until you get hit with peritonitis and then everything changes. You're tender. Everything is too hard. (Male, 40s, HD, CAPD 
and APD) Yeah, it is not something to be taken easy. Yeah, it can cause a lot of damage to the internal lining of the… Yeah, 
because doctors told me what happens when the peritonitis takes place. So the internal lining is kind of scarred and all that, 
yeah. (Male, 50s, APD and HD) 
Debilitating pain Like I said I was in hospital, you're stuck to bed and can't move around and all those things and most of all the pain was 
enormous. (Male, 40s, CAPD and APD) 
I didn't know that I was going to cramp over like I was having a baby - done with labour, that's [seriously] bad pain. (Female, 
40s, HD, CAPD and APD) 
I just remember pain. Being asleep and being in pain. Painkillers, sleeping tablets, pain. It was shocking. It was the worst 
feeling. (Male, 40s, HD, CAPD and APD) 
Losing control and dignity I was constipated which didn’t help matters much too so I was in a pretty bad way in hospital there for a while and I lost all … 
you lose your dignity because you’ve got no control over your body. It just does what it wants to do (Male, 60s, HD and 
CAPD) 
Then it would have been only about eight hours later I needed to go to the toilet and I threw up and it wasn't vomit. It was - so 
it has basically come out the other end. (Male, 50s, Transplant and CAPD) 
I'd come home from work because I wasn't feeling well and I had a bit of pain and then I remember doing a bag and just 
sitting there vomiting while I was doing my bag and waiting for the colour to see what was coming out, see if it was cloudy or 
not. (Female, 30s, Transplant, CAPD and APD) 
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Incapacitating lifestyle interference 
Financial strain Not great because I had to spend a lot of time at the hospital so obviously I couldn't go to work for a full day. I only had part 
time days or half days. (Male, 30s, HD and APD) 
But at the time I was more concerned about how long am I going to be in hospital, is this going to get worse, am I going to be 
able to pay the mortgage, that’s how I felt at the time. (Male, 40s, APD and CAPD) 
Didn't go to work for five weeks and what it costs you through loss of income. I had to shut down my catering business. I 
lost half a million dollars. (Male, 40s, HD, CAPD and APD) 
Isolation and separation Yeah the pain is really bad and then it keeps me away from my family for at least a couple of weeks in the hospital. So yeah 
it's a small thing and then you pay a big price. (Male, 40s, CAPD and APD) 
Well I couldn't work, or couldn't see my family for a week. The kids couldn't come in, because I was in isolation. (Female, 
40s, HD, CAPD and APD) 
The children, it affected them in that if I was in hospital they'd have to go their father's. Even though we share half care 
anyway, but while I was in hospital they'd have to stay there more often and they're missing me and stuff like that … (Female, 
30s, Transplant, CAPD and APD) 
Exacerbating burden on 
family 
Family life, yeah obviously there was a little bit of disruption because obviously I had to - again my mum was a saint at the 
time when she was able to help me. She would help me every morning and she'd make sure I was okay before I went to work. 
Or make sure I was okay after I went and saw the doctors. (Male, 30s, HD and APD) 
My mother came down and stayed with my wife to help out with my little boy a little bit … (Male, 40s, APD and CAPD) 
I was actually here by myself because my children were with their father and I ended up ringing my mum and saying mum, I 
think I've got peritonitis, you're going to have to come down and take me to the hospital. That's probably my worst experience 
of peritonitis. (Female, 30s, Transplant, CAPD and APD) 
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Exasperation with hospitalisation 
Dread of hospital 
admission 
I had a very good run the last three months or so, four months, but before that it was nearly every second month I was in 
hospital. … I'm thinking my God, I'm back to hospital again. (Male, 40s, CAPD and APD) 
It's just you go in and you know you're going to end up in emergency.  You know you are going to have a night with no sleep 
in there. Then you'll be spending a few days while they do all the stuff they have to do, to make sure that everything is alright. 
No-one likes being in hospital and I don't like it either. (Male, 50s, APD and CAPD) 
Oh my god, here we go again. (Male, 50s, APD and HD) 
Exposure to infection … somebody told me I could go for a walk while they made my bed round. Then, the one from PD ward came in and she; 
and what is she doing up? The nurse said, oh - you know. I said, I was told I could go for a walk. She said - because I'd just 
had the operation, and then they used it - because I didn't have time to have - 10 days to heal, she said you can get leakage. 
(Female, 70s, APD and CAPD) 
A doctor could've even infected me, didn't even wash his hands, and I saw how he changed me. (Female, 40s, HD, CAPD and 
APD) 
Gruelling follow-up 
schedule 
Then, I had to go into the clinic every other day I think, and had a blood test and then they'd let me know when they got the 
result back. They'd give me the bag with the antibiotics, and then [either they'd ring me or] I'd ring them to say, yes have that 
bag with the antibiotics in it until it cleared up. (Female, 70s, APD and CAPD) 
I'd have to break my normal routine of a morning where I'd have to get up a little bit earlier. I'd have to run around and do all 
the antibiotics into the bag and do the fresh bag. That took a little bit longer than normal but it wasn't too bad it was just the 
odd - every two or three days I'd be at the hospital for check-ups and blood tests. (Male, 30s, HD and APD) 
So it all depends on how - whether they can see anything or what the levels are, I'm not really up on that. But I know it was 
inconvenient because you had to drag in there. Even though it's not that far but you've still got to drive in there, park and - 
yeah. (Female, 50s, CAPD) 
Receiving inattentive care Within the first seven days I was in hospital after the surgery, they put me on the machine straight away and that was painful 
because they didn't really monitor it all that well.  It's a hospital, it's new. (Male, 30s, HD and APD) 
Then I had a session in there where they put me up in the bed and then, because my blood pressure was really, really high, 
they put me on this blood pressure stuff to reduce my blood pressure. Then they walked away and they left the machine on, so 
my blood pressure went down to 80/20 or something. I was blacking out and I said to the patient next - even though I had 
buzzed and no one had come, I said, help. (Male, 50s, Transplant and CAPD) 
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Table 6.3: Suggestions for clinical practice 
 
 
 
Domain 
 
Suggested strategies and action 
Information, education 
and training 
Provide more frequent retraining for patients 
 Provide a home visit by a PD nurse (e.g. in the first week of dialysis at 
home, 3 months after starting dialysis, following a PD-related infection) 
 Allow family members/carers to attend training with the patient 
 Develop educational materials for family members/carers 
 Educate general hospital staff about the PD method and importance of 
infection prevention 
Psychological support Offer referral to psychological services after a peritonitis episode 
Technical/clinical 
support 
Provide a PD nurse or nephrologist on call who can visit patients when 
they are admitted to a general ward or the ICU 
 Have renal unit make up the dialysis bags with antibiotics for patients to 
use 
 Make it possible for patients who work to attend for tests and dialysis bag 
collection before and after normal work hours 
Social support Offer patients access to child care associated with the hospital during the 
peritonitis treatment period 
 Offer patients access to free or low-cost parking at the renal unit/hospital 
during the peritonitis treatment period 
  PD = peritoneal dialysis; ICU = intensive care unit. 
 
 
 
 
 
 
 
 
 
 
Chapter 6: Patients’ perspectives on the prevention and treatment of peritonitis in peritoneal 
dialysis: a semi-structured interview study 
 
314  
Figure 6.1: Thematic schema representing patient perspectives on the prevention 
and treatment of peritonitis in peritoneal dialysis
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Chapter 7: Discussion 
7.1 Summary of findings 
 
The prevention of peritonitis in PD patients is an important clinical activity. 
There has been a shift in thinking from the treatment of infection to the 
prevention of infection in PD patients. Peritoneal dialysis-associated 
peritonitis is the most acute complication of PD, is the main cause of 
technique failure and transfer to hemodialysis, causes significant morbidity 
and carries some risk of mortality. Peritonitis rates vary widely from centre to 
centre and from patient to patient (1,2). While some patient factors are 
thought to contribute to peritonitis (e.g. older age, diabetes mellitus), the 
quality of patient training, social factors and clinical practice patterns are also 
thought to play a role. It has been reported that the incidence and clinical 
outcomes of PD-associated peritonitis found in routine clinical audits of large 
unselected PD populations are not as good as those reported in a meta-
analysis by the Cochrane Renal Group or in centres that have an established 
research and clinical interest in PD (3). The findings from the research that 
forms this thesis inform the discussion about: what are the main strategies in 
use for the reduction of PD-related infections, what are the current practice 
patterns in relation to the prevention of these infections in ANZ PD units, 
what are some of the perceived barriers to the application of relevant 
guideline recommendations into practice, what are effective strategies for the 
reduction of PD-related infections, and what is the patient perspective in 
relation to the prevention and treatment of peritonitis. These findings can help 
clinicians to develop a family- and patient-centred approach towards the 
management of patients going through a peritonitis episode, can also help 
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clinicians to assess the value of the different approaches that are suggested to 
reduce the chances of a PD-related infection, and can highlight the variation 
in practice that exists from centre to centre and pose the question as to 
whether or not this variation is linked to the wide variation in peritonitis 
outcomes that is known to exist in ANZ (4,5). 
Prevention of peritoneal dialysis-related infections 
 
A large number of prophylactic strategies have been used to reduce the 
occurrence of peritonitis. There have been previous reviews on this topic and 
the narrative review presented in chapter 2 is an update of the topic and 
summarises the existing evidence evaluating these interventions. Overall, 
there is a lack of RCTs for many interventions and consequently, data from 
less rigorous study designs such as cohort studies are the current best 
available evidence. In addition, systematic reviews have few RCTs that can 
be included in the analysis. The quality of the RCTs is also variable with 
some having small patient numbers, short follow-up times and an increased 
risk of bias because of poor or unclear randomisation and blinding processes. 
The quality of the evidence is strong for some aspects such as the PD 
connection method, the use of intravenous antibiotic administration prior to 
PD catheter insertion, and the use of antibiotic to prevent ESI but is weak for 
other areas such as the method for training patients. No advantage can be 
found for using different catheter designs, surgical implantation techniques, 
catheter placement or automated peritoneal dialysis (APD) versus chronic 
peritoneal dialysis (CPD). Adoption of a team-based, multifaceted approach 
to continuous quality improvement with regular audit of infection rates and 
outcomes is considered essential to improving peritonitis rates. The training 
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of patients is recognised as a modifiable risk factor for PD peritonitis and the 
review noted that research into how to best deliver this training, how often to 
retrain patients and how to train the trainers are an important research area. 
Assessment of current practice and barriers to prophylaxis 
in peritoneal dialysis patients 
The study described in chapter 3 presents the results of a baseline study of 
current practice conducted with 8 renal units located in Australia (7) and New 
Zealand (1). The current practice was in relation to the use of antibiotic and 
antifungal prophylaxis in PD patients as per current ISPD and KHA-CARI 
guidelines. We found that prophylactic practice varied widely between the 
units and the PD-related infection outcomes (exit-site infection [ESI], 
peritonitis) also varied widely between the units. We also found that the 
definitions of PD- related infections used by some units varied from those 
recommended by the ISPD, particularly with regard to ESI. Some units were 
consequently over-reporting ESI while others were under-reporting it. 
Perceived barriers to the uptake of guideline recommendations included lack 
of knowledge of the recommendation/s, procedural lapses, lack of a 
centralised patient database, patients with non-English speaking background, 
professional concern about antibiotic resistance, medication cost, and the 
inability of nephrologists and infectious diseases staff to reach consensus on 
unit protocols. 
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Antimicrobial agents for preventing peritonitis in peritoneal dialysis 
patients (Cochrane Review) 
Chapter 4 is an update to a Cochrane systematic review first conducted 10 
years ago. The review assesses the evidence base for nine categories of 
intervention that have been used to reduce the risk of peritonitis and exit-
site/tunnel infections in PD patients. Most of these comparisons are based 
on a small number of RCTs. Only two of the antimicrobial interventions 
appear to reduce the risk of peritonitis. 
 
 
Infection prophylaxis in peritoneal dialysis patients: results from an 
Australia/New Zealand survey 
 
Chapter 5 outlines the responses of 133 consultant nephrologists to an online 
survey which asked a series of questions about their use of antibiotic and 
antifungal prophylaxis in PD patients. There have been no recent large scale 
surveys of this type perfomed in ANZ. The findings show that practice in 
relation to various prophylactic measures is variable and may relate to 
whether the guideline recommendation is evidence- or opinion-based, leaves 
allowance for consideration of local conditions or reflects 
unawareness/disagreement with the guideline recommendations. It is possible 
that some of this variation contributes to the disparity in PD-related infection 
rates that exist between units in ANZ. 
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Patients’ perspectives on the prevention and treatment of 
peritonitis in peritoneal dialysis: a semi-structured 
interview study 
The patient perspective in relation to the prevention and treatment of 
peritonitis has not been studied much. Chapter 6 is a qualitative analysis of 
patient beliefs, needs and experiences regarding the prevention and treatment 
of peritonitis. Patients perceived that peritonitis could threaten their health, 
treatment modality and lifestyle which motivated vigilance and attention to 
hygiene. A number of patients were unsure how to monitor for signs of 
peritonitis. The findings from this study could be used to enhance patient- and 
family-centred care and education strategies which could address some of the 
concerns patients have about the possibility of peritonitis and the impacts of a 
peritonitis episode. 
7.2 Strengths and limitations 
 
The studies in this thesis address the clinical problem of the need to 
reduce the risk of peritonitis in PD patients. The study findings have 
implications for clinical practice, policy making and future research. 
Each study was designed to be methodologically sound and reporting 
standards were followed. Apart from the limitations specific to each 
study that have already been discussed in the relevant chapters, the main 
limitation is that there is a lack of adequately powered and high quality 
RCTs to inform decision making about strategies to prevent peritonitis. 
This would have affected the results of the analysis done in the Cochrane 
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Review. Some interventions appear to have no or very little effect on an 
outcome but this might only be a consequence of a lack of power and 
suboptimal study performance/reporting. A limitation of the survey study is 
that we did not think to include questions about why nephrologists choose to 
not adhere to guideline recommendation/s. 
7.3 Clinical implications 
 
The findings from the work comprising this thesis have implications for 
clinical practice in the area of the prevention of peritonitis in patients on PD. 
Based on the findings, it is apparent that there is considerable variation in 
practice between ANZ units as regards the use of prophylactic measures in 
PD patients. The reasons for this are not clear. Some barriers have been 
identified in the baseline study, which act to stop the uptake of certain 
guideline recommendations. The findings from the Cochrane Review call 
into question whether the use of nasal antibiotic to clear S. aureus carriage is 
an effective measure. It also raises questions as to whether the use of topical 
disinfectant at the exit site is effective in reducing the risk of PD-related 
infection.  
Family- and patient-centred strategies are proposed in chapter 6 of this thesis 
to help educate and support patients, which may lead to improved treatment 
satisfaction and outcomes. It is accepted that patients with chronic disease 
should be engaged with their health care provider as a full partner in 
managing their disease and that this leads to better outcomes for the patient 
and is a prerequisite for effective and efficient health care (6). Patients can 
also help to set the agenda for future research, as has occurred with the 
inclusion of patients in the Outcome Measures in Rheumatology 
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(OMERACT) conferences. Patient input has influenced the scope and 
conduct of outcomes research in rheumatology by widening the research 
agenda, including patient relevant outcomes in core sets and enhancing 
patient reported instruments, as well as other effects (7). In the same way, the 
patient interview study described in chapter 6 highlighted deficiencies in 
patient knowledge and understanding and underlined the need for more 
support (psychological, technical, clinical, social) when a patient experiences 
a peritonitis episode. The resulting suggestions for clinical practice are an 
important outcome of the study and have the potential to help prevent 
peritonitis and make the patient experience less onerous. 
 
The effects of employing continuous quality improvement and quality 
management have been investigated in a number of different clinical settings. 
Continuous quality improvement uses the Plan, Do, Study, Act cycle to 
improve the procedures followed during the care of a patient. Improvements 
in various important patient outcomes have been found, which include a 
significant decrease in the rate of catheter-related bloodstream infections in 
the Intensive Care Unit after the implementation of five systems interventions 
(over a 5 year period) (8) and a 50% reduction in overall sepsis mortality in 
the Emergency Departments and Inpatient Units at 11 acute care hospitals 
(over a 6 year period) after putting into practice the recommendations from a 
series of evidence-based guidelines (9). The use of various quality 
improvement interventions at one PD unit over 17 years also resulted in 
reduced infection rates in the PD patients, with the peritonitis rate and exit-
site infection rate both reducing significantly (10). Another PD unit 
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introduced a number of changes as part of a quality improvement program, 
after observing consistent differences in peritonitis rates between patients 
using various PD connection systems. The quality improvement program 
resulted in a fivefold reduction in peritonitis rates at the unit (11).  
 
The development of key performance indicators (KPIs) provides a means of 
measuring performance of renal services in relation to evidence-based 
practices and can be used to improve services. Appropriate KPIs for the 
prevention of PD-related infection include 100% prophylactic antibiotic 
administration prior to catheter insertion, achieving a PD peritonitis rate 
<0.36 episodes per patient per year, and 100% prescribing of antifungal agent 
during treatment of peritonitis (12). The development of KPIs enables a unit 
to determine its performance against agreed best practice parameters (13). A 
recent program run in Victoria by the Renal Health Clinical Network 
developed four KPIs relating to CKD and dialysis and two KPIs relating to 
transplant. One of the KPIs was ‘peritonitis rate of PD patients for each 
service hub’ with a target of peritonitis rate less than one episode per patient 
in 18 months. Nine units submitted data for this KPI. Data for the state was 
assessed for the 2 years that KPI use had been in place and showed that the 
average number of months between peritonitis episodes in Victoria had 
increased 2 months per year during that time (13). 
 
It has been recognised for some time that in Australia and New Zealand, in 
many cases, poor peritonitis outcomes reflect significant deviations from the 
ISPD guidelines (14). A review of the data held by the Australian Peritonitis 
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Registry 2003-2006 revealed many deviations in Australian practice from the 
guideline recommendations. One of the conclusions of this review was that 
“A concerted unified approach to clinical governance with strong leadership 
in each unit is imperative to improve PD outcomes in ANZ.” In the US, the 
Medicare definition of the medical director of a dialysis centre is: “…the 
leader of the interdisciplinary team and the person ultimately accountable for 
quality, safety, and care provided in the center.” The medical director is 
expected to be knowledgeable about the quality assessment and performance 
improvement (QAPI) process and to demonstrate active leadership with a 
hands-on approach (15). This is considered essential in order for high quality 
outcomes to be achieved in a dialysis centre. The medical director is also 
expected to “help centers to prioritize improvement projects and direct efforts 
to identify and address systemic issues.” In becoming involved in quality 
improvement, the medical director moves from a patient care provider role to 
a population health management role with responsibility for facility patient 
care and outcome. This requires the performance of different tasks to those 
required with direct patient care. The medical director is in a position to set 
the tone and culture of the dialysis centre and can influence whether quality 
improvement processes become an integral part of patient care or are viewed 
as yet one more task that needs to be done. PD units in Australia and New 
Zealand need medical directors to lead the way, and drive quality 
improvement using process-driven KPIs that are published and socialised 
internally and externally. 
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7.4 Implications for future research 
 
From the systematic review, it is apparent that there is a need for more well-
conducted RCTs of sufficient power that investigate some of the prophylactic 
interventions that are commonly used in practice. For example, nasal versus 
exit-site application of mupirocin, pre-operative screening and elimination of 
nasal S. aureus, and the type of cleansing agent used at the exit 
site are suitable topics for investigation. Prospective cohort studies could also 
be conducted which investigate the infection and technique survival outcomes 
of different training methods and different retraining frequencies (e.g. 
proactive versus reactive). 
From the survey of nephrologists, we know that current practice in ANZ as 
regards the use of prophylactic measures in PD patients is quite variable, as 
are the peritonitis rates. Research could be done which explores why 
nephrologists apply certain guideline recommendations in practice but not 
others. An investigation could also be made into the practices of those units 
that have good PD-related infection outcomes in order to identify practices 
that appear to help reduce the risk of these infections. 
The data we have from the survey could be further analysed in relation to 
this. Some of the suggestions for clinical practice made in the qualitative 
study could be put into practice. It would be worthwhile to assess patient 
satisfaction and improvement in outcomes after implementation of the 
family- and patient-centred strategies for education and care that are 
outlined here. 
These are some potential areas for research that have come out of this thesis. 
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7.5 Conclusion 
 
This thesis outlines what clinical practice in relation to the use of 
prophylaxis in PD patients is like in ANZ and identifies some barriers to the 
uptake of relevant guideline recommendations. The optimal preventive 
strategies to reduce the occurrence of peritonitis remain unclear, with only a 
few interventions showing a significant effect on PD-related infection 
outcomes. 
Studies on the prevention of PD-related infections are limited both in 
terms of quality and quantity, and consequently, guideline 
recommendations are based on a mixture of expert opinion and the 
available evidence. 
Clinical governance with strong leadership at the unit level is essential to improve 
outcomes for PD patients. The use of continuous quality improvement programs 
and key performance indicators have the potential to reduce deviations from  
current best practice and improve clinical outcomes.  
Patients experience ongoing anxiety about peritonitis and are impacted 
physically, socially and financially when they experience a peritonitis 
episode. Understanding the experiences and needs of PD patients who 
have had peritonitis can be used to inform strategies for patient-centred 
health care. Understanding the beliefs of patients about peritonitis and their 
knowledge of symptoms can help inform training strategies aimed at 
educating them. 
Future research into the education and care strategies suggested in the 
qualitative interview study may help to improve PD patient outcomes. 
Chapter 7: Discussion 
326  
7.6 References 
 
1. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye W-
C, et al. ISPD position statement on reducing the risks of peritoneal 
dialysis-related infections. Perit Dial Int. 2011;31(6):614-30. 
2. Li PKT, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, 
et al. ISPD peritonitis recommendations: 2016 update on prevention 
and treatment. Perit Dial Int 2016; 36(5): 481-508. 
3. Mactier R. Peritonitis is still the Achilles' heel of peritoneal dialysis. Perit Dial 
Int. 2009;29:262-6. 
 
4. Boudville N, Dent H, McDonald S, Hurst K, Clayton P. 
Peritoneal Dialysis. In: Clayton P, McDonald S, Hurst K, 
editors. ANZDATA Registry Report 2013. Adelaide, South 
Australia: Australia and New Zealand Dialysis and Transplant 
Registry; 2014. p. 1-31. 
5. Brown F, Gulyani A, Dent H, Hurst K, McDonald S. 
Peritoneal dialysis In: McDonald S, Clayton P, Hurst K, 
editors. ANZDATA Registry Report 2011 Adelaide, SA: 
ANZDATA Registry; 2012. p. 6-1 - 6-32.  
6. Holman H, Lorig K. Patients as partners in managing 
chronic disease. BMJ 2000; 320: 526-527. 
7. De Wit MPT, Koelewijn van Loon MS, Collins S, Abma 
TA, Kirwan J. Patients’expectations and experiences at the 
Outcome Measures in Rheumatology conference 2010. 
Patient 2013; 6: 179-187.  
 
Chapter 7: Discussion 
327  
8. Berenholtz SM, Pronovost PJ, Lipsett PA, Hobson D, 
Earsing K, Farley JE, et al. Eliminating catheter-related 
bloodstream infections in the intensive care unit. Crit Care 
Med 2004; 32(10): 2014-2020.  
9. Doerfler ME, D’Angelo J, Jacobsen D, Jarrett MP, 
Kabcenell AI, Masick KD, et al. Methods for reducing 
sepsis mortality in emergency departments and inpatient 
units. The Joint Commission Journal on Quality and Patient 
Safety 2015; 41(5): 205-211.  
10. Qamar M, Sheth H, Bender FH, Piraino B. Clinical 
outcomes in peritoneal dialysis: impact of continuous 
quality improvement initiatives. Adv Perit Dial 2009; 25: 
76-79.  
11. Borg D, Shetty A, Williams D, Faber MD. Fivefold reduction 
in peritonitis using a multifaceted continuous quality initiative 
program. Adv Perit Dial 2003; 19: 202- 205. 
12. Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: 
towards improving evidence, practices and outcomes. Am J 
Kidney Dis 2014; 64(2): 278-289. 
13.  Toussaint N, McMahon LP, Dowling G, Soding J, Safe M,    
              Knight R, et al. Implementation of renal key performance  
              indicators: promoting improved clinical practice.       
              Nephrology  (Carlton) 2015; 20: 184-193. 
14.  Jose MD, Johnson DW, Mudge DW, Tranaeus A, Voss D,  
             Walker R, et al. Peritoneal dialysis practice in Australia and  
Chapter 7: Discussion 
328  
           New Zealand: a call to action. Nephrology (Carlton) 2011;  
           16: 19-29.  
15. Schiller B. The medical director and quality requirements in  
            the dialysis facility. Clin J Am Soc Nephrol 2015; 10(3):  
            493-499.     
  
Appendix A: Supporting data for chapter 2 
329  
 Appendix A: Supporting data for chapter 2 
A1. EMBASE search strategy for chapter 2 
 
 
The following search strategy was used to identify randomised controlled 
trials, meta- analyses and systematic reviews about peritoneal dialysis-
related infection in EMBASE (1980- December 2013) 
1. peritoneal dialysis/ 
 
2. peritoneal dialysis.tw. 
 
3. (PD or CAPD or CCPD).tw. 
 
4. or/1-3 
 
5. bacterial peritonitis/ 
 
6. peritoneal dialysis catheter/ 
 
7. catheter infection/ 
 
8. catheter$.tw. 
 
9. (exit site$ or exit-site$).tw. 
 
10. (tunnel$ and infection$).tw. 
 
11. or/5-10 
 
12. and/4,11 
 
13. randomized controlled trial/ 
 
14. crossover procedure/ 
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15. double-blind procedure/ 
 
16. single-blind procedure/ 
 
17. random$.tw. 
 
18. factorial$.tw. 
 
19. (crossover$ or cross-over$).tw. 
 
20. placebo$.tw. 
 
21. (double$ adj blind$).tw. 
 
22. (singl$ adj blind$).tw. 
 
23. assign$.tw. 
 
24. allocat$.tw. 
 
25. or/13-24 
 
26. and/12,25 
 
27. limit 12 to meta analysis 
 
28. limit 12 to "systematic review" 
 
29. limit 12 to "reviews (maximizes specificity)" 
30. 27 or 28 or 29 
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A2. MEDLINE search strategy for chapter 2 
 
The following search strategy was used to identify randomised 
controlled trials, meta- analyses and systematic reviews about 
peritoneal dialysis-related infection in  MEDLINE (1950- December 
2013) 
1. exp Peritoneal Dialysis/ 
 
2. peritoneal dialysis.tw. 
 
3. (PD or CAPD or CCPD).tw. 
 
4. or/1-3 
 
5. Peritonitis/ 
 
6. peritonitis.tw. 
 
7. Catheters, Indwelling/ 
 
8. Catheter-Related Infections/ 
 
9. (exit site$ or exit-site$).tw. 
 
10. (tunnel$ and infection$).tw. 
 
11. catheter$.tw. 
 
12. or/5-11 
 
13. and/4,12 
 
14. randomized controlled trial.pt. 
 
15. controlled clinical trial.pt. 
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16. randomized.ab. 
 
17. placebo.ab. 
 
18. clinical trials as topic/ 
 
19. randomly.ab. 
 
20. (crossover or cross-over).tw. 
 
21. Cross-over Studies/ 
 
22. trial.ti. 
 
23. or/14-22 
 
24. animals/ not (humans/ and animals/) 
 
25. 23 not 24 
 
26.  and/13,25meta analysis.pt. 
 
27. Meta-Analysis/ 
 
28. (systematic$ and (review$ or overview$)).tw. 
 
29. meta?analy$.tw. 
 
30. meta analy$.tw. 
 
31. review.pt. and medline.tw. 
 
33. or/27-32 
 
34. and/13,33 
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Appendix B: Supporting data for chapter 3 
 
B1. Relevant ISPD and KHA-CARI Guideline Recommendations 
 
 
 
Guideline Organization  Year of Publication  Guideline Recommendation 
KHA‐CARI  2004  Antibiotic prophylaxis with a first generation 
cephalosporin should be used at peritoneal 
dialysis catheter insertion to reduce the incidence 
of peritonitis (Level II evidence). Although 
vancomycin prophylaxis has also been 
demonstrated to be effective (Level II evidence), 
its routine use is not recommended because of 
the potential development of resistant 
microorganisms such as vancomycin‐resistant 
enterococci (VRE) and vanomycin‐resistant 
Staphylococcus aureus. 
KHA‐CARI  2004  Prophylactic therapy using mupirocin ointment, 
especially for Staphylococcus aureus carriage 
intranasally is recommended to decrease the risk 
of S. aureus catheter exit site/tunnel infections 
and peritonitis (Level II evidence). 
KHA‐CARI  2004  The use of oral nystatin should be considered at 
the time of antibiotic administration to peritoneal 
dialysis patients to reduce the occurrence of 
fungal peritonitis (Level II evidence). 
ISPD  2011  Prophylactic antibiotics administered at the time 
of insertion decrease the infection risk. 
ISPD  2011  Prevention of catheter infections (and thus 
peritonitis) is the primary goal of exit site care. 
Antibiotic protocols against S. aureus are effective 
in reducing the risk of S. aureus catheter 
infections. 
ISPD  2011  All PD patients should use topical antibiotic either 
at the catheter exit site or intranasally or both. 
ISPD  2011  Fungal prophylaxis during antibiotic therapy may 
prevent some cases of Candida peritonitis in 
programs that have high rates of fungal 
peritonitis. 
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B2.  Peritoneal Dialysis Implementation Project Selection 
Criteria 
 
 
1. Unit has a problem achieving good infection control in new PD patients 
 
2. Achieving good infection control in new PD patients is considered a 
priority issue by the unit 
3. Belief that prevention of PD-related infections in new PD patients 
at the unit can be improved 
4. Key staff members are willing to proactively identify barriers 
to achieving good infection control in new PD patients 
5. A good data collection system exists at the unit 
 
6. Unit is willing to allow the project coordinator to access the unit’s 
records held by the ANZDATA registry 
7. Unit is willing to gain local ethical clearance if this is needed 
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Appendix C: Supporting data for chapter 5 
 
Consultant nephrologist survey form, initial introductory letter, 
revised introductory letter, reminder survey letter  
 
C1. Consultant nephrologist survey form 
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C2. Initial introductory letter  
Prophylactic antibiotic and antifungal use in peritoneal dialysis patients and 
technique used for catheter insertion: survey of consultant nephrologists 
Dear All 
This survey is being undertaken by the Steering Committee responsible for the current 
KHA- CARI Guidelines implementation project, which is looking at guideline 
concordant use of antibiotics and antifungal agents in incident peritoneal dialysis (PD) 
patients in 8 renal units. We are conducting the survey to determine if renal unit 
characteristics help explain the variation in peritonitis rates that is seen between the 
centres that report to ANZDATA. The data collected will help us to understand the 
variations in practice that exist. This knowledge in turn, should help us to improve the 
care of PD patients in Australia and New Zealand. 
The survey is online and should take no more than 10-15 minutes to complete. The 
survey is in 4 parts with some Demographics questions and a General Comments box 
at the end; there are a total of 23 questions. This survey is completely confidential and 
anonymous and participation is voluntary. One of the questions in the survey asks for 
your unit name. We have requested this so that we can correlate responses to unit size, 
location and satellite services. Any data presented from this survey will be de-
identified and all responses will be kept confidential. Your responses will only be 
analysed in aggregate with the responses of other respondents and at no time will your 
individual responses be made available to anyone. The results of the survey will be 
published in a peer reviewed journal and/or scientific presentation. You can reach the 
survey by clicking on the following link (if clicking on the link does not work, please 
copy and paste the link into the address bar of your internet browser) 
https://www.surveymonkey.com/s/N9C5DYW 
Please answer questions as they apply to the renal unit where you mainly work. You 
may need to ask other staff in your unit to assist you to complete some questions. If 
you have any questions about the survey, contact Denise Campbell on (02) 9845 1477 
for more information (Email: denise.campbell@health.nsw.gov.au). 
This project has been approved by The Sydney Children’s Hospital Network Human 
Research Ethics Committee. If you have any worries or questions about the study, 
please call the Research Ethics Manager (02 9845 3017), who is the Secretary of the 
Ethics Committee and quote the approval number 12/SCHN/194. 
Please note that for each completed survey we will donate $5 to Kidney Health 
Australia. Thank you in advance for your time and cooperation. 
 
 
Assoc. Prof David Mudge Denise Campbell 
Convenor Project Officer 
KHA-CARI PD Implementation Project KHA-CARI PD Implementation 
Project 
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C3. Revised introductory letter 
Dear All 
Peritoneal Dialysis Survey of Consultant Nephrologists 
This survey is being administered in Australia and New Zealand. It is intended to 
elicit current practice as regards prophylactic antibiotic and antifungal use in 
peritoneal dialysis patients. It has been developed by the Steering Committee 
responsible for the current KHA- CARI Guidelines implementation project. 
The survey consists of 23 multiple-choice questions that can be completed in 
approximately 10 minutes. All responses will be kept confidential. 
The information collected will be analysed to see if renal unit characteristics help 
explain the variation in peritonitis rates that is seen between the centres that report to 
ANZDATA. We will also publish the results in manuscript form. 
We would very much appreciate it if you would take the time to complete the survey. 
You can either complete the enclosed printed copy and mail it back to the KHA-
CARI office (reply paid envelope enclosed) or you can answer the survey online. The 
link to the survey is: https://www.surveymonkey.com/s/N9C5DYW 
Please answer questions as they apply to the renal unit where you 
mainly work. Thank you to those who have already completed the 
survey. 
Kind regards 
 
 
 
Assoc. Prof David Mudge 
 
Convenor, KHA-CARI PD Implementation 
Project Tel: (07) 3176 5080 
Email: David_Mudge@health.qld.gov.au 
Denise Campbell 
Project Officer, KHA-CARI PD Implementation 
Project Tel: (02) 9845 1477 
Email: denise.campbell@health.nsw.gov.au 
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C4. Reminder survey letter 
Reminder: Peritoneal Dialysis Survey of Consultant Nephrologists 
This survey is being administered in Australia and New Zealand. It is intended to 
elicit current practice as regards prophylactic antibiotic and antifungal use in 
peritoneal dialysis patients. It has been developed by the Steering Committee 
responsible for the current KHA- CARI Guidelines implementation project. 
The survey consists of 23 multiple-choice questions that can be completed in 
approximately 10 minutes. All responses will be kept confidential. 
The information collected will be analysed to see if renal unit characteristics help 
explain the variation in peritonitis rates that is seen between the centres that report to 
ANZDATA. We will also publish the results in manuscript form. 
We would very much appreciate it if you would take the time to complete the 
survey. Link to the survey: https://www.surveymonkey.com/s/N9C5DYW 
Please answer questions as they apply to the renal unit where you 
mainly work. Thank you to those who have already completed the 
survey. 
 
Kind regards 
Assoc. Prof David Mudge 
Convenor, KHA-CARI PD Implementation 
Project Tel: (07) 3176 5080 
Email: David_Mudge@health.qld.gov.au 
 
Denise Campbell 
Project Officer, KHA-CARI PD Implementation 
Project Tel: (02) 9845 1477 
Email: denise.campbell@health.nsw.gov.au 
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Appendix D: Supporting data for chapter 6 
Interview guide, participant information sheets consent forms  
D1. Interview guide 
Patient experiences and views on peritoneal dialysis: a 
qualitative study Introduction/briefing (interviewer) 
How are you? 
Thank you very much for agreeing to be interviewed. I am a PhD student enrolled 
with Sydney University and am conducting research about patients’ perspectives 
on peritoneal dialysis. The interviews conducted through this study, with people 
who have/ have had experience with peritoneal dialysis, will hopefully generate 
information which will help doctors provide better care and support for people 
receiving peritoneal dialysis. 
I will be asking you questions about your experiences with peritoneal dialysis, to get 
a sense of what life is like on peritoneal dialysis and what impact it has had on you 
and your family/carers. It shouldn’t take more than one hour. I would like to record 
the interview with my voice recorder because this will help me later on to analyse the 
information generated. 
The recording will be kept confidential. What you tell me will be de-identified and 
will not impact the care you receive. Please let me know if you want me to stop 
recording at any time. 
Before we begin, would you like to ask me any questions? 
 
1. Introduction 
a. Explain study information sheet and obtain informed consent 
b. What is your date of birth? 
c. Where were you born? 
d. Who lives with you? (married, single, divorced, widowed) 
e. How long have you been/ were you on peritoneal dialysis? 
f. Which type of PD are/ were you on? (APD, CAPD) 
g. Are you now on haemodialysis? Have you received a kidney transplant? 
h. Are you on the waitlist for a transplant? Do you have blood sent to the 
Red Cross each month? 
2. General experiences and perspectives of peritoneal dialysis 
a. How did you come to be on peritoneal dialysis? 
b. What are some of the biggest challenges or difficulties you face with 
peritoneal dialysis and how do you cope with them? 
c. Has peritoneal dialysis made an impact on your life - how? (work, social 
life) 
d. Has going on peritoneal dialysis changed the way you see yourself and 
how you feel - how? (positive and negative impact on identity, self-
esteem, emotions) 
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e. Do you think that being on peritoneal dialysis affects the people  close 
to you - how? (family, close friends) 
3. PD technical aspects/ complications/ modality failure 
a. What aspects of doing peritoneal dialysis are/were you most/least 
confident about? Why? 
b. What dialysis complications are/were you most concerned about? Why? 
c. You have been on both APD and CAPD – what do you think are the 
main differences between the two in terms of managing your dialysis? 
Do you feel one is easier to do than the other? How? 
d. Why would you switch/have you switched to haemodialysis? 
 
4. Perspectives on peritonitis 
a. What is the first thought that comes to your mind when I say peritonitis? 
b. Can you describe to me your most recent episode of peritonitis? What 
was your initial thought/feeling when you were told you had 
peritonitis? 
c. How did having peritonitis impact your day to day living? (work, 
family, social activities) 
d. What do you think caused your peritonitis? Did your healthcare provider 
explain why they think you got peritonitis – what were you told? 
e. What sorts of things do you think makes a person on peritoneal 
dialysis have a higher chance of getting peritonitis? 
f. What do you do to prevent yourself from getting peritonitis again? 
g. What were the most difficult things to deal with when you had 
peritonitis? What did you do to cope with those issues? 
 
5. Support and education 
a. What advice would you give to someone who was about to start 
peritoneal dialysis? 
b. What would you tell them about your experience of peritoneal dialysis? 
c. What programs/initiatives can you suggest that might help to 
improve the patient experience of PD? (education, support 
groups) 
 
6. Healthcare service provision 
a. What aspects of care are/were most important to you? (access to PD 
nurses, access to nephrologists, home visits by PD staff) 
b. In an ideal world, what would be 1 or 2 things that you would do to 
improve peritoneal dialysis treatment? (healthcare, technical, 
support) 
Closing question: 
 
Is there anything else that you think is important about peritoneal dialysis that you  
want to add before we finish? Thank you for your time. 
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D2. Participant information sheet (QLD), 
 
 
 
 
Princess Alexandra 
Hospital 
 
Patient experiences and views on peritoneal dialysis: a qualitative study 
 
PARTICIPANT INTERVIEW INFORMATION SHEET 
 
Primary Investigators: 
 
Ms. Denise Campbell, Centre for Kidney Research, The Children’s Hospital at Westmead, NSW Tel: (02) 
9845 1477 Dr Allison Tong, Centre for Kidney Research, The Children’s Hospital at Westmead, NSW Tel: 
(02) 9845 1482 Associate Investigators: 
 
Assoc. Prof David Mudge, Dept. of Nephrology, Princess Alexandra Hospital, QLD Tel: (07) 
3176 7765 Dr John Saunders, Dept. of Renal Medicine, Royal Prince Alfred Hospital, NSW 
Tel: (02) 9515 6600  Dr Germaine Wong, Dept. of Renal Medicine, Westmead Hospital, 
NSW Tel: (02) 9845 6962 
Assoc. Prof Martin Gallagher, Dept. of Nephrology, Concord Hospital, NSW Tel: (02) 
9993 4552 Dr Fiona Brown, Dept. of Nephrology, Monash Medical Centre, VIC Tel: 
(03) 9594 3529 
 
 
Dear Patient 
 
You are invited to participate in a research study looking into the experiences, views and needs of 
patients on peritoneal dialysis and the effect that being on peritoneal dialysis has on a patient’s quality 
of life. We know that commencing dialysis has an impact on a patient’s quality of life. We also know 
that having an in-depth understanding of the experiences, views and needs of patients on peritoneal 
dialysis can be used to develop more patient-centred health care. We want to learn about your 
experience of being on peritoneal dialysis and hopefully, find out ways to improve the treatment and 
support given to patients. 
 
The study is being conducted by all of the investigators listed above. 
 
The study is an Australian multi-centre study coordinated by Australian researchers based at the 
Centre for Kidney Research, Children’s Hospital at Westmead, NSW. The study is funded by the 
Centre for Kidney Research, NSW. 
 
What is the study about? 
 
There are two main types of dialysis available for patients with end-stage kidney failure – haemodialysis 
and peritoneal dialysis. Quality of life is a term used to describe how you feel and how well you are able 
to do your usual activities. Health-related quality of life questionnaires have shown that after 1 year of 
dialysis, there are differences in the quality of life experienced by patients according to which type of 
dialysis they are on. We want to get an idea of the effect that being on peritoneal dialysis has had on 
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your quality of life. We also want to find out what are common experiences, needs and views of patients 
on peritoneal dialysis because this information can be used to improve the treatment, education and 
support given to patients and their families. 
The purpose of this study is to investigate the experiences and views of patients who have been or are 
currently on peritoneal dialysis and have experienced one or more episodes of peritonitis. 
Who can participate in the study? 
 
You are invited to participate in this study because you have been diagnosed with end-stage kidney 
disease and are currently on or have been on peritoneal dialysis as your treatment. You have also 
experienced at least one episode of peritonitis. You will need to be able to read and communicate in 
English to participate. 
 
Do you have a choice? 
 
Participation in this study is voluntary. It is completely up to you whether or not you participate. If you 
decide not to participate, it will not affect the treatment you receive now or in the future. Whatever your 
decision, it will not affect your relationship with the staff caring for you. New information about the 
treatment being studies may become available during the course of the study. You will be kept informed 
of any significant new findings that may affect your willingness to continue in the study. If you wish to 
withdraw from the study once it has started, you can do so at any time without having to give a reason. 
However, it may not be possible to withdraw your data from the study results if these have already had 
your identifying details removed. 
What will the study involve? 
 
If you agree to participate in the study, you will be asked to sign the Patient Consent Form. This 
study will be conducted over approx. 18 months. 
Participation in this project is entirely voluntary and if you decide not to take part or decide to withdraw at 
any time, this will not affect your care at the Hospital or that of your family in any way. The data from this 
study will be kept for 5 years and it is acceptable for you to withdraw from the study at any point during 
this time. 
You will be asked to participate in a face-to-face interview with a researcher from the Centre for Kidney 
Research, NSW. The interview will take place either in your home or an alternative setting where you 
feel comfortable. If you wish, your carer may be present during the interview. Each interview will take 
approx. 30 minutes to 1 hour to complete and will be audio recorded. We will ask you some basic 
demographic questions (e.g. age, marital status, type of PD treatment) and questions about your 
experiences and views on peritoneal dialysis and healthcare service in general. The interview will be 
transcribed verbatim and if you wish, you will be sent a summary of the interview which you can give 
feedback on. 
Please feel free to talk to the Associate Investigator at your Renal Unit if you want to discuss how 
you felt answering the questions. You can also call the researcher at the Centre for Kidney Research 
who interviewed you. The coordinating centre for this study is located at the Centre for Kidney 
Research, Children’s Hospital at Westmead, Westmead, NSW. 
 
If you have any questions about the study, please call the study coordinator (Tel: (02) 9845 1477). 
 
The information we collect during the interview will have your name and details removed and will then 
be analysed to identify common and uncommon themes and concepts. We will try to identify 
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relationships between themes and from this build a model that adequately describes the information 
patients have given us during the interviews. From this, we will assess what effect the peritoneal dialysis 
treatment and peritonitis has had on your quality of life. We will also gain insight into ways that patients 
on peritoneal dialysis could be better supported and clinical care improved. The results of the study will 
be published so that other health care professionals will benefit from our findings. Should the stored 
data be used for any other purpose, then Ethical Approval will need to be granted. 
 
Are there any risks from participating in the study? 
 
There may be risks associated with this study that are presently unknown or unforeseeable. 
 
Are there any benefits from participating in the study? 
 
This study aims to further medical knowledge and patient support/education and may improve future 
treatment of people on peritoneal dialysis, however, it may not directly benefit you. 
Are there any side-effects and risks associated with this study? 
 
There are no side-effects or risks. The questions asked during the interview are related to your 
dialysis treatment, episode of peritonitis and about your quality of life and are not intended to 
upset you. 
Other information 
The information we collect is kept strictly confidential. The data is accessible only to the researchers 
involved in this research project and it will be stored for 5 years at the Centre for Kidney Research, 
Children's Hospital at Westmead, Westmead, NSW. 
Complaints 
 
If you have any concerns about the conduct of this study, or your rights as a study participant, you may 
contact the Associate Researcher at you unit (see phone number on page 1) or the Metro South HREC 
Coordinator (07 3443 8049; email: PAH_Ethics_research@health.qld.gov.au) and quote HREC 
reference number HREC/13/QPAH/286. 
 
Thank you for taking the time to consider this study. This Information sheet is for you to keep. 
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D3. Participant information sheet and consent form (VIC) 
MONASH HEALTH 
Participant Information 
Sheet/Consent Form 
 
 
 
Title Patient experiences and views on peritoneal dialysis: a 
qualitative study 
Short Title Patient experiences and views on peritoneal dialysis 
Protocol Number  
Project Sponsor Centre for Kidney Research 
Coordinating Principal Investigator/ 
Principal Investigator 
Dr Fiona Brown 
Associate Investigator(s)  
Location (where CPI/PI will recruit) Department of Nephrology 
 
 
Part 1 What does my participation involve? 
1 Introduction 
You are invited to take part in this research project, ‘Patient experiences and views on 
peritoneal dialysis’. This is because we want to find out about the experiences, views and 
needs of patients on peritoneal dialysis and the effect that being on peritoneal dialysis has on a 
patient’s quality of life. The research project is aiming to learn about your experience of being 
on peritoneal dialysis and hopefully, find out ways to improve the treatment and support given 
to patients. 
This Participant Information Sheet/Consent Form tells you about the research project. It 
explains the tests and research involved. Knowing what is involved will help you decide if 
you want to take part in the research. 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or local doctor. 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. 
You will receive the best possible care whether or not you take part. 
If you decide you want to take part in the research project, you will be asked to sign the 
consent section. By signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in the research project 
• Consent to the tests and research that are described 
Non-Interventional Study - Adult providing own consent 
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• Consent to the use of your personal and health information as described. 
You will be given a copy of this Participant Information and Consent Form to keep. 
 
 
2 What is the purpose of this research? 
 
The purpose of this study is to investigate the experiences and views of patients who have been or are 
currently on peritoneal dialysis and have experienced one or more episodes of peritonitis. 
We want to find out what are common experiences, needs and views of patients on peritoneal dialysis 
because this information can be used to improve the treatment, education and support given to patients 
and their families. 
This study aims to further medical knowledge and patient support/education and may improve future 
treatment of people on peritoneal dialysis. 
There are two main types of dialysis available for patients with end-stage kidney failure – haemodialysis 
and peritoneal dialysis. Quality of life is a term used to describe how you feel and how well you are able 
to do your usual activities. Health-related quality of life questionnaires have shown that after 1 year of 
dialysis, there are differences in the quality of life experienced by patients according to which type of 
dialysis they are on. We want to get an idea of the effect that being on peritoneal dialysis has had on 
your quality of life. 
 
This research is being undertaken as part of the work being submitted for a PhD by Denise Campbell 
(Centre for Kidney Research, Westmead, NSW) and is funded partly by the University of Sydney and by 
the Centre for Kidney Research, Westmead, NSW. 
This research is being conducted by Australian researchers based at the Centre for Kidney Research, 
Sydney Children’s Hospital Network (Westmead), NSW. 
3 What does participation in this research involve? 
 
If you agree to participate in the study, you will be asked to sign the Patient Consent Form before the 
interview takes place. 
You will be eligible to participate in this study if you have been diagnosed with end-stage kidney disease 
and are currently on or have been on peritoneal dialysis as your treatment. You will have also 
experienced at least one episode of peritonitis. You will need to be able to read and communicate in 
English to participate. 
You will be asked to participate in a face-to-face interview with a researcher from the Centre for Kidney 
Research, NSW. The interview will take place either in your home or an alternative setting where you 
feel comfortable. If you wish, your carer may be present during the interview. Each interview will take 
approx. 30 minutes to 1 hour to complete and will be audio recorded. We will ask you some basic 
demographic questions (e.g. age, marital status, type of PD treatment) and questions about your 
experiences and views on peritoneal dialysis and healthcare service in general. The interview will be 
audio recorded and transcribed verbatim. If you wish, you will be sent a summary of the interview 
which you can give feedback on. 
This research project has been designed to make sure the researchers interpret the results in a 
fair and appropriate way and avoids study doctors or participants jumping to conclusions. 
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There are no costs associated with participating in this research project, nor will you be paid. 
 
4 What do I have to do? 
You will be asked to participate in a face-to-face interview with a researcher from the Centre for 
Kidney Research, NSW. Each interview will take approx. 30 minutes to 1 hour to complete and will be 
audio recorded. 
5 Other relevant information about the research project 
 
Approximately 30 people will take part in the study overall, with approximately 8 participants coming 
from the Monash Health site. 
Interviews will take place with participants from 5 Renal Units at metropolitan hospitals – 3 Units in 
NSW, 1 in QLD and 1 In VIC. 
Two Associate Investigators from the Centre for Kidney Research, Westmead, NSW, will conduct 
the face to face interviews. 
6 Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you do not have to. If 
you decide to take part and later change your mind, you are free to withdraw from the project at any 
stage. 
If you do decide to take part, you will be given this Participant Information and Consent Form to sign and 
you will be given a copy to keep. 
Your decision whether to take part or not to take part, or to take part and then withdraw, will not 
affect your routine treatment, your relationship with those treating you or your relationship with 
Monash Health. 
7 What are the alternatives to participation? 
 
You do not have to take part in this research project to receive treatment at this hospital. 
 
8 What are the possible benefits of taking part? 
 
We cannot guarantee or promise that you will receive any benefits from this research, however possible 
benefits may include improved future treatment of people on peritoneal dialysis. 
9 What are the possible risks and disadvantages of taking part? 
 
There are no side-effects or risks. The questions asked during the interview are related to your 
dialysis treatment, episode of peritonitis and about your quality of life and are not intended to 
upset you. 
If you become upset or distressed as a result of your participation in the research, the study doctor will 
be able to arrange for counselling or other appropriate support. Any counselling or support will be 
provided by qualified staff who are not members of the research project team. This counselling will be 
provided free of charge. 
13        What if I withdraw from this research project? 
 
If you decide to withdraw from this research project, please notify a member of the research team before 
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you withdraw. Participation in this project is entirely voluntary and if you decide not to take part or decide 
to withdraw at any time, this will not affect your care at the Hospital or that of your family in any way. The 
data from this study will be kept for 5 years and it is acceptable for you to withdraw from the study at any 
point during this time. You will need to complete and submit a withdrawal of consent form. 
If you do withdraw your consent during the research project, the study doctor and relevant study staff 
will not collect additional personal information from you, although personal information already 
collected will be retained to ensure that the results of the research project can be measured properly 
and to comply with law. You should be aware that data collected by the sponsor up to the time you 
withdraw will form part of the research project results.  If you do not want them to do this, you must tell 
them before you join the research project. 
15 What happens when the research project ends? 
 
The interview will be transcribed verbatim and if you wish, you will be sent a summary of the interview 
which you can give feedback on. The results of the study will be published so that other health care 
professionals will benefit from our findings. 
 
Part 2 How is the research project being conducted? 
16 What will happen to information about me? 
 
The information we collect during the interview will have your name and details removed and will 
then be analysed to identify common and uncommon themes and concepts. You will not be 
individually identifiable. 
The information we collect is kept strictly confidential. The data is accessible only to the researchers 
involved in this research project and it will be stored at the Centre for Kidney Research, Sydney 
Children's Hospital Network (Westmead), Westmead, NSW. 
The study data will be stored for 7 years following completion of the study. The audio recordings will be 
stored on a computer file (external hard disk). Both electronic and paper copies of the transcripts will be 
stored. At the end of 7 years, both will be destroyed in a secure manner. Paper copies will be shredded. 
Data on electronic files will be reformatted or rewritten. 
 
The participant is being asked to provide consent to the use of their data for this 
project only. The study does not involve the establishment of a databank. 
By signing the consent form you consent to the study doctor and relevant research staff collecting and 
using personal information about you for the research project. Any information obtained in connection 
with this research project that can identify you will remain confidential. The interview with you will be 
transcribed and will have your name and details removed. You will not be individually identifiable. Your 
information will only be used for the purpose of this research project and it will only be disclosed with 
your permission, except as required by law. 
It is anticipated that the results of this research project will be published and/or presented in a variety of 
forums. In any publication and/or presentation, information will be provided in such a way that you 
cannot be identified, except with your permission. The data obtained from your interview will be included 
with the data from other interviews and analysed to identify themes and concepts. If something you have 
said during interview is included in the publication/presentation, it will not include details that identify you. 
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In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the 
right to request access to the information collected and stored by the research team about you. You also 
have the right to request that any information with which you disagree be corrected. Please contact the 
research team member named at the end of this document if you would like to access your information. 
Any information obtained for the purpose of this research project that can identify you will be 
treated as confidential and securely stored.  It will be disclosed only with your permission, or as 
required by law. 
 
17 Complaints and compensation 
 
If you suffer any injuries or complications as a result of this research project, you should contact the 
study team as soon as possible and you will be assisted with arranging appropriate medical 
treatment. If you are eligible for 
Medicare, you can receive any medical treatment required to treat the injury or complication, free of 
charge, as a public patient in any Australian public hospital. 
18 Who is organising and funding the research? 
 
The study is an Australian multi-centre study coordinated by Australian researchers based at the 
Centre for Kidney Research, Sydney Children’s Hospital Network (Westmead), NSW. The study is 
funded by the Centre for Kidney Research, Westmead, NSW. 
No member of the research team will receive a personal financial benefit from your involvement in 
this research project (other than their ordinary wages). 
19 Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people called a 
Human Research Ethics Committee (HREC). The ethical aspects of this research project have been 
approved by the HREC of Monash Health. 
This project will be carried out according to the National Statement on Ethical Conduct in Human 
Research (2007). This statement has been developed to protect the interests of people who agree 
to participate in human research studies. 
20 Further information and who to contact 
 
The person you may need to contact will depend on the nature of your query. 
 
If you want any further information concerning this project or if you have any medical problems 
which may be related to your involvement in the project (for example, any side effects), you can 
contact the principal study doctor on (03) 9594 3529 or any of the following people: 
Clinical contact person 
 
Name Dr Fiona Brown 
Position Consultant Nephrologist, Dept. of Nephrology 
Telephone (03) 9594 3529 
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Email Fiona.brown@monash.edu 
 
 
For matters relating to research at the site at which you are participating, the details of the local site 
complaints person are: 
 
 
Complaints contact person 
 
Name Ms Deborah Dell 
Position Manager, Human Research Ethics Committee 
Telephone (03) 9594 4605 
Email Deborah.Dell@monashhealth.org 
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xConsent Form - Adult providing own consent 
 
Title Patient experiences and views on peritoneal 
dialysis: a qualitative study 
Short Title Patient experiences and views on peritoneal 
dialysis 
Protocol Number  
Project Sponsor Centre for Kidney Research 
Coordinating Principal Investigator/ Dr Fiona Brown 
Associate Investigator(s)  
Location (where CPI/PI will recruit) Department of Nephrology 
Declaration by Participant 
 
I have read the Participant Information Sheet or someone has read it to me in a language that 
I understand. I understand the purposes, procedures and risks of the research described in 
the project. 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
 
I freely agree to participate in this research project as described and understand that I am free to 
withdraw at any time during the project without affecting my future health care. 
 
I understand that I will be given a signed copy of this document to keep. 
 
Name of Participant (please print) 
 
Signature Date 
 
Name of Witness* to Participant’s 
Signature (please print) 
 
Signature Date 
* Witness is not to be the investigator, a member of the study team or their delegate. In the event 
that an interpreter is used, the interpreter may not act as a witness to the consent process. 
Witness must be 18 years or older. 
 
Declaration by Study Doctor/Senior Researcher† 
 
I have given a verbal explanation of the research project, its procedures and risks and I 
believe that the participant has understood that explanation. 
 
Name of Study Doctor/ 
 
Senior Researcher† (please print) 
 
Signature Date 
† A senior member of the research team must provide the explanation of, and information concerning, 
the research project. Note: All parties signing the consent section must date their own signature. 
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Form for Withdrawal of Participation - Adult providing 
own consent 
 
Title Patient experiences and views on peritoneal
dialysis: a qualitative study 
Short Title Patient experiences and views on peritoneal 
dialysis 
Protocol Number  
Project Sponsor Centre for Kidney Research 
Coordinating Principal Investigator/ Dr Fiona Brown 
Associate Investigator(s)  
Location (where CPI/PI will recruit) Department of Nephrology 
Declaration by Participant 
 
I wish to withdraw from participation in the above research project and 
understand that such withdrawal will not affect my routine treatment, my 
relationship with those treating me or my relationship with Monash Health. 
 
Name of Participant (please print)    
Signature  Date 
 
In the event that the participant’s decision to withdraw is communicated 
verbally, the Study Doctor/Senior Researcher will need to provide a 
description of the circumstances below. 
 
Declaration by Study Doctor/Senior Researcher† 
 
I have given a verbal explanation of the implications of withdrawal from the 
research project and I believe that the participant has understood that 
explanation. 
 
Name of Study Doctor/ 
Senior Researcher†  (please print) 
Signature Date 
† A senior member of the research team must provide the explanation of and information 
concerning withdrawal from the research project. 
Note: All parties signing the consent section must date their own signature. 
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D4. Participant information sheet and consent form (NSW) 
PARTICIPANT INFORMATION AND CONSENT FORM 
 
Study Title: Patient experiences and views on peritoneal 
dialysis: a qualitative study 
 
Chief Investigator:  
Dr Germaine Wong, Department of Renal Medicine Introduction 
We are conducting a research study into the experiences, views and needs of patients 
on peritoneal dialysis and the effect that being on peritoneal dialysis has on a patient’s 
quality of life. We know that commencing dialysis has an impact on a patient’s quality 
of life. We also know that having an in-depth understanding of the experiences, views 
and needs of patients on peritoneal dialysis can be used to develop more patient-
centred health care. We want to learn about your experience of being on peritoneal 
dialysis and hopefully, find out ways to improve the treatment and support given to 
patients. 
 
The study is being conducted by the following investigators:  
Associate Investigators: 
Ms. Denise Campbell, Centre for Kidney Research, Sydney Children’s Hospital 
Network (Westmead), NSW Tel: (02) 9845 1477 
 
Dr Allison Tong, Centre for Kidney Research, Sydney Children’s Hospital 
Network (Westmead), NSW Tel: (02) 9845 1482 
 
Principal Investigators: 
 
Assoc. Prof David Mudge, Dept. of Nephrology, Princess Alexandra Hospital, QLD 
Tel: (07) 3176 7765 
 
Dr John Saunders, Dept. of Renal Medicine, Royal Prince Alfred Hospital, NSW 
Tel: (02) 9515 6600 
 
Dr Germaine Wong, Dept. of Renal Medicine, Westmead Hospital, NSW Tel: (02) 9845 
6962 
 
Assoc. Prof Martin Gallagher, Dept. of Nephrology, Concord Hospital, NSW 
Tel: (02) 9993 4552 
Dr Fiona Brown, Dept. of Nephrology, Monash Medical Centre, VIC Tel: (03) 9594 
3529 
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Before you decide whether or not you wish to participate in this study, it is important 
for you to understand why the research is being done and what it will involve. Please 
take the time to read the following information carefully and discuss it with others if 
you wish. 
 
What is the purpose of the study? 
 
The purpose is to investigate the experiences and views of patients who have been 
or are currently on peritoneal dialysis and have experienced one or more episodes 
of peritonitis. 
 
There are two main types of dialysis available for patients with end-stage kidney 
failure – haemodialysis and peritoneal dialysis. Quality of life is a term used to 
describe how you feel and how well you are able to do your usual activities. Health-
related quality of life questionnaires have shown that after 1 year of dialysis, there are 
differences in the quality of life experienced by patients according to which type of 
dialysis they are on. We want to get an idea of the effect that being on peritoneal 
dialysis has had on your quality of life. We also want to find out what are common 
experiences, needs and views of patients on peritoneal dialysis because this 
information can be used to improve the treatment, education and support given to 
patients and their families. 
Who will be invited to enter the study? 
 
You are invited to participate in this study because you have been diagnosed with 
end-stage kidney disease and are currently on or have been on peritoneal dialysis as 
your treatment. 
You have also experienced at least one episode of peritonitis. You will need to be 
able to read and communicate in English to participate. 
 
Do you have a choice? 
 
Participation in this study is voluntary. It is completely up to you whether or not you 
participate. If you decide not to participate, it will not affect the treatment you receive 
now or in the future. Whatever your decision, it will not affect your relationship with the 
staff caring for you. New information about the treatment being studied may become 
available during the course of the study. You will be kept informed of any significant 
new findings that may affect your willingness to continue in the study. If you wish to 
withdraw from the study once it has started, you can do so at any time without having 
to give a reason. 
 
However, it may not be possible to withdraw your data from the study results if 
these have already had your identifying details removed. 
What will happen on the study? 
 
If you agree to participate in this study, you will be asked to sign the Participant 
Information and Consent Form. This study will be conducted over approximately 18 
months with individual participation of 30-60 minutes. 
 
You will be asked to participate in a face-to-face interview with a researcher from 
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the Centre for Kidney Research, NSW. The interview will take place either in your 
home or an alternative setting where you feel comfortable. If you wish, your carer 
may be present during the interview. Each interview will take approx. 30 minutes to 
1 hour to complete and will be audio recorded. We will ask you some basic 
demographic questions (e.g. age, marital status, type of peritoneal dialysis 
treatment) and questions about your experiences and views on peritoneal dialysis 
and the healthcare service in general. The interview will be recorded word for word 
and if you wish, you will be sent a summary of the interview which you can give 
feedback on. 
 
Please feel free to talk to the Principal Investigator at your Renal Unit if you want to 
discuss how you felt answering the questions. You can also call the researcher at 
the Centre for Kidney Research who interviewed you. The coordinating centre for 
this study is located at the Centre for Kidney Research, Sydney Children’s Hospital 
Network (Westmead), Westmead, NSW. 
 
The information we collect during the interview will have your name and personal 
details removed and will then be analysed to identify common and uncommon themes 
and concepts. We will try to identify relationships between themes and from this build 
a model that adequately describes the information patients have given us during the 
interviews. From this, we will assess what effect the peritoneal dialysis treatment and 
peritonitis has had on your quality of life. We will also gain insight into ways that 
patients on peritoneal dialysis could be better supported and clinical care improved. 
The results of the study will be published so that other health care professionals will 
benefit from our findings. 
 
Are there any risks? 
 
There may be risks associated with this study that are presently unknown or 
unforeseeable. There are no side-effects or risks. The questions asked during the 
interview are related to your dialysis treatment, episode of peritonitis and about your 
quality of life and are not intended to upset you. If you experience any distress as a 
result of participating in the interview, we will arrange for you to speak to a social 
worker/ psychologist at the hospital. 
Are there any benefits? 
 
This study aims to further medical knowledge and patient support/education and may 
improve future treatment of people on peritoneal dialysis, however it may not directly 
benefit you. 
 
Confidentiality / Privacy 
 
Of the people treating you, only those named above or necessary others will know 
whether or not you are participating in this study. Any identifiable information that is 
collected about you in connection with this study will be coded by the study staff, and 
will not be labeled with or identified by your name, picture or any other information 
that can directly identify you.  It will remain confidential and will be disclosed only with 
your permission, or except as required by law. Only the researchers named above will 
have access to your details and results that will be held securely at the Centre for 
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Kidney Research, Sydney Children’s Hospital Network (Westmead), Westmead, 
NSW. 
Will taking part in this study cost me anything, and will I be paid? 
 
Participation in this study will not cost you anything and you will not be paid 
for your participation. You will be reimbursed for reasonable travel expenses. 
 
What happens with the results? 
 
If you give us your permission by signing the consent document, we plan to 
present the results at conferences or other professional forums and publish the 
findings in a peer- reviewed journal. In any publication, information will be 
provided in such a way that you cannot be identified. Results of the study will be 
provided to you, if you wish. 
 
Complaints 
This study has been approved by Western Sydney Local Health District Human 
Research Ethics Committee. If you have any concerns about the conduct of the 
study, or your rights as a study participant, you may contact: Westmead Hospital 
Patient Representative, telephone 9845 7014. You should quote HREC project 
number HREC2013/12/4.10 (3888) AU RED HREC/13/WMEAD/419. 
 
Contact details 
 
When you have read this information, the researcher [Denise Campbell/Allison 
Tong] will discuss it with you and any queries you may have. If you would like to 
know more at any stage, please do not hesitate to contact him/her on [9845 
1477/9845 1482]. If you have any problems while on the study, please contact 
 
Dr Germaine Wong 
 
Working hours Telephone No – 9845 6962 
 
After hours Telephone No – (mobile) 0411 603 282 
 
Thank you for taking the time to consider this study. 
 
If you wish to take part in it, please sign the attached 
consent form. This information sheet is for you to keep. 
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CONSENT TO PARTICIPATE IN RESEARCH 
 
Chief Investigator: 
 
1. I understand that the researcher will conduct this study in a manner conforming to ethical and 
scientific principles set out by the National Health and Medical Research Council of Australia 
and the Good Clinical Research Practice Guidelines of the Therapeutic Goods Administration. 
 
 
2. I acknowledge that I have read, or have had read to me the Participant Information Sheet 
relating to this study. I acknowledge that I understand the Participant Information Sheet. I 
acknowledge that the general purposes, methods, demands and possible risks and 
inconveniences which may occur to me during the study have been explained to me by     
(“the researcher”) and I, being over the age of 18 acknowledge that I understand the 
general purposes, methods, demands and possible risks and inconveniences which may occur 
during the study. 
 
 
3. I acknowledge that I have been given time to consider the information and to seek other advice. 
 
 
4. I acknowledge that refusal to take part in this study will not affect the usual treatment of my 
condition. 
 
 
5. I acknowledge that I am volunteering to take part in this study and I may withdraw at any time. 
 
 
6. I acknowledge that this research has been approved by the Western Sydney Local Health 
District Human Research Ethics Committee. 
 
 
7. I acknowledge that I have received a copy of the Participant Information, and this form 
which I have signed. 
 
8. I acknowledge that any regulatory authorities may have access to my medical records relevant 
to this study to monitor the research in which I am agreeing to participate. However, I 
understand my identity will not be disclosed to anyone else or in publications or presentations. 
 
Before signing, please read ‘IMPORTANT NOTE’ following. 
 
IMPORTANT NOTE: 
This consent should only be signed as follows: 
 
1.   Where a participant is over the age of 18 years, then by the participant personally. 
 
 
Name of participant Date of Birth    
 
Address of participant  _ 
 
Signature of participant Date:      
Signature of researcher Date:    
Signature of witness Date:    
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D5. Consent form (QLD) 
 
 
Princess Alexandra 
Hospital 
INTERVIEW PARTICIPANT CONSENT FORM 
Patient experiences and views on peritoneal dialysis: a qualitative study 
Primary Investigators: 
Ms. Denise Campbell, Centre for Kidney Research, The Children’s Hospital at Westmead, NSW Tel: (02) 
9845 1477 
Dr Allison Tong, Centre for Kidney Research, The Children’s Hospital at Westmead, NSW Tel: (02) 9845 1482 
 
Associate Investigators: 
Assoc. Prof David Mudge, Dept. of Nephrology, Princess Alexandra Hospital, QLD Tel: (07) 3176 
7765 Dr John Saunders, Dept. of Renal Medicine, Royal Prince Alfred Hospital, NSW Tel: (02) 9515 
6600 
Dr Germaine Wong, Dept. of Renal Medicine, Westmead Hospital, NSW Tel: (02) 9845 6962 
Assoc. Prof Martin Gallagher, Dept. of Nephrology, Concord Hospital, NSW Tel: (02) 9993 
4552 Dr Fiona Brown, Dept. of Nephrology, Monash Medical Centre, VIC Tel: (03) 9594 3529 
 
I have read and understand the Participant Information Sheet, and give my consent to participate in this 
research study, which has been explained to me by 
 
 
 
NAME OF INDIVIDUAL:  (Please print) 
SIGNATURE OF INDIVIDUAL: Date:     
NAME OF RESEARCHER: (Please print) 
SIGNATURE OF RESEARCHER:  Date:     
I understand that I am free to withdraw from the study at any time, without having to provide a reason, and 
this decision will not otherwise affect my treatment at the Hospital. 
 
I have been informed that if I wish to withdraw my consent and not be involved in the study, I need to phone, send 
an email or letter to: 
 
Denise Campbell PhD student 
Centre for Kidney Research, The Children’s Hospital at Westmead 
 
Locked Bag 4001 
Westmead NSW 2145 
Phone: (02) 9845 1477 
Email: denise.campbell@health.nsw.gov.au 
 
 
I have also been advised that I may only withdraw prior to the approval of the interview transcript and that I will 
be asked to complete and sign a ‘Withdrawal of Consent’ form. 
 
If I decide to leave the study, I have been told the researchers would like to keep the personal and/ health information 
about me that has been collected. If I do not want them to do this, I must tell them before I withdraw from the study 
